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Abstract 
 
Cell therapy is a promising strategy for treating ischaemic chronic heart failure. 
However, its therapeutic efficacy has not been fully established. In addition, 
arrhythmia occurrence is a concern of this treatment. In this work, therapeutic 
benefits, arrhythmogenicity and underlying mechanisms, which were 
hypothesised to be modulated by cell-delivery route into the heart, were 
investigated with the aim of optimising cell therapy. 
 
Injection of either skeletal myoblasts or mononuclear bone marrow cells into the 
rat ischaemic chronically failing heart via either direct intramyocardial or 
retrograde intracoronary route similarly improved both cardiac function and 
physical activity over the 84 days analysed. Survival of the grafted cells in the 
myocardium was extremely poor and trans-differentiation or fusion of the grafted 
cells into cardiomyocytes or vessels were only rarely identified via either cell-
delivery route. Therefore, paracrine effects including increased neovascular 
formation and attenuated fibrosis in the myocardium were considered to play an 
important role in the therapeutic benefits of cell therapy using either cell-type. 
 
Of note, direct intramyocardial injection of either cell-type, but not retrograde 
intracoronary injection, produced spontaneous ventricular arrhythmias including 
ventricular tachycardia in the early periods following cell injection. Local 
heterogeneity in the myocardium induced by clusters of grafted cells, which also 
involved inflammatory response, was considered to be a cause of the arrhythmias 
following intramyocardial cell injection. In contrast, in the late periods, injection 
of skeletal myoblasts via either route, but not mononuclear bone marrow cells, 
caused latent ventricular tachycardia possibly via regression of connexin43 in the 
native myocardium.  
 
Efficiency of engraftment of mononuclear bone marrow cells in the myocardium 
following intracoronary injection was very poor in the normal heart, but was 
enhanced by induction of ischaemia-reperfusion prior to cell injection. Most of the 
enhanced cell-engraftment was dependent on P-selectin-mediated cellular 
interaction between donor cells and endothelium. 
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CHAPTER 1: BACKGROUND 
 
 
1.1 Chronic Heart failure 
 
1.1.1 Epidemiology of chronic heart failure (HF) 
 
Chronic heart failure (HF) is a major cause of human disability and death, with 
the annual mortality rate of 30-40% in patients with end-stage HF (Lloyd-Jones et 
al., 2002; Thom et al., 2006). HF is clinically defined by its signs (i.e., peripheral 
oedema, increased heart size and a third heart sound) and symptoms (i.e., 
shortness of breath, fatigue, orthopnea and paroxysmal nocturnal dyspnoea) (Berk 
et al., 2007). Chronic HF is progressive in accordance with the pathological 
cellular and molecular alterations within the myocardium (Colucci, 1997).  
 
1.1.2 Aetiology of HF and pathogenesis of post-MI chronic HF 
 
While idiopathic dilated cardiomyopathy, valvular heart disease and hypertensive 
heart disease can cause chronic HF, a common contributor to the development of 
chronic HF is currently myocardial infarction (MI) (Thom et al., 2006). Therefore, 
post-MI chronic HF was studied in this thesis. 
 
As a consequence of progressive atherosclerotic change in coronary arteries and 
subsequent MI, the heart becomes unable to meet the functional demands placed 
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upon it. Sustained work-overload eventually leads to contractile dysfunction and 
HF through a variety of mechanisms as follows (Frey and Olson, 2003). 
 
1.1.2.1 Loss of cardiomyocytes 
MI causes a rapid death of cardiomyocytes via both necrosis and apoptosis. 
Decreased number of functional cardiomyocytes directly correlates with reduction 
in global contractility of the heart. In addition, apoptosis of cardiomyocytes 
following MI progressively occurs for a long time following the ischaemic event 
and correlates with development of chronic HF (Saraste et al., 1999). 
 
1.1.2.2 Alterations in cardiomyocytes 
Surviving cardiomyocytes following MI alter their properties and functions 
adaptively in response to increased workload in the initial stage of HF. However, 
sustained excessive workload following MI induces maladaptive cellular 
alterations in cardiomyocytes including pathological hypertrophy. Pathological 
hypertrophy of cardiomyocytes, which is a common feature of failing myocardium 
in the chronic phase, has been shown to correlate with calcium mishandling and 
increase in reactive oxygen species (ROS) (Lips et al., 2003).  
 
It has been shown that (a) reduced sarcoplasmic reticulum (SR) Ca2+-ATPase 
function, (b) increased expression and function of Na+- Ca2+ exchanger and (c) 
enhanced diastolic SR Ca2+ leak lead to reduction in Ca2+ transient and content in 
SR, causing contractile dysfunction (Ai et al., 2005; Bers et al., 2006). In addition, 
increase of ROS in cardiomyocytes and/or endothelial cells has been shown to 
cause cellular damage (Ferrari et al., 2004), though it is unclear whether 
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production is increased or degradation is reduced. Both calcium mishandling and 
increase in ROS eventually lead to cellular dysfunction and apoptosis of 
cardiomyocytes.  
 
Cellular interaction among the cardiomyocytes is also reported to be impaired in 
chronic HF. It has been suggested that connexin(Cx)43, which is a major gap-
junction protein of ventricular cardiomyocytes, is down-regulated in chronic HF 
(Teunissen et al., 2004; Severs et al., 2004a). Consequently, conduction velocity 
is reduced and, eventually, global contractile function is deteriorated. 
 
1.1.2.3 Change in extracellular matrix 
Extracellular matrix (ECM) is an important component to retain cardiac geometry 
and stiffness. Sustained wall stress following MI modulates both the synthesis and 
degradation of collagens, leading to collagen accumulation (fibrosis) in the 
extracellular space of the entire ventricular wall (Berk et al., 2007). While 
transforming growth factor (TGF)β is known to be one of the key inducers of 
collagen synthesis (Lijnen et al., 2000), degradation of ECM is regulated by 
matrix metalloproteinase (MMP) and its endogenous inhibitor, tissue inhibitor of 
matrix metalloproteinase (TIMP) (Creemers et al., 2001).  
 
Balanced expression of these proteins in the normal myocardium is reported to be 
impaired by a variety of factors which are related to HF, including hypoxia 
(Falanga et al., 2002), growth factors and proinflammatory cytokines (Bergman et 
al., 2003). Fibrosis in the ventricle, in turn, disrupts the coordination of 
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myocardial excitation-contraction coupling, consequently developing contractile 
dysfunction of the heart (Severs et al., 2004b). 
 
Furthermore, increased fibrosis in the ventricle creates re-entrant circuit and 
produces ventricular tachycardia (VT), which is one of the leading causes of 
mortality in post-MI chronic HF (Peters et al., 1997). In addition, down–
regulation of Cx43 in the ventricle was also reported to be correlated with the risk 
of VT (Severs et al., 2004b). 
 
1.1.2.4 Impaired myocardial blood flow 
Reduced coronary blood flow due to myocardial ischaemia is known to cause 
hibernating myocardium, which is a state of persistent myocardial and left 
ventricular ischaemia that can be partially or completely restored to normal by 
myocardial revascularisation (Rahimtoola, 1993).  
 
Myocardial hibernation by impaired myocardial blood flow has been shown to 
impair properties of cardiomyocytes, such as loss of sarcomeres, accumulation of 
glycogen, adaptations in size and shape of mitochondria, reorganisation of nuclear 
chromatin and depletion of SR, consequently leading to dysfunction of cellular 
contractile properties (Ausma et al., 1995; Elsasser et al., 1997). While such 
alterations in cellular properties might be recovered by increasing blood flow in 
the early stage, it has been suggested that prolonged hibernation exacerbates 
cellular alterations of cardiomyocytes in the ischaemic area, leading to permanent 
dysfunction of the myocardium (Schwarz et al., 1998).  
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1.1.3 Current therapy for end-stage HF 
 
Current therapies for HF consist of pharmacological and surgical approaches 
(McMurray and Pfeffer, 2005). Although angiotensin converting enzyme (ACE)-
inhibitor (1987; 1991; 1993), β-blockers (Waagstein et al., 1993; Poole-Wilson et 
al., 2003) and digitalis-type compounds (The Digitalis Investigation Group, 1997) 
are proved to have therapeutic benefits for HF, drug-therapy appears to be 
insufficient for end-stage HF (Rose et al., 2001), upon which a surgical approach 
has been focused on.  
 
Heart transplantation is the most effective therapy for end-stage chronic HF, but 
the benefits of heart transplantation are limited by a major global donor shortage, 
high-cost and immunosuppression-related complications (Pepper et al., 1995). 
Instead, the use of mechanical implantable left ventricular assist devises (LVAD) 
is being explored as a bridge to transplantation, destination therapy and bridge to 
recovery. Rose et al reported therapeutic benefits of LVAD implantation as a 
destination therapy for end-stage HF, compared to optimal medical management 
(Rose et al., 2001). Birks et al recently reported that LVAD implantation in 
combination with a specific pharmacologic regimen was useful in sustained 
reversal of end-stage HF (Birks et al., 2006).  
 
25 
1.2 Cell therapy for treating post-MI chronic HF 
 
Cell therapy for heart disease, which is defined as cell injection into the heart, is 
an emerging strategy for treating post-MI chronic HF (Yacoub et al., 2006). 
Experimental studies have suggested that cell therapy improves cardiac function 
not only via direct effects such as trans-differentiation of the injected cells 
(Tomita et al., 1999; Orlic et al., 2001), but also by secreting proinflammatory 
cytokines, angiogenic factors and/or growth factors (Kamihata et al., 2001; 
Murtuza et al., 2004).  
 
This promising experimental evidence has encouraged the start of clinical 
application of cell therapy for treating both acute MI (Assmus et al., 2002a; 
Strauer et al., 2002) and post-MI chronic HF (Hamano et al., 2001; Menasche et 
al., 2001).  
 
1.2.1 Clinical outcomes of cell therapy for post-MI chronic HF 
 
Phase-I clinical studies of cell therapy for post-MI chronic HF have been started 
using both autologous skeletal myoblasts (SMB) and bone marrow cells (BMC), 
while only one randomised study was carried out (Myoblast Autologous Grafting 
in Ischemic Cardiomyopathy [MAGIC] study; American Heart Association 2006). 
Of note, coronary artery bypass grafting (CABG) or LVAD implantation was 
concomitantly carried out with cell therapy in clinical studies using either SMB 
(Menasche et al., 2001; Pagani et al., 2003; Herreros et al., 2003; Siminiak et al., 
2004) or BMC (Hamano et al., 2001; Stamm et al., 2003).  
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1.2.1.1 Outcome of clinical trials using SMB for post-MI chronic HF 
Most of the phase-I clinical studies of SMB injection for post-MI chronic HF to 
date have shown promising results in cardiac function (table 1.1). Whilst the study 
by Biagini et al showed no improvement in left ventricular ejection fraction 
(LVEF) following the treatment, they described that significant improvement in 
LVEF was observed under dobutamine-induced stress, suggesting the therapeutic 
benefits of this treatment (Biagini et al., 2006).  
 
However, the therapeutic benefits seen in the clinical studies, most of which 
showed less than 10% improvement in LVEF, are not as substantial as those in 
experimental studies which have consistently showed more than 10% 
improvement in LVEF (Ghostine et al., 2002). Moreover, the first randomised 
placebo-controlled trial (MAGIC study) was stopped at the time when the Data 
Safety Monitoring Board concluded that it was unlikely to show any benefits after 
only 97 of the 300 initially planned patients were treated (American Heart 
Association 2006) (Jolicoeur et al., 2007).  
 
Of note, occurrence of VT has been repeatedly reported following SMB injection 
(Hagege et al., 2006; Biagini et al., 2006; Dib et al., 2005b; Siminiak et al., 2005; 
Siminiak et al., 2004), while MAGIC trial suggested that this risk may not be 
troublesome (American Heart Association 2006).  
 
Such inconsistency in the therapeutic outcomes of cell therapy in clinical studies 
to date might be due to the inconsistent protocols used. The protocol for SMB 
injection for post-MI chronic HF has not been established in clinical studies. They 
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used a variety of SMB-injection methods including different cell numbers injected 
or cell-delivery routes. In addition, quality of the donor cells might be inconsistent 
due to a different protocol in collection and culture of SMB. Therefore, it is a 
requisite to optimise the protocol to obtain consistent therapeutic benefits of cell 
therapy using SMB. 
 
28 
 
29 
1.2.1.2 Outcome of clinical trials using BMC for post-MI chronic HF 
The therapeutic effects of BMC injection for post-MI chronic HF appeared to be 
less than those of SMB injection (table 1.2). Six studies out of 15 described no 
significant improvement in LVEF following BMC injection (Hendrikx et al., 
2006; Blatt et al., 2005; Kuethe et al., 2005; Perin E., 2004; Fuchs et al., 2003; 
Tse et al., 2003). 
 
The inconsistent therapeutic outcomes following BMC injection for post-MI 
chronic HF might also be due to inconsistent protocols used. The intracoronary 
(IC) route was used for cell-delivery in 5 studies out of 15 and the other 10 studies 
injected BMC via the direct intramyocardial (IM) route, though little has been 
studied about difference in the therapeutic outcomes of cell therapy between the 
IC and IM injections in post-MI chronic HF. In addition, the cell number injected 
is greatly different between the studies. Therefore, it is required to optimise the 
protocol for cell therapy using BMC. 
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1.2.2 Clinical outcomes of cell therapy for acute HF 
 
Cell therapy has also been studied for treating acute MI in experimental and 
clinical settings. While the main work of this thesis studied post-MI chronic HF as 
a target of cell therapy, evidence from the cell therapy research for acute MI 
would provide important implications for cell therapy for post-MI chronic HF 
 
Experimental research has shown that injection of either SMB (Murry et al., 1996; 
Taylor et al., 1998; Scorsin et al., 2000; Suzuki et al., 2001a) or BMC (Orlic et al., 
2001; Yoon et al., 2005b; Tomita et al., 1999) improves cardiac function and 
perfusion of the heart with acute MI. Phase-I clinical studies of this strategy using 
BMC showed promising results in feasibility, safety and therapeutic efficacy of 
the treatment, in which autologous BMC was injected after successful 
recanalisation for acute MI (Assmus et al., 2002b; Fernandez-Aviles et al., 2004; 
Schachinger et al., 2004; Wollert et al., 2004). In contrast, clinical studies of SMB 
injection for acute MI have not been carried out to date.  
 
Of note, recent randomised clinical trials of cell therapy treating acute MI did not 
show as substantial therapeutic effects as expected, except for an open labelled 
study by Chen et al (Lunde et al., 2006; Schachinger et al., 2006; Meyer et al., 
2006; Janssens et al., 2006; Chen et al., 2004) (table 1.3). Meyer et al suggested 
that the therapeutic effects of cell therapy might be transient, as significant 
improvement of LVEF observed at 6 months after cell therapy disappeared at 18 
months (Meyer et al., 2006).  
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Importantly, cell injection protocol, including cell-type, cell number injected and 
cell injection timing was different among these studies. Lunde et al injected 
68×106 cells, which was only 3% of those Meyer et al injected and only 0.2% of 
those Chen et al injected (Lunde et al., 2006; Meyer et al., 2006; Chen et al., 
2004). While 4 studies injected non-cultured mononuclear BMC within 7 days 
after successful percutaneous coronary intervention (PCI) (Lunde et al., 2006; 
Schachinger et al., 2006; Meyer et al., 2006; Janssens et al., 2006), Chen et al 
injected cultured mesenchymal BMC 18 days after PCI (Chen et al., 2004). As a 
result, 3 studies out of 5 reported less than 5% improvement in LVEF following 
cell therapy (Lunde et al., 2006; Schachinger et al., 2006; Janssens et al., 2006).  
 
While the protocol by Chen et al (Chen et al., 2004) appears to be most promising 
to date, further studies will be required to verify the therapeutic effects of cell 
therapy for treating acute MI (Nadal-Ginard and Fuster, 2007).  
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1.2.3 Raised issues from clinical studies 
 
Thus, there are concerns relating to the degree and durability of improved cardiac 
function and the incidence of ventricular arrhythmias after injection of either 
SMB or BMC into the myocardium after MI, even though most of these clinical 
studies showed modest improvement in cardiac function and perfusion (Yacoub et 
al., 2006). In addition, there are other issues which need to be addressed, 
including choice of donor cell-type and cell-delivery route. All this information is 
essential to determine the optimal condition for cell therapy which provides the 
maximum therapeutic benefits with the least complications. 
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1.3 Choice of donor cell-type 
 
Although experimental research has shown that a variety of donor cell-types are 
able to improve cardiac function of damaged myocardium, the optimal donor cell 
type for cell therapy treating HF is not known.  
 
1.3.1 Embryonic stem (ES)  cells 
 
The use of embryonic stem (ES) cell is the most promising approach to regenerate 
the damaged heart, because of the unique features of these cells, which include 
self-renewal and differentiation to any types of cells including cardiomyocytes. 
ES cells are pluripotent cell lines derived from the inner cell mass and epiblast of 
embryos without the use of immortalising or transforming agents (Evans and 
Kaufman, 1981; Smith, 2001). These cells are maintained in an undifferentiated 
state in culture whilst retaining their indefinite differentiation potential and also 
exhibit a stable karyotype (Evans and Kaufman, 1981).  
 
It has been reported that cardiomyogenic differentiation of ES cells occur in vivo, 
which are enhanced by growth factors including TGFβ or fibroblast growth factor 
(FGF) (Behfar et al., 2002; Kofidis et al., 2005). He et al suggested that human ES 
cells can differentiate into multiple types of cardiomyocytes with atrial-, 
ventricular-, and pacemaker-like action potentials in vitro (He et al., 2003). 
Moreover, Menard et al reported that injection of cardiac-committed ES cells (by 
culturing the cells for 36 hours in 7.5% foetal bovine serum, leukaemia inhibitory 
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factor 1,000 U/L, and 2.5 µg/L bone morphogenetic protein 2) into the infarcted 
sheep heart improved systolic cardiac function (Menard et al., 2005). 
 
However, clinical use of ES cells for treating HF is seriously hampered by many 
hurdles, which include the risk of tumourgenicity, the use of xenogenic feeder 
cells for many of the currently available cell lines and the incomplete knowledge 
of the genes and transcriptional factors to regulate differentiation (Lees et al., 
2007). Thus, grafted ES cells in the myocardium might not consistently 
differentiate into mature cardiomyocytes and/or endothelial cells which have 
functional intercellular connections with the native cardiomyocytes and/or 
endothelium, but differentiate into unwanted tissues (Leor et al., 2007). In 
addition, there is a concern about the immunological incompatibility that might 
exist between the host and grafted cells (Keller, 2005). Finally, there are ethical 
concerns regarding the use of ES cells and other embryo-derived cells for both 
experimental and clinical studies at the moment.  
 
Therefore, the most practical source is currently from adult progenitor cells which 
are autologous and include bone marrow-derived, circulating or organ-specific 
progenitor cells from skeletal muscle or the heart itself (Dimmeler et al., 2005).  
 
1.3.2 Skeletal myoblasts (SMB) 
 
SMB were the first cell-type used in the clinical study of cell therapy (Menasche 
et al., 2001). SMB have several advantages as the donor cell-type treating 
ischaemic HF in clinical settings. Firstly, SMB can be isolated in an autologous 
manner and expanded rapidly to obtain sufficient cell-number injected into the 
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heart. Secondly, there is little risk of tumourgenicity. Finally, SMB have a high 
resistance to ischaemia (Beauchamp et al., 1999b).  
 
However, cardiomyogenic differentiation of the grafted SMB and formation of 
intercellular connections between the grafted SMB and the native cardiomyocytes 
have not been clarified in either experimental (Reinecke et al., 2002) or clinical 
studies, whereas grafted autologous SMB have been shown to survive in the 
native myocardium in the clinical studies (Scorsin et al., 2000; Dib et al., 2002; 
Dib et al., 2005a). In addition, paracrine effects of the grafted SMB have not been 
fully studied in post-MI chronic HF, though grafted SMB in acute MI-heart were 
reported to secrete mediators such as inflammatory cytokines, growth factors or 
anti-apoptotic factors to modulate the native myocardium (Murtuza et al., 2004; 
Suzuki et al., 2001a; Niagara et al., 2007). 
 
In clinical studies, injection of SMB has been shown to provide the therapeutic 
benefits in post-MI chronic HF, such as improvement in cardiac function and 
perfusion (Menasche et al., 2003; Pagani et al., 2003; Smits et al., 2003; Herreros 
et al., 2003; Zhang et al., 2003; Siminiak et al., 2004; Ince et al., 2004; Chachques 
et al., 2004; Siminiak et al., 2005), while these studies were not randomised, 
placebo-controlled or double-blinded. The phase II clinical trials named MAGIC 
study, which was a multi-centre, placebo-controlled trial, has recently 
discontinued to include patients due to insufficient functional improvement 
obtained (American Heart Association, 2006). In addition, the occurrence of VT is 
a concern of SMB injection as a serious complication (Menasche et al., 2003; 
Pagani et al., 2003; Siminiak et al., 2004).  
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For the successful application of SMB injection for treating HF to clinical settings, 
it would be essential to clarify the fundamental behaviour of the grafted SMB in 
the myocardium and the resulting functional benefits and arrhythmia occurrence, 
using a clinically-relevant model. 
 
1.3.3 Mononuclear bone marrow cells (BMC) 
 
Unfractionated mononuclear BMC have been considered to be a promising cell-
type currently in widespread clinical use, particularly for treating acute MI (Meyer 
et al., 2006; Lunde et al., 2006; Schachinger et al., 2006). However, the 
therapeutic efficacy of this treatment for treating post-MI chronic HF has not been 
fully established in clinical or experimental studies.  
 
Mononuclear BMC contain haematopoietic stem cells, mesenchymal stem cells 
and endothelial progenitor cells, which are considered to be able to regenerate the 
damaged myocardium via differentiation (Orlic et al., 2001). However, it is 
unclear whether the grafted BMC could consistently differentiate into the required 
phenotypes such as cardiomyocytes, endothelial cells and vascular smooth muscle 
cells (Murry et al., 2004; Balsam et al., 2004). Grafted BMC in the myocardium 
were reported to improve cardiac function and perfusion of acute MI-hearts by 
secreting proinflammatory cytokines, growth factors, angiogenic factors or anti-
apoptotic factors (Kamihata et al., 2001; Uemura et al., 2006; Gnecchi et al., 
2006), while the paracrine effects on the post-MI chronically failing hearts have 
not been fully investigated. In addition, little is known about arrhythmogenicity of 
BMC injection into the heart, though bone marrow-derived cells reportedly 
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acquire arrhythmogenic potential by co-culture with cardiomyocytes in vitro 
(Chang et al., 2006).  
 
1.3.4 Mesenchymal stem cells 
 
Mesenchymal stem cells, which are isolated from BMC, adipose tissue, liver or 
skin by the adherence ability, have been shown to differentiate into multiple 
mesenchymal lineages, including bone, cartilage and muscle (Pittenger et al., 
1999). Of note, bone marrow-derived mesenchymal stem cells were reported to be 
able to differentiate into mature functional cardiomyocytes in vitro (Makino et al., 
1999) and to improve cardiac function of the acute MI-heart (Tomita et al., 1999). 
In addition, grafted mesenchymal stem cells in the heart have been shown to 
improve cardiac function of the acute MI-hearts by the paracrine effects, including 
improvement of cardiac perfusion and attenuation of apoptosis of the native 
cardiomyocytes (Dai et al., 2005; Tang et al., 2005).  
 
In phase-I clinical studies, Chen et al and Katritsis et al suggested that injection of 
bone marrow-derived mesenchymal stem cells improves cardiac function of the 
post-MI heart (Chen et al., 2004; Katritsis et al., 2005). However, little is known 
about genes and transcriptional factors to regulate differentiation of mesenchymal 
stem cells into cardiomyocyte or vascular cell phenotypes. Therefore, there is a 
concern about differentiation into inappropriate phenotypes in the myocardium, 
including cartilage, bone or tumour. In addition, a universally accepted protocol 
for harvesting and culturing mesenchymal stem cells has not been established.  
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1.3.5 Fractionated stem/progenitor cells 
 
1.3.5.1 Multipotent adult stem cells 
The use of a purified fraction of BMC, which is considered to be promising for 
the therapeutic benefits, is another approach. Multipotent adult progenitor cells 
(MAPC) is one of the promising fractions of BMC, showing a variety of 
differentiation abilities to visceral mesoderm, neuroectoderm and endoderm in 
vitro (Jiang et al., 2002).  
 
Yoon et al also isolated pluripotent adult progenitor cells from BMC, but by a 
different protocol from Jiang et al (Jiang et al., 2002), and showed differentiation 
of these cells into cardiomyocytes, endothelial cells and vascular smooth muscle 
cells following injection into the infarcted rat heart (Yoon et al., 2005b). Orlic et 
al reported that c-kit+ lin- bone marrow-derived cells replaced infarcted mouse 
myocardium after injection into the heart by differentiating into cardiomyocytes, 
endothelial cells and vascular smooth muscle cells (Orlic et al., 2001), but this 
result is unrepeatable by other laboratories (Murry et al., 2004; Balsam et al., 
2004). Importantly, while both MAPC and c-kit+lin- cells were considered to 
generate new heart tissues by their differentiation, survival and proliferation of 
these cells in the myocardium have not been quantitatively evaluated.  
 
1.3.5.2 Endothelial progenitor cells 
CD34-positive peripheral blood derived-cells, which have been shown to have a 
multipotent stem cell character and be enriched in endothelial progenitor cells 
(Asahara et al., 1997), is another possible promising cell fraction for treating 
ischaemic HF. CD34-positive cells grafted in the heart reportedly differentiate 
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into cardiomyocytes, endothelial cells and vascular smooth muscle cells (Yeh et 
al., 2003) and improve cardiac function of the acute-MI heart (Ott et al., 2005b; 
Iwasaki et al., 2006; Kawamoto et al., 2006). In addition, it was suggested that 
CD34-positive cells secrete abundant angiogenic factors to enhance neo-
vascularisation (Yoon et al., 2005a). However, a randomised double-blind clinical 
trial of injection of CD34-positive cells for patients with severe angina only 
showed a trend of improvement in symptoms (Losordo et al., 2007).  
 
CD133-positive cell has been reported to be a pure population of endothelial 
progenitor cells with high capacity of proliferation (Quirici et al., 2001; Salven et 
al., 2003; Peichev et al., 2000) and therefore have been considered to be a 
promising fraction to improve myocardial blood flow following injection into the 
ischaemic heart. Clinical studies of this treatment reported preliminary promising 
results including improvement in cardiac function and symptoms (Stamm et al., 
2007; Klein et al., 2007; Manginas et al., 2007). However, it is not well known 
that the grafted CD133-positive cells are integrated to the native vascular network 
and to contribute for improvement in myocardial blood flow. Agbulut et al 
reported that the grafted human CD133-positive cells disappeared from the 
ischaemic nude rat heart within 1 month after injection (Agbulut et al., 2004).  
 
1.3.6 Cardiac stem cells 
 
Loss of cardiomyocytes induced by MI has been considered not to be replaced by 
regeneration, as seen in skin, skeletal muscle and liver. However, it has also been 
suggested that some dividing cardiomyocytes exist and the number of 
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cardiomyocytes re-entering the cell-cycle increased in pathologic conditions, such 
as ischaemia (Anversa and Kajstura, 1998). In addition, multipotent stem cells 
have been recently identified in the myocardium, which were termed cardiac stem 
cells (Beltrami et al., 2003; Messina et al., 2004; Oh et al., 2003b).   
 
It has been suggested that cardiac stem cells are able to be isolated from the heart, 
expanded in vitro and differentiated into cardiomyocytes and vascular cells in vivo. 
Beltrami et al isolated cardiac stem cells, which are self-renewing, clonogenic and 
multipotent, from adult rat hearts using an antibody against the surface marker c-
kit (Beltrami et al., 2003). When injected into the acute-MI heart, c-kit positive 
cardiac stem cells formed cardiomyocytes with the characteristics of young cells 
and blood-carrying new vessels. Oh et al isolated cardiac stem cells using an 
antibody against the surface marker Sca-1 (Oh et al., 2003a). Sca-1 positive 
cardiac stem cells differentiated into cells expressing cardiac specific markers 
after the treatment with the cytosine analogue 5-azacytidine. Cardiac side 
population cells, which are isolated by their ability to exclude Hoechst 33342 dye, 
are reported to differentiate into cells expressing cardiac-specific genes and 
proteins and showing spontaneous beatings in vitro (Oyama et al., 2007). Another 
cardiac progenitor population in the heart was isolated on the basis of expression 
of the transcriptional factor, Islet-1 (Laugwitz et al., 2005). Islet-1 positive cardiac 
stems cells were reported to enter fully differentiated cardiac lineage expressing 
cardiomyocyte markers and action potentials. Messina et al reported the isolation 
of undifferentiated cells which grew as self-adherent clusters, termed as 
cardiospheres, from subcultures of postnatal atrial and ventricular human 
specimens (Messina et al., 2004). The isolated cardiospheres were shown to 
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differentiate into cardiomyocytes and vascular endothelial or smooth muscle cells 
in vivo.  
 
While cardiac stem cells represent a potentially attractive cell source for cell 
therapy treating HF, they are still investigational. Little knowledge exists 
regarding the molecular networks which regulate their proliferation, self-renewal 
or lineage differentiation states. In addition, only limited laboratories have 
successfully established the protocol for the isolation and proliferation to date. 
 
1.3.7 Other cell-type 
 
1.3.7.1 Mature cardiomyocytes 
Cardiomyocytes themselves have been considered as a cell-source to recover 
damaged myocardium for a long time. It has been reported that isolated foetal or 
neonatal cardiomyocytes were able to form intercellular connections with the 
native cardiomyocytes following injection into the heart (Soonpaa et al., 1994; 
Koh et al., 1995; Matsushita et al., 1999). In addition, Li et al reported that 
injection of cultured foetal cardiomyocytes into the heart improves cardiac 
function of cryo-injured rat heart (Li et al., 1996). However, Zhang et al suggested 
that most of the grafted cardiomyocytes would be killed by environmental stress 
shortly after injection. In addition, there is a concern about immunological 
incompatibility and ethical issues. 
 
1.3.7.2 Smooth muscle cells / fibroblasts 
Adult smooth muscle cells were reported to improve cardiac function in a dilated 
cardiomyopathy hamster model (Yoo et al., 2000) and cryo-injured rat 
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myocardium (Li et al., 1999) following direct IM injection into the heart. 
Hutcheson et al reported that autologous dermal fibroblasts improved diastolic, 
but not systolic, cardiac function of cryo-injured rabbit hearts following direct IM 
injection into the heart (Hutcheson et al., 2000). However, mechanisms 
underlying the functional improvement following injection of either smooth 
muscle cells or fibroblasts are largely unknown.  
 
1.3.8 Use of SMB and mononuclear BMC in this work 
 
Thus, the most practical and promising donor cell type in cell therapy treating 
post-MI chronic HF currently appears to be SMB and bone marrow-derived cells, 
both of which have already shown the feasibility and therapeutic benefits in 
clinical studies. Among bone marrow-derived cells, mononuclear BMC are likely 
to be most promising, because they do not need culture in the laboratory, which 
might deteriorate the quality of cells. In addition, it is still unclear which fraction 
of mononuclear BMC is effective in treating post-MI chronic HF. Therefore, 
SMB and mononuclear BMC were used as donor cells in this work. 
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1.4 Therapeutic efficacy following cell therapy for chronic HF 
 
Therapeutic efficacy following cell therapy for post-MI chronic HF is mainly 
assessed by systolic and diastolic cardiac functions in experimental and clinical 
studies (Murry et al., 2006). In addition, clinical studies have assessed activity and 
symptoms following cell therapy as an indicator of the degree of HF. 
 
1.4.1 Therapeutic efficacy of SMB injection  
 
1.4.1.1 Systolic cardiac function following SMB injection 
Systolic cardiac function is commonly evaluated with LVEF. Experimental 
studies have shown a improvement in LVEF (>10%) following SMB injection for 
post-MI chronic HF compared to the control which were injected the vehicle only 
(Ghostine et al., 2002; Bonaros et al., 2006; Memon et al., 2005b). However, 
clinical studies of SMB injection without combination therapy such as CABG 
showed less LVEF improvement (<10%) than experimental studies. While Ince et 
al showed 5-10% LVEF improvement (Ince et al., 2004), Biagini et al reported no 
improvement in a rest condition (Biagini et al., 2006) and Siminiak et al reported 
only 2-8% improvement in 6 out of 9 patients studied (Siminiak et al., 2005).  
 
End-systolic left ventricular (LV) volume is also known to be an indicator of 
systolic cardiac function. Memon et al reported a significant reduction of end-
systolic LV volume following SMB injection into the post-MI chronically failing 
canine heart (Memon et al., 2005b). 
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1.4.1.2 Diastolic cardiac function following SMB injection 
Diastolic cardiac function is assessed by peak end-diastolic/atrial (E/A) mitral 
flow or tissue Doppler indices, such as the ratio of early to late annular diastolic 
peak velocity, using echocardiography (Kasner et al., 2007). Ghostine et al 
reported a significant increase in diastolic myocardial velocity gradient following 
SMB injection into the post-MI chronically failing sheep heart, using tissue 
Doppler imaging (Ghostine et al., 2002). In addition, end-diastolic LV volume, 
which is also reported to be an indicator of diastolic cardiac function (Gaasch and 
Little, 2007), was reduced following SMB injection in experimental studies 
(Bonaros et al., 2006; Memon et al., 2005b). 
 
1.4.1.3 Activity and symptoms following SMB injection 
Activity and symptoms are the most conventional indicator of the degree of post-
MI chronic HF, frequently expressed as New York Heart Association (NYHA) 
functional class in the clinical arena. Clinical studies have reported improvement 
in NHYA functional class following SMB injection for post-MI chronic HF 
(Hagege et al., 2006; Biagini et al., 2006; Siminiak et al., 2005; Ince et al., 2004; 
Chachques et al., 2004). However, there is no experimental report which 
examined benefits in physical activity or symptoms following SMB injection. 
 
1.4.2 Therapeutic efficacy of mononuclear BMC  injection  
 
1.4.2.1 Change in systolic function following mononuclear BMC  injection 
Experimental studies provided an inconsistent improvement in systolic cardiac 
function following BMC injection for post-MI chronic HF. Whereas improvement 
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in LVEF by more than 10% was obtained by Memon et al (Memon et al., 2005b) 
and Thompson et al (Thompson et al., 2005), Waksman et al reported no LVEF 
improvement following this treatment in a swine model (Waksman et al., 2004). 
Reduction in end-systolic volume following BMC injection was reported by the 
study using a canine HF model (Memon et al., 2005b).  
 
Phase-I clinical studies of this treatment without combination therapy such as 
CABG also reported inconsistent improvement in LVEF. While improvement in 
LVEF (<10%) was reported by some studies (de la Fuente et al., 2007; Assmus et 
al., 2006; Beeres et al., 2006b; Strauer et al., 2005), the other studies did not show 
significant LVEF improvement following this treatment (Blatt et al., 2005; Kuethe 
et al., 2005; Perin E., 2004; Tse et al., 2003). Significant reduction in end-systolic 
LV volume was reported only by Beeres et al (Beeres et al., 2006a), while 
Assmus (Assmus et al., 2006) reported no change in end-systolic LV volume. 
 
1.4.2.2 Change in diastolic function following mononuclear BMC  injection 
There were no experimental studies which showed a significant reduction in LV 
diastolic volume following mononuclear BMC injection into the post-MI 
chronically failing heart (Memon et al., 2005a; Thompson et al., 2005; Waksman 
et al., 2004). Clinical studies also reported no significant change in end-diastolic 
LV volume following this treatment (de la Fuente et al., 2007; Assmus et al., 
2006; Beeres et al., 2006a; Kuethe et al., 2005).  
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1.4.2.3 Change in physical activity following mononuclear BMC injection 
Perin et al reported a significant improvement in the NYHA functional class at 6 
and 12 months follow-up after mononuclear BMC injection for post-MI chronic 
HF (Perin et al., 2004). In contrast, de la Fuente et al reported no significant 
change in exercise tolerance following BMC injection (de la Fuente et al., 2007), 
while Kuethe et al reported no significant change in peak oxygen uptake or 
oxygen uptake at the anaerobic threshold (Kuethe et al., 2005). In contrast, there 
is no experimental report which examined benefits in physical activity or 
symptoms following BMC injection. 
 
1.4.3 Necessity of experimental study for clarifying therapeutic efficacy 
 
In summary, SMB injection for post-MI chronic HF has been shown to provide a 
significant improvement in systolic and diastolic cardiac functions in the 
experimental studies, while clinical studies have suggested that the therapeutic 
effects of this treatment may not be as substantial as the experimental studies. In 
contrast, the therapeutic efficacy of mononuclear BMC for post-MI chronic HF 
has not been fully studied in experimental studies, whereas phase-I clinical studies 
of this treatment have provided inconsistent functional improvement.  
 
It is likely that the reasons for the inconsistent functional results are due to the 
heterogeneous nature of patients assigned to the study, the small numbers of 
patients studied, the variable quality of donor cells and the different injection 
protocols including the site for injection and the cell number injected. In addition, 
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proper controls and long-term follow-up are required to determine the therapeutic 
efficacy following cell therapy. 
 
The degree of improvement in systolic and diastolic cardiac functions appears to 
be greater following SMB injection than mononuclear BMC injection in treating 
post-MI chronic HF in both experimental and clinical studies. In addition, 
physical activity following cell therapy has not been examined in experimental 
studies, though activity is one of the most important indicators of therapeutic 
effects of cell therapy. As sufficient evidence from experimental studies has not 
been provided to date, further investigations using an appropriate model with 
serial assessment of cardiac function and physical activity would be useful in 
determining if injection of either SMB or BMC is able to lead to a significant and 
consistent improvement in cardiac function of post-MI chronic HF. 
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1.5 Mechanism of improvement in cardiac function following 
cell therapy 
 
Although investigating the mechanisms of functional improvement after cell 
therapy is crucial in understanding the treatment and enhancing the therapeutic 
efficacy, neither fundamental behaviour of the grafted cell in the native 
myocardium or associated changes in the myocardium, which are essential to 
understand the mechanisms, are fully understood.  
 
1.5.1 Engraftment, survival and proliferation of grafted cells 
 
No matter what the mechanisms of the therapeutic benefits are, the number of 
grafted cells present in the native myocardium (surviving and/or proliferating) is 
an important issue (Pouzet et al., 2001; Suzuki et al., 2004a; Poh et al., 2007; 
Meluzin et al., 2006; Yau et al., 2005c; McConnell et al., 2005; Iwasaki et al., 
2006). The graft size in the myocardium following cell therapy is determined by 
the initial engraftment and subsequent survival and proliferation of the grafted 
cells. However, factors affecting the engraftment, survival or proliferation have 
not been fully identified. 
 
1.5.1.1 Initial engraftment in the myocardium 
The majority of the injected donor cells is known to be lost from the heart 
immediately after injection without being engrafted in the myocardial interstitium, 
regardless of donor cell-type (Suzuki et al., 2004b; Muller-Ehmsen et al., 2006; 
Hou et al., 2005). Cells injected via the IM route were suggested to be 
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immediately escape into the cardiac veins/lymphatics and the outside of the heart 
from the injection site (Yasuda et al., 2005; Hou et al., 2005), while the cells 
injected via the IC route are reported to be flushed out into the systemic 
circulation without trans-endothelial migration into the myocardial interstitium 
(Hou et al., 2005). 
 
1.5.1.2 Death of engrafted cells in the myocardium 
Following engraftment into the myocardium, the number of grafted cells is 
reported to be largely decreased within 7 days, presumably due to death of grafted 
cells (necrosis and/or apoptosis) (Muller-Ehmsen et al., 2006; Yasuda et al., 2005). 
My laboratory reported that the grafted cell death in the early stage after direct IM 
injection of SMB occurs via two pathways: free-radical generation in the 
myocardium surrounding the grafted cells and subsequent interleukin (IL)-1β 
associated inflammatory response (Suzuki et al., 2004b; Suzuki et al., 2004a).  
 
1.5.1.3 Proliferation of grafted cells 
Proliferation of the grafted cells in a cardiac environment is not fully understood, 
regardless of cell-type. My laboratory showed that grafted SMB proliferate in the 
acute MI-heart by labelling the SMB with both Lac-Z and [14C]thymidine prior to 
injection (Suzuki et al., 2004b). However, such a quantitative analysis for 
proliferation of the grafted cells in the myocardium has not been reported in case 
of BMC injection. In addition, little is known about the rate of proliferation of the 
donor cells in the post-MI chronically failing heart, which is likely to have a 
different influence on the grafted cells from the acute MI-heart.  
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1.5.2 Generation of new myocardium via differentiation 
 
It used to be viewed that the central nervous system and heart are static tissues 
which are unable to repair or regenerate themselves due to terminal differentiation 
and an apparent absence of tissue-specific stem cells in the adult, unlike blood, 
skin or gut. However, it has been recently suggested that injection of 
stem/progenitor cells into the heart could generate new cardiomyocytes and/or 
new vessels. For direct contribution for global cardiac function, these newly 
generated tissues need to form appropriate intercellular connections with the 
native myocardium, including gap and adherence junctions with the native 
cardiomyocytes and/or incorporation into the native vascular network. 
 
1.5.2.1 Differentiation of SMB in a cardiac environment 
It is still unclear whether SMB differentiate into a cardiomyogenic phenotype in a 
cardiac environment. Iijma et al reported that differentiated SMB, which express 
cardiac specific proteins such as cardiac troponin T and atrial natriuretic peptide, 
possess contractile properties and adequate electrical connections with an adjacent 
cardiomyocytes in vitro (Iijima et al., 2003). In contrast, Reinecke et al reported 
that both undifferentiated SMB and differentiated myotubes are able to form 
functional Cx43-gap junctions with adjacent cardiomyocytes without trans-
differentiation in vitro (Reinecke et al., 2000).  
 
Suzuki et al reported that grafted SMB in the myocardium formed Cx43-gap 
junctions with the native cardiomyocytes in vivo (Suzuki et al., 2000a), while 
Reinecke et al or Leobon et al reported that either cardiomyogenic trans-
differentiation of the grafted SMB or electro-mechanical coupling between the 
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grafted SMB and the native cardiomyocytes did not occur in the myocardium in 
vivo (Reinecke et al., 2002; Leobon et al., 2003). These inconsistent results in the 
in vivo studies might be due to the different cell-delivery routes and cell-type used. 
Suzuki et al injected SMB derived from cell-line via the IC route, which 
disseminates donor cells widely into the myocardium (Suzuki et al., 2000a), 
whereas Reinecke et al and Leobon et al injected primary SMB via the IM route, 
which forms islet-like cell-clusters which are isolated from the native myocardium 
(Reinecke et al., 2002; Leobon et al., 2003). 
 
1.5.2.2 Differentiation of BMC  into cardiomyocytes/endothelial cells 
Mononuclear BMC were reported to be able to differentiate into cardiomyocyte-
like and/or endothelial cell-like phenotypes in vitro. It was reported that a specific 
population of BMC treated by 5-azacytidine is able to differentiate into 
cardiomyocyte-like cells, which show spontaneous and synchronous beating with 
each other, express cardiac markers such as myocyte enhancer factor (MEF)-2A 
and MEF-2D (Makino et al., 1999) and express functional adrenergic and 
muscarinic receptors (Hakuno et al., 2002) in vitro. Fukuhara et al and Xu et al 
showed that cardiomyogenic differentiation of bone marrow cell-derived cells is 
able to be induced by direct interaction with adjacent cardiomyocytes (Fukuhara 
et al., 2003; Xu et al., 2004).  
 
Orlic et al and Kajstura et al showed that grafted c-kit+lin- BMC into the acute MI-
heart generate new myocardium by differentiating into cardiomyocytes, 
endothelial cells and vascular smooth muscle cells and improve global cardiac 
function and perfusion (Orlic et al., 2001; Kajstura et al., 2005). However, it is 
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unclear whether differentiation of the grafted BMC into the required phenotypes 
could consistently occur in the myocardium (Murry et al., 2004; Balsam et al., 
2004) and that these cells, if any, could form functional intercellular connections 
with the native cardiomyocytes or vascular endothelium.   
 
1.5.3 Fusion of the donor-derived cells with native myocardial cells 
 
It was reported that fusion of SMB with cardiomyocytes could occur at a low 
frequency in vitro (Reinecke et al., 2004a) and in vivo (Rubart et al., 2004). BMC 
could also reportedly fuse with cardiomyocytes at a low frequency in vitro 
(Garbade et al., 2005). In addition, it has also been suggested that injected BMC 
into the heart acquire a cardiomyogenic phenotype through cell fusion with native 
cardiomyocytes, but not through cardiomyogenic trans-differentiation (Nygren et 
al., 2004; Ishikawa et al., 2006). Therefore, it is speculated that cell fusion might 
play a role in acquiring a phenotype of cardiomyocytes and/or vascular cells, 
which was originally considered to be through trans-differentiation. However, 
little is known about the effects of fusion between the grafted cells and the native 
cells on the global cardiac function or perfusion. 
 
1.5.4 Paracrine effects on the native myocardium 
 
Paracrine effects of the grafted cells on the native myocardium have also been 
considered to be an important mechanism of functional improvement following 
cell therapy. Both grafted SMB and BMC are reported to be able to improve 
cardiac function by secreting a variety of mediators, including proinflammatory 
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cytokines, angiogenic factors, growth factors or anti-apoptotic factors (Kamihata 
et al., 2001; Gnecchi et al., 2006; Uemura et al., 2006; Murtuza et al., 2004).  
 
1.5.4.1 Extracellular matrix change 
Accumulation of collagen in the extracellular space in the myocardium is known 
to be related to post-MI ventricular remodelling, and diastolic LV dysfunction 
(Pfeffer and Braunwald, 1991). Collagen accumulation in the post-MI heart is 
known to be induced by an imbalance between synthesis and degradation of ECM, 
which is regulated by several proinflammatory cytokines, MMPs, TIMPs and 
growth factors (Spinale, 2002). Experimental and clinical studies have shown that 
cell therapy decrease extracellular collagen deposition and improves diastolic LV 
function of the acute-MI heart (Jain et al., 2001; Murtuza et al., 2004; Taylor et al., 
1998). In addition, cell therapy is reported to affect expression of growth factors 
or proinflammatory cytokines in the myocardium (Kamihata et al., 2001). 
Murtuza et al suggested that IL-1 and its endogenous inhibitor, IL-1 receptor 
antagonist, play an important role in LV remodelling process following injection 
of SMB into the acute-MI heart (Murtuza et al., 2004). 
 
1.5.4.2 Vascular formation 
Increase in myocardial blood flow and capillary density, which are independent of 
newly formed vessels by graft differentiation, has been reported following 
injection of either SMB or BMC into the acute MI-heart in experimental studies 
(Iwasaki et al., 2006; Niagara et al., 2007). In addition, it was also reported that 
perfusion and capillary density of post-MI chronically failing hearts was increased 
following injection of either SMB or BMC in experimental (Tran et al., 2007; 
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Bonaros et al., 2006; Tse et al., 2007; Li et al., 2007) and clinical (Stamm et al., 
2007) studies.  
 
These angiogenic effects of cell therapy on the native myocardium are likely to be 
associated with upregulated angiogenic factors in the native myocardium 
(Kobayashi et al., 2000; Kamihata et al., 2001). The secreted angiogenic factors 
from the grafted SMB or BMC, such as vascular endothelial growth factor 
(VEGF), FGF, TGF-β, platelet-derived growth factor (PDGF), hepatocyte growth 
factor (HGF), hypoxia inducible factor (HIF)-α or angiopoietins as shown in vitro 
(Suzuki et al., 2001a; Takahashi et al., 2006), could enhance the neovascular 
formation in the native myocardium (Matsunaga et al., 2000; Tomanek et al., 
2004). In addition, upregulated proinflammatory cytokines such as interleukin 
(IL)-1β and tumour necrosis factor (TNF)α following cell injection (Kamihata et 
al., 2001) might enhance angiogenesis in the myocardium by further upregulating 
VEGF (Maruyama et al., 1999) or by other angiogenic activities (Giulian et al., 
1988). 
 
1.5.4.3 Alternations of native cardiomyocytes  
Pathological hypertrophy and associated reduction in contractility of 
cardiomyocytes are known to occur during post-MI ventricular remodelling and 
be one of the most important features of chronic HF. Murtuza et al  suggested that 
SMB injection into the acute MI-heart suppressed progression of pathological 
hypertrophy of the native cardiomyocytes (Murtuza et al., 2004).  
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Progressive loss of cardiomyocytes by apoptosis is known to occur in the post-MI 
chronically failing heart and to be one of the causes of progressive deterioration of 
the cardiac function (Narula et al., 2006). Bonaros et al suggested that cell therapy 
attenuates apoptosis of the native cardiomyocytes by enhancing neoangiogenesis 
and increasing blood supply to the native myocardium in a rat post-MI chronic HF 
model (Bonaros et al., 2006). In addition, Gnecchi et al and Uemura et al 
suggested that growth factors released from the donor cells, such as VEFG, FGF, 
HGF or insulin-like growth factor (IGF)-1, might inhibit cardiomyocyte apoptosis 
in the post-MI heart (Gnecchi et al., 2006; Uemura et al., 2006).  
 
1.5.4.4 Harnessing endogenous stem cells for myocardial regeneration 
Although it used to be considered that adult cardiomyocytes are terminally 
differentiated cells and have no resource for regeneration, Quaini et al identified 
new mature cardiomyocytes of recipient origin in the gender-mismatched 
transplanted human myocardium (Quaini et al., 2002), suggesting that endogenous 
stem cells might be able to be recruited to the donor heart and differentiate into 
mature cardiomyocytes. This evidence encouraged experimental and clinical 
studies for cytokine administration, such as granulocyte-colony stimulating factor 
(G-CSF) or stem cell factor (SCF), to increase BM-derived circulating stem cells, 
consequently enhance recruitment of the stem cells into the heart and regenerate 
the damaged myocardium. However, data from the experimental studies are 
inconsistent (Dawn et al., 2006; Fukuhara et al., 2004) and clinical studies showed 
no effects of G-CSF/SCF therapy on global cardiac function following acute MI 
(Engelmann et al., 2006; Zohlnhofer et al., 2006).  
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Hou et al suggested that cell injection into the rat heart upregulated stem cell 
derived factor (SDF)-1 in the myocardium (Hou et al., 2007), which was reported 
to enhance homing of circulating stem cells into the tissue (Askari et al., 2003; 
Abbott et al., 2004) and, consequently, regenerate the damaged myocardium. 
Moreover, Beltrami et al and Oh et al reported the presence of residential stem 
cells in the adult myocardium, which are capable of differentiating into mature 
cardiomyocytes both in vitro and in vivo (Beltrami et al., 2003; Oh et al., 2003a). 
However, little is known about effects of cell therapy on recruitment of these 
endogenous stem cells into the heart. 
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1.6 Arrhythmogenicity after cell therapy 
 
Arrhythmia occurrence is a serious complication after cell therapy for treating HF. 
Occurrence of VT was repeatedly reported in clinical studies of direct IM 
injection of SMB into the post-MI chronically failing heart (Hagege et al., 2006; 
Dib et al., 2005b; Siminiak et al., 2005; Siminiak et al., 2004; Smits et al., 2003). 
However, the degree, time-course and mechanisms of arrhythmia occurrence 
following this treatment are not fully understood. Furthermore, while occurrence 
of ventricular arrhythmia has been rarely reported in clinical studies of BMC 
injection into either the acute or chronic MI-heart, these studies administered 
drugs with anti-arrhythmic effects, such as β-blockers, which would mask the 
arrhythmogenicity. 
 
1.6.1 Occurrence of ventricular arrhythmia following SMB injection 
 
Preliminary clinical studies of IM injection of SMB for treating post-MI chronic 
HF reported frequent occurrence of VT following the treatment (table 1.4) 
(Hagege et al., 2006; Dib et al., 2005b; Siminiak et al., 2005; Siminiak et al., 
2004; Smits et al., 2003). Hagege et al reported that VT occur either in the early-
phase or late-phase following injection of SMB and that these two time-dependent 
VT were not necessarily observed in the same patients (Hagege et al., 2006). 
Importantly, SMB injection was carried out via the IM route in all clinical studies 
to date, as antegrade IC injection of SMB, which have a larger cell size than BMC, 
has been shown to carry a risk of coronary embolism (Suzuki et al., 2000a). 
 
60 
 
61 
1.6.1.1 Early-phase arrhythmia in clinical studies 
Dib et al suggested that the early-phase VT was more likely to be seen in the 
patients who received injection of the higher number (>1×108) of SMB (Dib et al., 
2005b). Siminiak et al  suggested that prophylactic use of amiodarone is very 
effective in occurrence of the early-phase VT, as 3 patients who were not 
administered amiodarone presented VT in the early period after cell injection, 
while the rest of 17 patients with prophylactic amiodarone administration did not 
present VT (Siminiak et al., 2005; Siminiak et al., 2004). In addition, the use of 
corticosteroids in the first 2 days following SMB injection also appeared to be 
effective in attenuating the early-phase VT (Menasche et al., 2003). These reports 
have encouraged the routine prophylactic use of amiodarone in other clinical 
studies of SMB injection into the heart, which have not shown occurrence of VT 
following the treatment to date (Chachques et al., 2004; Siminiak et al., 2005). 
 
1.6.1.2 Late-phase arrhythmia in clinical studies 
Most of these early-phase ventricular arrhythmias disappeared spontaneously or 
by medical treatment within 1 month after cell injection. However, there were 
patients who persistently presented sustained VT even under full-medication and 
required automatic cardiac defibrillators (ACD) (Menasche et al., 2003; Smits et 
al., 2003; Dib et al., 2005b).  
 
1.6.1.3 Evidence in experimental model in arrhythmogenicity of SMB injection 
Arrhythmogenicity of SMB into the heart is not fully understood to date. 
Fernandes et al (Fernandes et al., 2006) and Mills et al (Mills et al., 2007) 
suggested that SMB injection into the post-MI heart induces arrhythmogenicity in 
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vivo, while Fouts et al reported no arrhythmogenicity observed following SMB 
injection into the infarct canine heart (Fouts et al., 2006).  
 
1.6.2 Possible arrhythmogenicity after BMC injection 
 
In the case of BMC injection, occurrence of ventricular arrhythmias has been 
rarely reported in either experimental or clinical studies. Furthermore, Katritsis et 
al reported that antegrade IC injection of bone marrow-derived cells into the post-
MI chronically failing heart does not induce arrhythmogenicity in patients studied 
by electrophysiological testing (Katritsis et al., 2007). However, all the patients 
enrolled in clinical studies were medically treated with drugs having an anti-
arrhythmic effect, such as β-blockers, which would have masked the 
arrhythmogenicity. There is still a lack of experimental evidence for 
arrhythmogenicity following BMC injection. 
 
1.6.3 Possible mechanism of arrhythmogenicity following cell therapy 
 
Possible mechanism of arrhythmogenicity following cell therapy includes the 
direct adverse effect of the grafted cells which acquire both arrhythmogenic 
potential and intercellular connections with surrounding native cardiomyocytes 
(Zhang et al., 2002). Abraham et al reported that SMB could acquire 
arrhythmogenic potential in vitro (Abraham et al., 2005). In addition, Chang et al 
reported proarrhythmic potential of bone marrow-derived cells in vitro (Chang et 
al., 2006). However, it is still unclear that either grafted SMB or BMC in the 
myocardium acquire arrhythmogenic potential in vivo or that they, if any, form 
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intercellular electrical connection with the native cardiomyocytes to induce 
ventricular arrhythmias. An appropriate experimental drug-free model with 
continuous monitoring of electrocardiogram (ECG) would enable to clarify the 
severity, time-course and mechanisms of arrhythmia occurrence following cell 
therapy.  
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1.7 Cell-delivery route into the heart 
 
1.7.1 Possible routes for cell-delivery into the heart 
 
The cell-delivery route has been considered to affect the fundamental behaviour of 
the grafted cells and the resulting therapeutic outcomes (Robinson et al., 1996; 
Suzuki et al., 2000a). Therefore, selection of the route for cell-delivery is vital to 
determine the optimal protocol for cell therapy for treating post-MI chronic HF.  
 
Possible routes for cell-delivery into the heart include direct IM route, IC route 
and systemic intravenous (IV) route (Robinson et al., 1996; Hayashi et al., 2004). 
Unlike the IM and IC route which enables local delivery into the heart, systemic 
route via either peripheral vein or right/left atrium is highly likely to largely limit 
efficiency in delivering donor cells into the heart, as cells injected via peripheral 
vein or right atrium might be entrapped in other organs before reaching the heart. 
Therefore, the IM and IC routes have been considered to be more effective in 
delivering the donor cells into the heart than the systemic route and have been 
tested in clinical settings. 
 
1.7.2 Direct IM route for cell-delivery 
 
The direct IM route has been frequently used for either SMB or BMC injection 
into the heart in both clinical and experimental studies of cell therapy. Direct IM 
cell injection enables selective cell-delivery into the infarct and/or peri-infarct 
myocardium (Murry et al., 1996; Taylor et al., 1998; Yoon et al., 2005b; Orlic et 
al., 2001). There are several technical approaches for direct IM injection. Syringe-
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needle injection from the epicardial side is the most common approach in both 
clinical and experimental studies. However, stress and systemic inflammatory 
response associated with general anaesthesia and thoracotomy is inevitable in this 
method, while special equipment or techniques are not required.  
 
For the patients who need surgical treatment such as CABG, direct IM cell 
injection is able to be carried out via epicardial approach with little additional 
stress. In contrast, direct IM cell injection from the endocardial side can be 
performed by electromechanical LV mapping and NOGA injection catheter, 
which does not require general anaesthesia or invasive surgical procedure (Fuchs 
et al., 2003; Perin E., 2004). In addition, Siminiak et al (Siminiak et al., 2003) and 
Brasselet et al (Brasselet et al., 2005) suggested that direct IM cell injection via 
the coronary venous approach, which is also be able to be carried out without 
general anaesthesia or thoracotomy, is feasible and safe in clinical arena. They 
inserted a catheter into the cardiac vein draining the LV and penetrated the venous 
wall to inject the cells directly into the LV myocardium. 
 
Direct IM cell injection, regardless of the approach, causes mechanical injury and 
inflammation, which accelerate early graft death and damage to the native 
myocardium (Suzuki et al., 2004a; Suzuki et al., 2004b; Murtuza et al., 2004). 
Furthermore, the grafted cells via this route were reported to form isolated islet-
like cell-clusters which do not have direct contacts with the native myocardium 
(Reinecke et al., 2002; Leobon et al., 2003). Thus, newly-formed cardiomyocytes, 
endothelial cells or vascular smooth muscle cells by differentiation of grafted cells, 
if any, are unlikely to form functional connections with the native tissues. In 
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addition, such heterogeneity in the myocardium following IM cell injection could 
affect myocardial geometry/consistency and cause ventricular arrhythmia. 
 
1.7.3 Intracoronary routes for cell-delivery 
 
In contrast, IC injection disseminates cells in a more widespread manner with less 
mechanical damage and less inflammation than the direct IM injection (Robinson 
et al., 1996; Suzuki et al., 2000a; Suzuki et al., 2001b; Suzuki et al., 2004d; 
Suzuki et al., 2004c). My laboratory suggested that cells injected via the IC route 
are more likely to have direct contacts with the native cardiomyocytes than those 
via the IM route (Suzuki et al., 2004c). The direct communication between these 
two cells, in turn, could enhance cardiomyogenic trans-differentiation of the 
grafted cells (Suzuki et al., 2000a; Fukuhara et al., 2003). Moreover, widely 
distributed grafted cells via the IC route might be more likely to survive in the 
myocardium than those via the IM route, which are involved in a severe 
inflammatory response of the native myocardium (Suzuki et al., 2004a). There are 
two options for the IC route; antegrade IC (injection into coronary arteries) and 
retrograde IC (injection into cardiac veins) routes. 
 
1.7.3.1 Antegrade IC route 
The antegrade IC route (injection into the coronary arteries) is widely used for 
BMC injection in clinical studies (Schachinger et al., 2004; Meyer et al., 2006; 
Hirsch et al., 2006), as this route is easily accessed by the same approach as the 
routine coronary angiography or PCI. While the use of antegrade IC route appears 
to be promising, there are several limitations in using this route for cell therapy 
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treating post-MI chronic HF. Firstly, the efficiency of engraftment of injected 
BMC via the antegrade IC route in the myocardium is reported to be extremely 
poor (Hofmann et al., 2005; Hou et al., 2005). Secondly, injection of either SMB 
(Suzuki et al., 2000a) or BMC (Vulliet et al., 2004) via this route reportedly carry 
a risk of coronary embolism, which will be particularly critical when treating 
post-MI chronic HF where coronary arteries often show diffuse narrowing at a 
number of sites with jeopardized collateral arteries. Finally, there is no 
reproducible model for antegrade IC cell injection in small animals. 
 
1.7.3.2 Retrograde IC route 
In contrast, my laboratory demonstrated that retrograde IC injection (injection into 
the cardiac veins) achieves a wide donor-cell dissemination with little risk of 
coronary embolism, into the normal and acute MI hearts (Suzuki et al., 2004d; 
Suzuki et al., 2004c). Retrograde IC injection in this model has been shown to 
perfuse the entire LV free wall (LVFW) of the acute-MI heart generated by left 
coronary artery (LCA) ligation (figure 1.1).  
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Figure 1.1: Perfusion area of retrograde IC route LCA-ligated rat. (A) IV injection of 
Evans blue dye into rats, of which the LCA had been ligated. The dye stained right 
ventricular free wall (RVFW) and interventricular septum (IVS) in blue, whereas a wide 
area of LVFW was not stained (shown in red) and thus not perfused. (B) Retrograde IC 
injection of Evans blue dye into the LCA-ligated hearts. The dye positively stained (blue 
colour) a wide area of LVFW. RVFW or IVS was not stained (shown in red). Arrowheads 
show the LCA ligation site. Comparison between (A) and (B) indicates that the perfusion 
area by retrograde IC injection encompasses the infarct/ischaemic and the border zones 
induced by LCA ligation. Arrowheads show the LCA ligation site.  
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Retrograde IC cell injection has theoretical advantages over the antegrade IC cell 
injection. Firstly, retrograde IC injection could allow a longer time for injected 
cells to interact with myocardial vasculature by occluding the stem of cardiac vein, 
compared to antegrade IC injection in which occluding the coronary arteries may 
induce myocardial ischaemia. Secondly, the cells injected via the retrograde IC 
route are directly delivered to post-capillary venules, where migration of 
inflammatory cells is known to take place. Cellular interaction with the native 
endothelium in this unique part of vessel for a certain time period following 
retrograde IC injection could enhance cell-migration into the myocardial 
interstitium, resulting in enhanced graft survival and therapeutic effects. Thirdly, 
the use of the retrograde IC route delivers cells into ischaemic and infarcted areas 
where antegrade IC cell-delivery has a limited efficiency without reperfusion 
(Suzuki et al., 2004d; Suzuki et al., 2004c). Finally, SMB, which have a high risk 
of coronary embolism due to large cell size when injected via the antegrade IC 
route (Suzuki et al., 2000a), might be able to be safely injected into the post-MI 
heart via the retrograde IC route. 
 
1.7.4 Cell engraftment following IC injection 
 
For successful cell-engraftment following IC injection, injected cells are required 
to adhere to the endothelium, subsequently, cross trans-endothelial barrier and 
migrate into the myocardial interstitium. While the efficiency of cell-engraftment 
following IC injection was reported to be poor (Hou et al., 2005), little is known 
about mechanisms of cell-engraftment following IC injection. 
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1.7.4.1 Efficiency of donor cell engraftment following IC injection 
Hou et al reported that only less than 5% of injected human peripheral blood-
derived mononuclear cells were engrafted in the sheep acute-MI heart at 1 hour 
after IC injection (Hou et al., 2005), suggesting poor efficiency in adherence to 
the endothelium and/or trans-endothelial migration of the injected cells following 
IC cell injection.  
 
1.7.4.2 Possible interactions between BMC and endothelium 
While the underlying mechanism of cell-engraftment following IC cell injection 
have not been fully studied, it has been suggested that BMC injected via the IC 
route could be engrafted through adhesion molecule-mediated cellular interaction. 
Wu et al and Yoon et al recently reported that homing of endothelial progenitor 
cells to ischaemic muscle requires interaction between intercellular adhesion 
molecule (ICAM)-1 and CD18 (Wu et al., 2006; Yoon et al., 2006). In addition, 
Segers et al suggested that TNF-α and IL-1β may play an important role in 
cellular interaction between mesenchymal stem cells and cardiac endothelial cells 
(Segers et al., 2006).  
 
1.7.4.3 Adhesion molecules-related cellular interaction 
Adhesion molecules such as P-selectin and ICAM-1 are known to regulate 
cellular interaction between the leukocytes and myocardial endothelium during 
the course of acute inflammation (Kokura et al., 1999; Frangogiannis et al., 2002).  
 
Myocardial ischaemia-reperfusion increases ROS in the endothelial cells, which 
stimulate P-selectin, which is stored in the Weibel-Palade bodies of the 
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endothelial cell, to be rapidly expressed on the cell surface (Briaud et al., 2001). 
Upregulated P-selectin on the endothelial cells forms molecular links with P-
selectin glycoprotein ligand (PSGL)-1, which is constitutively expressed on the 
surface of circulating leukocytes. Interaction between PSGL-1 and P-selectin 
initiates rolling of leukocytes on the endothelial surface, particularly at post-
capillary venules. Rolling leukocytes, in turn, either redistribute (Bruehl et al., 
1997; Lorant et al., 1995) or proteolytically shed (Gardiner et al., 2001; 
Davenpeck et al., 2000) PSGL-1 from their surface in order to form stable, firm 
adhesion to the endothelium, which is mediated by ICAM-1/lymphocyte function 
antigen (LFA)-1 (CD11a/CD18, αLβ2) interaction.  
 
ICAM-1 is constitutively expressed at low levels on the endothelial cell surface 
and is markedly upregulated by proinflammatory cytokine stimulation, such as IL-
6 or IL-8, produced by ischaemic cardiomyocytes (Gwechenberger et al., 1999; 
DiVietro et al., 2001). Messenger ribonucleic acid (mRNA) of ICAM-1 is induced 
within the first hour of reperfusion followed by protein expression with a peak at 
6 hours after reperfusion (Kukielka et al., 1993a). ICAM-1 is known to be most 
upregulated at post-capillary venules where adherence and trans-endothelial 
migration of leukocytes take place (Briaud et al., 2001).  
 
LFA-1, which is also constitutively expressed on the surface of circulating 
leukocytes, is activated by either chemokines released by endothelial cells 
(Laudanna et al., 2002), direct signalling of PSGL-1 (Atarashi et al., 2005) or 
other selectin family members such as L-selectin (Hwang et al., 1996). Activated 
LFA-1, in turn, interacts with ICAM-1 on the endothelial cell surface to form firm 
72 
adhesion between the leukocytes and endothelium (Kukielka et al., 1993b). 
Subsequently, trans-endothelial migration into the myocardial interstitium is 
facilitated.  
 
It is hypothesised that engraftment of BMC into the myocardium following IC 
injection might take place through a similar mechanism to leukocyte-endothelial 
interaction. 
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1.8 Feasibility and safety of retrograde IC route 
 
A variety of experimental and clinical studies for retrograde IC injection have 
been carried out for a different purpose from cell therapy. My laboratory carried 
out two sets of experimental studies to show utility of retrograde IC route for 
drug-administration for myocardial ischaemia-reperfusion injury before this work 
(Fukushima et al., 2006a; Fukushima et al., 2006b). These studies suggested the 
feasibility and safety of retrograde IC route for cell therapy treating post-MI 
chronic HF.  
 
1.8.1 Current use of the retrograde IC route in clinical settings 
 
The retrograde IC route has been widely used as a delivery route for cardioplegic 
solution for cardioprotection under cardiac arrest during open-heart surgery. 
Cardioplegic solution administered via this route is known to be widely delivered 
into both non-ischaemic and ischaemic myocardium where the antegrade IC route 
has a limited efficacy (Ruengsakulrach and Buxton, 2001). This specific property 
of the retrograde IC route is useful in protecting the ischaemic myocardium. In 
addition, it was reported that perfusion of the myocardium with oxygenated blood 
via the retrograde IC route was safely carried out by a percutaneous approach 
during recanalisation for acute MI (Boekstegers et al., 1998).  
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1.8.2 Drug-administration against ischaemia-reperfusion  injury 
 
My laboratory has reported that the retrograde IC route is a promising route for 
drug-administration against myocardial ischaemia-reperfusion injury (Fukushima 
et al., 2006a; Fukushima et al., 2006b).  
 
1.8.2.1 Myocardial ischaemia-reperfusion injury 
While early reperfusion is the only established way to save the ischaemic 
myocardium, it is inevitably associated with reperfusion injury, which remains 
one of the major issues in clinical settings such as primary angioplasty for acute 
MI, heart transplantation and heart surgery using cardiac arrest (Grines et al., 
1993). Ischaemia-reperfusion injury involves ROS-related cellular damage and 
subsequent acute inflammatory response (Frangogiannis et al., 2002). While 
experimental studies have shown that a number of pharmacological treatments, 
including administration of superoxide-dismutase (SOD) or antibodies for 
adhesion molecules, are effective in attenuating for myocardial ischaemia-
reperfusion injury, the therapeutic effects of these treatments have not been 
established in clinical studies (Moukarbel et al., 2004). 
 
1.8.2.2 Enhanced SOD-mediated cardioprotection by retrograde IC injection 
Although SOD is a promising reagent to treat free radicals-associated reperfusion 
injury (Wang et al., 1998; Suzuki et al., 1999), clinical trials of systemic 
administration of SOD following recanalisation for acute MI failed to show 
significant therapeutic benefits (Murohara et al., 1991; Flaherty et al., 1994). The 
failure of the clinical trials might be due to insufficient delivery of SOD into the 
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ischaemic myocardium where free radicals are generated within seconds after 
reperfusion (Becker, 2004).  
 
In contrast, retrograde IC injection of SOD showed marked therapeutic benefits 
compared to systemic IV injection in a rat myocardial ischaemia-reperfusion 
injury model (Fukushima et al., 2006a). In this study, either SOD or phosphate 
buffered saline (PBS) only was administered via either the retrograde IC or 
systemic IV route just before reperfusion following 30 minutes myocardial 
ischaemia by LCA ligation. The dosage of SOD injected was 1,500 U/Kg weight 
for retrograde IC injection and 15,000 U/Kg weight for systemic IV injection. 
LVEF, evaluated at 24 hours after reperfusion, was largely improved by 
retrograde IC injection of SOD (71.3±1.7%), compared to systemic IV injection 
of SOD (60.8±2.3%), retrograde IC injection of PBS (52.4±2.3%) and systemic 
IV injection of PBS (54.7±2.9%). The functional improvement following 
retrograde IC injection of SOD was associated with a reduction in infarct size 
(figure 1.2), increased regional myocardial blood flow and reduction of the 
inflammatory response.  
 
These therapeutic benefits observed following retrograde IC injection of SOD 
were considered to result from the specific property of the retrograde IC route; 
pre-treatment by efficient incubation with the SOD for the ischaemic myocardium 
before reperfusion.   
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Figure 1.2: Infarct size after SOD-treatment for myocardial ischaemia-reperfusion 
injury. Either SOD or PBS was administered via either the systemic IV or retrograde IC 
route just before reperfusion following 30 minutes myocardial ischaemia by LCA ligation 
in rat. The infarct area and the area at risk of infarction at 24 hours after reperfusion were 
evaluated with Evans blue and triphenyltetrazolium chloride (TTC) staining. The area not 
stained with Evans blue was defined as the area at risk of infarction. TTC staining 
separated the infarct area (non-stained white area) from the viable area (red-stained 
area). Retrograde IC injection of SOD (the R-SOD group) showed the smallest size of 
infarct among all the groups, which was calculated as the percentage to the area at risk 
of infarction. In contrast, systemic IV injection of SOD did not show significant difference 
compared to systemic IV injection of PBS. V-PBS; systemic intravenous injection of PBS, 
R-PBS; retrograde IC injection of PBS, V-SOD; systemic intravenous injection of SOD 
(15,000 U/Kg weight), R-SOD; retrograde IC injection of SOD (1,500 U/Kg weight).  n=6 
in each group. *p<0.01 vs. the V-PBS group, the R-PBS group and the V-PBS group.  
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1.8.2.3 Adhesion molecule-induced acute inflammation 
Systemic IV administration of antibodies against adhesion molecules has been 
shown to be a promising treatment for ischaemia-reperfusion myocardial injury in 
experimental studies (Ma et al., 1992; Weyrich et al., 1993; Yamazaki et al., 
1993; Hartman et al., 1995; Lefer et al., 1996). However, clinical trials failed to 
show significant therapeutic benefits of this treatment following recanalisation for 
acute MI (Baran et al., 2001; Rusnak et al., 2001; Faxon et al., 2002). 
 
My laboratory reported that retrograde IC route was an effective route for 
administration of antibodies against P-selectin and ICAM-1 to treat ischaemia-
reperfusion myocardial injury (Fukushima et al., 2006b). In this study, either 
monoclonal anti-P-selectin antibody (150 µg/Kg weight), monoclonal anti-ICAM-
1 antibody (200 µg/Kg weight), both antibodies or control IgG were administered 
via the retrograde IC route just before reperfusion following 30 minutes 
myocardial ischaemia by LCA ligation in rat. At 24 hours after reperfusion, co-
inhibition of both molecules showed a greater improvement in LVEF (68.4±2.0%) 
than inhibition of P-selectin (60.1±2.2%) and inhibition of ICAM-1 (65.1±1.3%), 
which showed a significant LVEF improvement compared to the control 
(52.3±2.0%). The functional improvement following inhibition of P-selectin 
and/or ICAM-1 was associated with reduction of infarct size, increased regional 
myocardial blood flow and reduction in accumulation of polymorphonuclear 
leukocytes (PMNL) (figure 1.3).  
 
As the retrograde IC route has a direct access to the post-capillary venules where 
the target antigens are upregulated, the antibodies injected via the retrograde IC 
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route were efficiently delivered to this specific region, and consequently produce 
the marked therapeutic benefits. 
 
 
 
 
 
 
Figure 1.3: PMNL infiltration into ischaemia-reperfused myocardium after antibody 
therapy. Either anti-P-selectin antibody, anti-ICAM-1 antibody, both antibodies or control 
IgG was administered via the retrograde IC route just before reperfusion following 30 
minutes ischaemia by LCA ligation in rat. At 24 hours after reperfusion, myocardial 
damage and PMNL infiltration, which were typically seen after the control IgG injection, 
appeared to be attenuated by antibody administration, most clearly following 
administration of both antibodies. The number of PMNL infiltrating into the area at risk of 
infarction was significantly less after administration of both antibodies than single 
antibody administration, which also showed significantly less accumulation of PMNL 
compared to the control IgG injection. Control; control IgG injection, P-selectin; injection 
of monoclonal antibody for P-selectin, ICAM-1; injection of monoclonal antibody for 
ICAM-1, Co-inhibition; injection of both antibodies. Scale bar = 100 µm. n=5 in each 
group. *p<0.05 vs. the Control group, †p=0.024 vs. the P-selectin group, ‡p=0.021 vs. the 
ICAM-1 group. 
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1.9 Experimental models to study cell therapy for HF 
 
Previous experimental and clinical studies have suggested the necessity of further 
experiments in order to optimise cell therapy for treating post-MI chronic HF 
(enhancing the therapeutic effects and reducing arrhythmogenicity). Firstly, the 
degree and durability of the therapeutic benefits and the incidence of ventricular 
arrhythmias following injection of either SMB or BMC have to be clarified. 
Secondly, the optimal cell-type and cell-delivery route should be determined. 
Finally, underlying mechanisms need to be identified. For comprehensively 
clarifying these issues, a rodent model mimicking clinical settings is thought to be 
most suitable, as a large number of samples will be required. 
 
1.9.1 Post-MI chronic HF model 
 
Experimental HF model in small animals has been generated by a variety of 
methods, such as LCA ligation, cryo-injury (Murry et al., 1996), doxorubicin 
administration (Siveski-Iliskovic et al., 1995), autoimmune myocarditis (Taylor et 
al., 2004) and rapid-pacing (Hata et al., 2006). Among them, the most common 
method to generate post-MI chronic HF model is currently to occlude coronary 
arteries (DeFelice et al., 1989; Litwin et al., 1994).  
 
Permanent ligation of LCA through thoracotomy in small animals has been shown 
to consistently deteriorate both systolic and diastolic cardiac functions and induce 
progressive LV cavity dilatation. These physiological changes are associated with 
pathological hypertrophy of the surviving myocardium (Litwin et al., 1994). All 
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of these changes in the heart following LCA ligation are seen in clinical settings 
of post-MI chronic HF. Small animal models of post-MI chronic HF generated by 
LCA ligation has been used for investigations, pathogenesis (Anversa et al., 1986; 
Pfeffer, 1991; Yue et al., 1998) and treatments (Freed et al., 2005) of post-MI HF.  
 
1.9.2 Cell injection models 
 
A variety of cell injection model have been reported in small animals, using 
different routes of cell-delivery, different cell number injected and different 
protocols for donor cell preparation. 
 
1.9.2.1 Models of direct IM cell injection 
Direct IM cell injection from the epicardial approach is a common method for 
cell-delivery into the heart in clinical and experimental studies. However, the 
injection site, the number of injection site or the number of donor cells injected in 
each site have not been optimised in either clinical or experimental studies. Most 
of the studies injected cells into the peri-infarct myocardium, where the injected 
cells are more likely to survive and communicate with native cardiomyocytes than 
infarct myocardium (Ghostine et al., 2002; Suzuki et al., 2004a). Therefore, either 
SMB or BMC were injected into two sites of the peri-infarct rat myocardium in 
the work presented in this thesis. 
 
1.9.2.2 Models of antegrade IC cell injection 
Antegrade IC cell injection is a promising cell-delivery method for cell therapy 
treating HF. Experimental models of antegrade IC cell injection have been carried 
out by a catheter approach in large animals (Hou et al., 2005; Thompson et al., 
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2005). However, there is no reproducible model in antegrade IC cell injection into 
the heart of rodents. While Qian et al injected cultured bone marrow-derived cells 
into the coronary arteries of rat by temporary occlusion of the ascending aorta 
during cell-injection into the LV cavity (Qian et al., 2007), it is unlikely that this 
method enables to consistently deliver donor cells into the coronary circulation. 
Therefore, antegrade IC route could not be studied in this thesis. 
 
1.9.2.3 Models of retrograde IC cell injection 
My laboratory has recently established a reproducible model of retrograde IC cell 
injection in rat, which has been shown to consistently deliver donor cells into 
LVFW (Suzuki et al., 2004d; Suzuki et al., 2004c). In addition, retrograde IC cell 
injection was successfully carried out via percutaneous catheter approach in large 
animals (Hou et al., 2005). As retrograde IC cell injection is technically unable to 
be performed in mouse due to small size of the heart, the work in this thesis used a 
rat model.  
 
1.9.2.4 Cell number injected 
The cell number injected into the post-MI failing heart was widely various in 
experimental and clinical settings. It has been suggested that a larger cell-number 
injected produces greater therapeutic benefits in both SMB (Pouzet et al., 2001) 
and BMC (Iwasaki et al., 2006). As the most common cell-number injected in rat 
is 1-5×106 in SMB (Ghostine et al., 2002; Suzuki et al., 2001a) and 1-10×106 in 
mononuclear BMC (Memon et al., 2005b; Muller-Ehmsen et al., 2006), either 
5×106 of SMB or 10×106 of mononuclear BMC injected into the rat heart in the 
work presented in this thesis. 
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1.9.2.5 Preparation method of primary SMB for cell therapy for HF 
Quality of SMB is reported to be an important factor to determine the therapeutic 
effects and arrhythmogenicity following cell therapy (Hutcheson et al., 2000). The 
cells obtained from mince of muscle were reported to include 20-30% of CD56, 
skeletal myoblast marker, negative cells (Vazquez et al., 2005), which are less 
likely to improve cardiac function of damaged heart than pure SMB (Hutcheson et 
al., 2000). With this traditional method for SMB isolation, the myogenic cells are 
usually inundated by such nonmyogenic cells and thus additional procedures are 
needed to enrich the myogenic cell fraction, such as preplating (Rando and Blau, 
1994), differential centrifugation (Allen et al., 1991) or sedimentation in a Percoll 
density gradient (Feldman and Stockdale, 1991). However, these procedures only 
marginally increase purity, often at the expense of a substantial loss of myogenic 
cells.   
 
In contrast, single fibre method, which was established in a rodent model, has 
been shown to provide virtually 100% pure primary SMB, that are able to be 
maintained in an undifferentiated state with keeping myogenic ability for 2 weeks 
(Rosenblatt et al., 1995). While there is a concern that repeated passaging of 
primary SMB in vitro might cause possible detrimental effects on important 
cellular properties such as fusion or differentiation (Rosenblatt et al., 1995), SMB 
obtained from the single fibre method have been successfully passaged and grown 
in vitro to obtain a sufficient number of cells for injection into the heart (Suzuki et 
al., 2001a). Therefore, the single fibre method was used for preparation of SMB in 
the work of this thesis. 
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1.9.2.6 Preparation of mononuclear BMC for cell therapy for HF 
Isolation of mononuclear BMC has been consistently carried out using a gradient 
centrifugation in both experimental (Kamihata et al., 2001) and clinical 
(Schachinger et al., 2006) studies. Therefore, the gradient centrifugation was used 
for preparation of mononuclear BMC in the work described in this thesis. 
 
1.9.3 Evaluation of outcomes of cell therapy for HF 
 
1.9.3.1 Cardiac function and dimensions 
One of the primary end points of cell therapy for treating HF is improvement of 
cardiac function in most of the clinical studies (Murry et al., 2006). Cardiac 
function of rat is assessed by echocardiography (Suzuki et al., 2004c) or 
intraventricular pressure measurement by catheter in vivo (Tambara et al., 2003) 
or ex vivo (Ogino et al., 1996). While magnetic resonance imaging (MRI) and 
positron emission tomography (PET) are also useful tools to evaluate cardiac 
function and dimension of rat (Higuchi et al., 2007), these highly-specialised 
equipments can be used in limited laboratories. As echocardiography enables a 
sufficient range of measurements of cardiac parameters to evaluate the effects of 
cell therapy treating HF in rodent (Murtuza et al., 2004), the work of thesis used 
echocardiography to assess cardiac function and dimensions.  
 
In echocardiography, LVEF can be measured as a systolic cardiac function by 
both 2-dimensional tracing and M-mode. As M-mode would provide less accurate 
measurements of LVEF due to asymmetrical movement of LV wall following MI, 
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compared to 2-dimensional tracing (Cury et al., 2005), LVEF was assessed by 2-
dimensional tracing in the work reported in this thesis. 
 
1.9.3.2 Physical activity 
Symptoms and quality of life are also important end points of cell therapy for HF. 
Most of the clinical studies of cell therapy have assessed symptoms, physical 
activity and quality of life by using Canadian Cardiovascular Society (CCS) class 
or NHYA functional class (Jolicoeur et al., 2007). Although no experimental 
study has assessed this aspect following cell therapy to date, the work in this 
thesis used a telemetry system to serially evaluate physical activity of rat 
following cell therapy for post-MI chronic HF (Howarth et al., 2006). 
 
1.9.3.3 Spontaneous occurrence of arrhythmia 
Spontaneous occurrence of arrhythmias, which is a major complication of cell 
therapy for HF, can also be assessed in rat using the telemetry system, which 
enables continuous monitoring of ECG in the absence of anaesthesia (Fernandes 
et al., 2006). The work in this thesis continuously monitored ECG and assessed 
spontaneous occurrence of arrhythmias following cell therapy using the telemetry. 
 
1.9.3.4 Evaluation of latent arrhythmogenicity 
Latent arrhythmogenicity has been assessed by several methods in a rat model, 
including isoproterenol administration (MacDonnell et al., 2005) and programmed 
electrical stimulation (PES) (Fernandes et al., 2006). As latent arrhythmogenicity 
is also a possible important complication of cell therapy for post-MI chronic HF, 
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the work in this thesis induced arrhythmias by administrating isoproterenol into 
the heart following cell therapy under isolated heart perfusion. 
 
1.9.4 Methods to track donor-derived cells in the native myocardium 
 
Donor cell identification is essential in cell therapy research to investigate the 
fundamental behaviour of grafted cells in the native myocardium. Several cell-
tracking systems have been used for this purpose to date. 
 
1.9.4.1 Green fluorescent protein (GFP) 
Among all the cell-tracking methods, the use of genetically modified green 
fluorescent protein (GFP)-expressing donor cells have been most common. As 
GFP is stably expressed, donor cells are able to be identified reproducibly in the 
wild-type myocardium by their GFP-expression (Orlic et al., 2001). As in vitro 
viral transfection of GFP prior to injection into the heart is reported to impair 
cellular properties (Agbulut et al., 2007), the use of GFP-expressing cells derived 
from GFP-transgenic animals was considered to be a suitable cell-tracking method 
for the work in this thesis. 
 
However, there were issues to be addressed before using SMB or BMC derived 
from GFP-transgenic rat in the main work in this thesis. Firstly, it was unclear that 
donor cells derived from GFP-transgenic rat have the same properties as those 
from wild-type rat. Secondly, visualisation methods of the grafted cells derived 
from GFP-transgenic rat in the wild-type rat myocardium have not been 
established. Endogenous GFP expression only was reported to be insufficient due 
to the weak GFP signal-strength (Mothe et al., 2005). Therefore, both SMB and 
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BMC derived from GFP-transgenic rat were characterised in vitro and 
immunolabelling for GFP to amplify the endogenous GFP signal was tested to 
visualise GFP-expressing cells in the wild-type myocardium before the main work 
in this thesis.  
 
1.9.4.2 β-galactocidase 
Donor cells expressing β-galactocidase have also been frequently used for the 
cell-tracking method (Suzuki et al., 2000a; Murtuza et al., 2004). Donor cells 
expressing β-galactocidase are able to be identified by β-galactocidase staining. In 
addition, this method enables quantitative assessment of donor cells by measuring 
β-galactocidase activity (Suzuki et al., 2000a).  
 
1.9.4.3 Y-chromosome 
Identification of male cells in the female heart is achieved by polymerase chain 
reactions (PCR) or in-situ hybridisation for Y-chromosome specific gene (Muller-
Ehmsen et al., 2002; Murtuza et al., 2004; Quaini et al., 2002). While there is a 
concern of accuracy in quantitative analysis by conventional PCR or in-situ 
hybridisation, real-time PCR for Y-chromosome specific gene, Sry, has been 
shown to be a reliable, reproducible method to quantitatively assess the presence 
of male donor-derived cells in the female myocardium (Muller-Ehmsen et al., 
2002; Hayashi et al., 2004; Yasuda et al., 2005).  
 
1.9.4.4 Radio-labelling 
Radiolabelling of donor cells with [methyl-14C]thymidine prior to injection into 
the heart is used to assess the surviving, but not proliferating, donor cell number 
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(Beauchamp et al., 1999a; Suzuki et al., 2004b; Hou et al., 2005). The distribution 
of the injected radio-labelled cells in the living animal or human could be assessed 
by using PET (Oku et al., 1994).  
 
1.9.4.5 Magnetic-labelling 
Magnetic-labelling of donor cells with iron oxide nanoparticles prior to injection 
into the heart is also reported to enable to assess the distribution of the injected 
cells in the living animal or human by using MRI, which provides a more spatial 
resolution than PET (Riviere et al., 2005). However, there is a concern about the 
toxicity of iron oxide nanoparticles, efficiency in magnetic-labelling and 
sensitivity in detecting the labelled cells (Riviere et al., 2005).  
 
1.9.4.6 Dye-labelling 
Labelling donor cells with dye, such as BrdU, 4’,6-diamidino-2-phehylindone 
(DAPI) or PKH26, prior to injection has been used to identify the grafted cells in 
histological studies. However, the cells labelled by this method may provide 
insufficient signal strength, compared to the cells expressing GFP particularly in  
a long-term study (Fukuhara et al., 2002). In addition, there is a risk that the dye 
released from the dead donor cells could be taken up by the adjacent surviving 
native cells and consequently lead to false positives.  
 
1.9.4.7 Use of dual cell-tracking markers in this work 
The use of GFP-expressing donor cells derived from GFP-transgenic rat is 
thought to be most reliable to visualise the donor cells in the myocardium in both 
histological and living-cell analysis. In addition, the use of the male cells which 
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are injected into the female heart appears to be most reliable to quantitatively 
assess the presence of donor-derived cells in the native myocardium. Therefore, 
dual cell-tracking markers, GFP and Y-chromosome, were used for identification 
of donor-derived cells in the native myocardium in the work of this thesis. 
 
1.9.5 Possible immune response 
 
The main work in this thesis was determined to use the model, in which either 
male SMB or BMC derived from GFP-transgenic rat were injected into the female 
post-MI chronically failing rat heart. As GFP-transgenic inbred rat has not been 
established, GFP-transgenic Sprague Dawley (SD) rat was used.  
 
A possible limitation in this model included immune response against allogenicity, 
Y-chromosome or GFP. SD rat is not an inbred strain in a strict definition, but is 
very close to inbred. Actually, it has been successfully used for an organ or cell 
transplantation model for heart disease (Suzuki et al., 1997; Miyahara et al., 2006). 
These reports have described little immune response-related inflammation, 
vasculopathy or organ dysfunction. In addition, GFP-transgenic animals have 
been frequently used for a variety of cell therapy models (Orlic et al., 2001), 
which did not show any evidence of host-immune response against the GFP. 
Moreover, gender mismatched-cell therapy or organ transplantation has been 
carried out with few findings of the immune rejection (Muller-Ehmsen et al., 
2002; Orofino et al., 2006).  
 
All these data strongly suggest that the experimental model in which donor cells 
derived from male GFP-transgenic SD rats are injected into female wild-type SD 
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rats is highly unlikely to induce considerable immune response. However, a set of 
experiments was carried out before the main work, in order to firmly exclude the 
host-immune response, which could affect the behaviour of grafted cells and 
resulting therapeutic outcomes. 
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1.10 Hypotheses and aims of this work 
 
Cell therapy using either SMB or BMC is a promising strategy for treating post-
MI chronic HF. However, the therapeutic efficacy has not been fully established. 
In addition, occurrence of ventricular arrhythmia is a concern of this treatment.  
 
This study aims to optimise cell therapy by investigating the therapeutic benefits, 
arrhythmogenicity and underlying mechanisms following cell therapy for post-MI 
chronic HF, in comparison between the cell-types and between the cell-delivery 
routes using a reliable experimental model. The specific goals were to; 
1) establish a rat model of cell therapy treating post-MI chronic HF. 
2) determine the therapeutic efficacy following cell therapy for post-MI chronic 
HF and clarify the underlying mechanisms, in comparison between the direct 
IM and retrograde IC routes. 
3) define arrhythmogenicity following cell therapy for post-MI chronic HF and 
clarify the underlying mechanisms, in comparison between the direct IM and 
retrograde IC routes. 
4) clarify the efficiency and mechanism of engraftment of mononuclear BMC 
into the myocardium following IC injection. 
 
The hypotheses of this work included: 
1) Either SMB or BMC injection into the heart improves cardiac function of 
post-MI chronically failing heart via either differentiation into cardiomyocytes 
and/or vascular cells or paracrine effects on the native myocardium. 
2) Either SMB or BMC injection into the heart lead to occurrence of ventricular 
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arrhythmia. 
3) Cell-delivery route affects the fundamental behaviour of the grafted cells, 
including survival, distribution, differentiation and intercellular connection 
with the native cardiomyocytes, and resulting therapeutic benefits and 
arrhythmogenicity. 
4) BMC injected from the coronary arteries are engrafted in the myocardium via 
adhesion molecule-mediated cellular interactions with the endothelium. 
 
The outline of the work described in this thesis is as follows. 
 
Establishing experimental model of cell therapy for chronic HF (Chapter 3) 
Experimental model of cell therapy for ischaemic chronic HF was designed to use 
male GFP-transgenic SD rats as donor cell supply and female wild-type SD rats as 
recipient. In order to verify the suitability of this model, several experiments were 
carried out prior to the main work, as follows. Firstly, the post-MI chronic HF 
model generated by LCA ligation in female SD rats was examined in terms of 
cardiac parameters, physical activity, ECG, collagen deposition and capillary 
density. Secondly, SMB and mononuclear BMC derived from male GFP-
transgenic rats were characterised. Thirdly, methods to identify donor cells in the 
myocardium, such as real-time PCR for Y-chromosome specific gene, Sry, and 
immunolabelling for GFP, were established. Finally, a possible host immune 
response in this model was investigated. 
 
Therapeutic efficacy of cell therapy and underlying mechanisms (Chapter 4) 
Using the experimental model established in the work above, therapeutic efficacy 
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and underlying mechanisms following cell therapy were investigated. Changes in 
cardiac parameters and physical activity were serially examined in comparison 
between the direct IM and retrograde IC injections of either SMB or mononuclear 
BMC. In addition, survival/distribution/phenotypical fate of the grafted cells and 
changes in collagen contents/capillary density in the myocardium were assessed to 
explore the mechanisms of the therapeutic benefits of cell therapy.  
 
Arrhythmogenicity following cell therapy (Chapter 5) 
In order to clarify arrhythmogenicity following cell therapy, the occurrence of 
spontaneous and induced arrhythmias was assessed in comparison between direct 
IM and retrograde IC injections of either SMB or BMC. In addition, heterogeneity 
and inflammatory response in the myocardium, intercellular connections between 
the grafted cells and native cardiomyocytes and distribution of Cx43-gap 
junctions in the native myocardium were investigated as possible mechanisms of 
arrhythmogenicity. 
 
Engraftment of mononuclear BMC following IC injection (Chapter 6) 
The work described in Chapter 4 and 5 suggested that cell-engraftment (adherence 
and subsequent trans-endothelial migration) might be a limiting factor for graft 
survival following IC cell injection. In order to explore a strategy to improve cell-
engraftment following IC cell injection, the efficiency and mechanisms of the 
engraftment of mononuclear BMC were investigated using an experimental model, 
in which mononuclear BMC derived from GFP-transgenic mouse were injected 
into the coronary arteries under isolated perfusion of the wild-type mouse heart. 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1 Animal species and strains 
 
All studies using animals were performed with the approval of the institutional 
ethics committee for animal research at The Harefield Heart Science Centre and 
the Home Office in accordance with the Animals (Scientific Procedures) Act 1986 
(PIL 70/18397 and PPL 70/5313, 70/6441).  
 
2.1.1 Sprague Dawley (SD)  rats 
 
SD rats (Hsd:Sprague Dawley®™SD®™; Harlan UK), originally derived from 
Wistar stock, were used as a recipient animal. Despite being an outbred strain, 
they have been used for models of organ transplantation including heart 
transplantation and cell therapy for heart disease (Suzuki et al., 1997; Miyahara et 
al., 2006). In addition, they have been shown to consistently develop ischaemic 
HF after coronary artery ligation (DeFelice et al., 1989). 
 
2.1.2 GFP-transgenic SD rats  
 
GFP-transgenic SD rats (SD-Tg [GFP] Bal; Rat Research & Resource Center, US) 
were used for the supply of donor cells. They were generated using lentiviral-
based vectors engineered to carry the cytomegalovirus (CMV) enhancer and 
human ubiquitin-C promoter driving GFP expression (Lois et al., 2002). They 
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have been shown to express GFP in spinal cord, retina, cortex, cerebellum, 
brainstem, kidney, testis, lung, spleen and neural stem cells, while there were 
variations within GFP fluorescence intensity in the same tissue derived from 
different animals (Mothe et al., 2005). As homozygous GFP-transgenic SD rat has 
not been established, heterozygous rats were used in the work in this thesis. 
 
2.1.3 Nude rats 
 
Athymic T lymphocyte deficient rats (Hsd:RH-Foxn1rnu) (Hougen, 1991) were 
purchased from Harlan UK and used as a recipient to investigate immune 
response after allogeneic cell therapy by comparing with SD rats. 
 
2.1.4 C57BL/6J mice 
 
C57BL/6J mice (C57BL/6NHsd; Harlan UK), which is the most widely used 
inbred mouse strain, were used as a recipient to study transendothelial migration 
of BMC following antegrade IC injection. 
 
2.1.5 GFP-transgenic C57BL/6J mice  
 
Homozygous GFP-transgenic C57BL/6J mice (C57BL/6-Tg[UBC-GFP]30Scha/J; 
Jackson Laboratories) were used for the supply of donor cells. They express GFP 
under the human ubiquitin C promoter. These mice have been shown to express 
GFP in all tissues examined, with high levels of GFP expression observed in 
haematopoietic cells (Schaefer et al., 2001). 
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2.2 Genotyping of GFP-transgenic SD rats 
 
2.2.1 Isolation and preparation of genomic DNA from tail biopsies 
 
Tail tips of a rat were collected and dipped into 1 mL tail buffer (100 mM 
disodium ethylenediaminetetra-acetic acid [EDTA] pH 7.5, 0.5% sodium dodecyl 
acid [SDS], 0.05 mM Tris-HCl pH 7.5) containing 20 µL of 100 µg proteinase K 
(Sigma; cat# P2308) and allowed to digest overnight with gentle shaking at 50°C. 
Each sample was collected (the tailbone discarded), gently mixed with the half 
volume of saturated NaCl solution and centrifuged at 12,000 g for 20 minutes. 
The top aqueous layer containing genomic deoxyribonucleic acid (DNA) was 
collected, gently mixed with twice the volume of 100% ethanol and centrifuged at 
12,000 g for 1 minute. The supernatant was discarded without disturbing the pellet 
containing DNA. After washing in 70% ethanol twice, DNA was air-dried and 
resuspended in 100 µL of H2O. All DNA samples were stored at - 20°C. 
 
2.2.2 PCR for genotyping 
 
All the GFP-transgenic SD rats were genotyped to identify whether they were 
heterozygous or homozygous at the GFP locus. PCR assays were performed in a 
final volume of 25 µL reaction buffer (1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-
HCl pH8.3, 0.01% gelatine, 300 nM each primer, 200 µM of each dATP, dCTP, 
dGTP, dTTP, 50 ng sample DNA and 0.2 U Taq polymerase [Roche; cat# 
11647679001]) with the PCR conditions as follows; 5 minutes at 94°C, followed 
by 40 cycles of (30 seconds at 94°C, 30 seconds at 58°C, 1 minute 15 seconds at 
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72°C) and 1 cycle of 7 minutes at 72°C. PCR products were then stored at 4°C 
until gel electrophoresis. (See {Chapter 2.7.3} for the primers used.) 
 
2.2.3 Agarose gel electrophoresis and analysis 
 
PCR products from tail biopsies were sized by gel electrophoresis using 1% 
agarose (VWR; cat# 443663U) gels and 1 Kb DNA Ladder (Invitrogen; cat# 
15615-016). Gels, which contained 1 µg/mL ethidium bromide (Sigma; cat# 
E8751), were run in TAE buffer (40 mM Tris-acetate, 1 mM disodium EDTA 
pH8.0) at 200 volts (BioRad). Samples were mixed with 1/6th final volume 
loading buffer (0.25 mg/mL Orange G [Sigma; cat# O3756] in 30% [v/v] 
glycerol) and were visualised on an ultraviolet (UV) transilluminator 
(CHEMIGENIUS2, Syngene), and recorded using an appropriate software 
(GeneSnap, Syngene).  
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2.3 Donor cell isolation, culture and characterisation 
 
2.3.1 Single fibre method for isolating primary skeletal myoblasts 
 
Primary SMB were isolated from male GFP-transgenic SD rats (200-250g) by the 
single fibre method, which provides pure SMB (Rosenblatt et al., 1995; Suzuki et 
al., 2001a). After cervical dislocation, the extensor digitorum longus (EDL) was 
completely removed from tendon to tendon and digested with 5 mL 0.2% type I 
collagenase (Sigma; cat# C0130) in Dulbecco’s Modified Eagle Media (DMEM, 
Invitrogen; cat# 41966) in a shaking water bath at 35°C for 60 minutes.  
 
The digested muscle was then transferred to a horse serum (HS, Invitrogen; cat# 
26050)-coated 35 mm Petri dish (VWR; cat# 391-0865) containing 8 mL DMEM 
at 37°C, where single muscle fibres were liberated by gentle tituration using heat-
polished Pasteur pipettes. The individual, viable, intact muscle fibres were placed 
onto a 1% Martrigel (Marathon Laboratory Supplies; cat# 354234)-coated culture 
plate containing 10% v/v HS and 0.5% v/v chick embryo extract (CEE, Sera 
Laboratories International; cat# CE-650-T) in DMEM with 100 IU/mL penicillin 
and 100 µg/mL streptomycin (Sigma; cat# P0781) at 37°C, where primary SMB 
dissociated and migrated within 24 hours (figure 2.1). 
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Figure 2.1: Single fibre method for isolating SMB. (A) Observation by phase contrast 
microscopy. (B) Observation by fluorescence microscopy. Single fibre (arrow) was 
isolated by enzymatic digestion from EDL of GFP-transgenic SD rat. Primary SMB (arrow 
heads) were dissociated and migrated form the single fibre. Scale bar = 100 µm. 
 
 
 
 
 
2.3.2 Culture of skeletal myoblasts and characterisation 
 
The myofibres were removed at 24 hours after plating. Dissociated and migrated 
SMB were placed in proliferation medium containing 20% v/v foetal bovine 
serum (FBS, Invitrogen; cat# 10500), 10% v/v HS and 0.5% v/v CEE in DMEM 
with 100 IU/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine (Sigma; 
cat# G7513) and 5 ng/mL recombinant human basic FGF (Invitrogen; cat# 
PHG0021). The SMB were passaged every 2 days using 0.25% w/v trypsin in 
EDTA (Sigma; cat# T3924) before reaching 50% confluence to maintain an 
undifferentiated state. The cell number was counted under haemacytometer 
(Improved Neubauer type, VWR; cat# 720-0585) on each passage. 
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GFP expression of the SMB derived from GFP-transgenic rats was assessed by 
fluorescence microscopy (TS100F, Nikon) and flow-cytometry (FACSaria, BD 
Biosciences). Proliferation of the SMB derived from GFP-transgenic rats was 
quantitatively evaluated by calculating doubling time using the formula. 
 
Doubling time between 1st and 2nd passage (hour) = 48 [hour] × 
Log(2) / Log(total cell number at 2nd passage / total cell number at 1st passage) 
 
The myogenic differentiation of the SMB was confirmed by culturing with low-
serum medium (2% HS in DMEM with 100 IU/mL penicillin, 100 µg/mL 
streptomycin) at a sub-confluent state (Suzuki et al., 2001a).  
 
2.3.3 Isolation of mononuclear BMC and characterisation 
 
Mononuclear BMC were isolated from male GFP-transgenic SD rats (200-250 g) 
and male GFP-transgenic C57BL/6J mice (15-20 g). After cervical dislocation, 
whole BMC were collected from both the femurs and tibias, suspended in Hank’s 
balanced salt solution (HBSS, Sigma; cat# H4385) with 10% v/v FBS and 100 
IU/mL penicillin, 100 µg/mL streptomycin at 4°C. After 5 minutes incubation 
with red blood cell lysis buffer (Sigma; cat# R7757) at 20°C, cell suspensions 
were loaded on discontinuous PercollTM gradient (55% and 70%, GE Healthcare; 
cat# 17-0891) and centrifuged at 1,600 g for 30 minutes (Kamihata et al., 2001). 
The interlayer containing mononuclear BMC was collected, diluted with 10× 
volume of HBSS with 10% FBS and centrifuged at 300 g for 5 minutes. Cell 
suspensions were washed twice with HBSS with 10% FBS and resuspended in 
HBSS with 10% FBS and 1% penicillin/streptomycin on ice until required. GFP 
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expression of the mononuclear BMC derived from GFP-transgenic rats and mice 
was assessed by fluorescence microscopy and flow-cytometry.  
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2.4  Surgical procedures 
 
2.4.1 Surgical anaesthesia and mechanical ventilation 
 
SD rats were endotracheally intubated with blunt 16 gauge catheter (3S 
Healthcare; cat# BT381157) through the mouth under inhalation of 5% isoflurane 
(IsobaTM, Schering-Plough Animal Health) via nose cone (Harvard Apparatus). 
They were then mechanically ventilated at a rate of 0.25 breaths/minute/g weight 
and a tidal volume of 15 µL/g weight using a small animal, volume-controlled 
ventilator (Model 683, Harvard Apparatus). Anaesthesia was maintained during 
the mechanical ventilation by 1.5% isoflurane inhalation. 
 
2.4.2 Generation of a rat ischaemic chronic HF model 
 
All the surgical procedures were carried out in a sterilised condition. Female wild-
type SD rats (150-200 g) underwent left thoracotomy at the 5th intercostal space 
under volume-controlled mechanical ventilation. Pericardium was incised to 
visualise the LCA, which was permanently occluded with a 6-0 polypropylene 
suture with a 8 mm curved-needle (BearMedic, Japan; cat# WVT8F06N) at the 
level of the bottom edge of the left atrial (LA) appendage (Liu et al., 1997). 
Myocardial ischaemia was confirmed by colour change and dyskinesis of the 
anterolateral LVFW (figure 2.2). The chest wall was closed by a continuous 
suture using a 4-0 polypropylene suture (BearMedic; cat# SVT17F04N) after 
removal of the air from the left thoracic cavity. Subsequently, the skin was closed 
with a continuous suture using a 3-0 silk suture (BearMedic; cat# SVT17V03H-
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75). The ventilation was then continued without isoflurane until the rats recover 
consciousness. After extubation, the rats were returned to cages in a temperature, 
humidity and light-controlled animal holding room.  
 
Body temperature was controlled between 35 to 38°C during the procedure, using 
a thermometer and heating pad (Harvard Apparatus). Buprenorphine (20 µg/Kg 
weight, Vetergesic, Alstoe Animal Health) was given subcutaneously every day 
until 7 days after the procedure. 
 
 
 
 
 
 
 
Figure 2.2: LCA ligation in rat. LCA of SD rat was permanently occluded by 6-0 
polypropylene suture at the bottom level of LA through left thoracotomy under mechanical 
ventilation with 1.5% isoflurane inhalation. Occlusion of LCA was confirmed by colour 
change and dyskinesis of antero-lateral LVFW. 
 
 
103 
2.4.3 Direct IM cell injection into a rat ischaemic chronic HF model 
 
Direct IM cell injection was carried out for SD rats at 21 days after LCA ligation. 
Following endotracheal intubation, the left thoracic space was re-opened by 
incising the 6th intercostal space under 1.5% isoflurane inhalation and volume-
controlled mechanical ventilation. Adhesion around the heart was carefully 
dissected without damaging the heart, left phrenic nerve or lung to expose the 
post-MI heart. 
 
Total volume of 100 µL of appropriate solution (cells suspended with PBS or PBS 
only) at 37°C was injected using a 30 gauge needle syringe (3S Healthcare; cat# 
B3320935) into 2 sites of the peri-infarct myocardium (figure 2.3) (Suzuki et al., 
2004a; Suzuki et al., 2004b). Visual leakage from the injection site was not seen. 
The rats were returned to cages for recovery after closing the chest wall with a 4-0 
polypropylene continuous suture and the skin with a 3-0 silk continuous suture 
followed by extubation. Buprenorphine (15 µg/Kg weight, Vetergesic, Alstoe 
Animal Health) was given subcutaneously every day until 7 days after the 
procedure. 
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Figure 2.3: Direct IM injection into the post-MI heart. Figures show direct IM cell 
injection into the post-MI chronically failing heart (A) and its schema (B). Donor cells 
suspended in 100 µL of PBS were injected directly into 2 sites (black arrows) at the peri-
infarct area (black dot lines), anterolateral and inferoposterior LV walls through left 
thoracotomy using 30 gauge needle-syringe. 
 
 
 
 
2.4.4 Retrograde IC injection into a rat ischaemic chronic HF model 
 
Exposure of the post-MI heart for retrograde IC injection was carried out in the 
same manner as that for direct IM injection. Then, heparin (100 IU/Kg weight, 
Sigma; cat# H-3393) suspended with 500 µL of PBS was systemically infused 
using a 30 gauge syringe needle through a purse string suture placed on the left 
superior vena cava (LSVC) using a 7-0 polypropylene suture (BearMedic; cat# 
WVT8F07N). A 6-0 polypropylene suture was then placed on the stem of left 
cardiac vein (LCV) for snaring the vein during the injection.  
 
Subsequently, a 24 gauge catheter (3S Healthcare; cat# BT381212) was inserted 
into the LCV through the purse string suture placed on the LSVC (figure 2.4). The 
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stem of the LCV was snared to prevent flush out of the injected solution into the 
coronary sinus using the suture placed on the stem of LCV. Through the catheter, 
total volume of 500 µL of the appropriate solution (cells suspended with PBS or 
PBS only) was gently injected over a period of 15 seconds. Then, the catheter was 
removed. The snare was released at 15 seconds after the end of injection. The 
suture for the snare was removed and the purse string suture was tied to prevent 
the bleeding from the catheter-injection site. Closure of chest and skin, extubation, 
analgesia and recovery were carried out in the same manner as that for the direct 
IM injection.  
 
 
 
 
 
Figure 2.4: Retrograde IC injection into the post-MI heart. Figures show retrograde IC 
cell injection into the post-MI chronically failing heart (A) and its schema (B). Donor cells 
suspended in 500 µL of PBS were injected via the catheter inserted into the LCV (white 
arrow) through left thoracotomy over 15 seconds. The stem of LCV was snared using the 
suture placed on it during retrograde IC injection. The suture was released in 15 seconds 
after the end of injection. 
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2.5  Physiological evaluations 
 
2.5.1 Echocardiography assessing function and structure of the heart 
 
Cardiac function and dimensions of rats were evaluated with percutaneous 
transthoracic echocardiography using 15-MHz probe (Sequoia 512, Acuson) 
under 1.5% isoflurane inhalation via nose cone (Yang et al., 1999). Images for 
LVEF and LV dimensions were taken at mid-papillary level. LVEF was assessed 
with 2-dimensional mode. Diastolic (LVDd) and systolic (LVDs) dimensions of 
LV were measured with M-mode. Heart rate (HR) was also assessed with M-
mode. Transmitral E/A flow ratio was assessed by Doppler traces (Kovacs et al., 
1997). Data was calculated as an average value of 3 measurements for each 
parameter. 
 
2.5.2 Telemetry for monitoring arrhythmia and physical activity 
 
Occurrence of spontaneous arrhythmia (Fernandes et al., 2006) and physical 
activity (Howarth et al., 2006) were quantitatively assessed by continuous 
monitoring of the ECG and signal strength using a telemetry system (Data 
Sciences International, US). Under 1.5% isoflurane inhalation via nose cone, the 
biocompatible transmitter (PhysioTel Implant TA10EA-F20, Data Science 
International) was fixed to the left peritoneal wall using 4-0 polypropylene suture 
through the median laparotomy. The electrodes were fixed in the right shoulder 
and the left axilla using 4-0 silk suture through subcutaneous tunnels. Each rat 
was then returned to the individual cage (42 cm in length, 25 cm in width and 20 
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cm in height) in a temperature, humidity and light-controlled animal holding room. 
ECG and signal strength of the rats were continuously recorded to the computer 
(Data Acquisition, Data Science International).  
 
The ECG waves, such as RR interval, P wave length, PR interval, QRS complex 
duration and QT interval, were analysed by an ECG analysis software (DSI 
Dataquest A.R.T. ™ Analysis, Data Science International). Data for each wave 
and the hourly number of ventricular premature contractions (VPC) were 
calculated as an average of 24-hour recording. Daily occurrence of multiform 
VPC and VT was also counted.  
 
The signal strength, which is changed by physical movement of the rat, was 
monitored at 64 Hz as an indicator of physical activity (Howarth et al., 2006). The 
average of 24 hours recording was calculated using a software (DSI Dataquest 
A.R.T. ™ Analysis, Data Science International). Low counts of change in signal 
strength indicate reduced physical activity. 
 
 
108 
2.6  Isolated heart perfusion 
 
2.6.1 Isolated rat heart perfusion and ECG monitoring 
 
Hearts of wild-type SD rat were excised after IV injection of heparin (100 IU/Kg 
weight) via the left femoral vein using 30 gauge syringe needle under 1.5% 
isoflurane inhalation. A blunt 14 gauge metal cannula (3S Healthcare; cat# 
BT381267) was inserted into the ascending aorta on ice and 4-0 silk suture was 
tied at the aortic root.  
 
The isolated rat heart was then perfused at a constant arterial pressure of 100 cm 
H2O with modified Krebs-Henseleit buffer (144.9 mM Na+, 126.3 mM Cl-, 4.9 
mM K+, 25.0 mM HCO3-, 1.2 mM SO4-, 1.2 mM Mg2+, 1.25 mM Ca2+, 1.2 mM 
PO43- and 10.0 mM glucose; gassed with 95% O2 + 5% CO2 at 37°C) using a 
modified Langendorff apparatus (Suzuki et al., 2000a). Coronary flow was 
assessed by collecting and weighing the effluent every minute during the 
perfusion. Heart temperature was controlled to 37°C using a heating jacket. 
 
Isoproterenol was administered under Langendorff perfusion to induce arrhythmia. 
After 20-minute stabilisation, 1×10-7 M isoproterenol (Sigma; cat# I5627) was 
administered continuously via the perfusate for 10 minutes (MacDonnell et al., 
2005). One electrode was attached to the LVFW, remote from the infarct and the 
other two electrodes were fixed at the aortic cannula. The ECG was then 
continuously monitored using MP35 and Biopac Systems (Linton 
Instrumentation) during the perfusion.  
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2.6.2 Isolated mouse heart perfusion and BMC injection 
 
Hearts of wild-type C57BL/6J mice were excised after IV injection of heparin 
(100 IU/Kg weight) via the inferior vena cava using 30 gauge syringe needle 
through the median laparotomy under 1.5% isoflurane inhalation. A blunt 24 
gauge metal cannula (3S Healthcare; cat# BT381212) was inserted into the 
ascending aorta on ice and 6-0 silk suture was tied at the aortic root.  
 
The isolated heart was then perfused at a constant arterial pressure of 100 cm H2O 
with modified Krebs-Henseleit buffer (120.0 mM NaCl, 4.5 mM KCl, 20.0 mM 
NaHCO3, 1.2 mM KH2PO4, 1.2 mM MgCl2, 1.25 mM CaCl2, and 10.0 mM 
glucose; gassed with 95% O2 plus 5% CO2 at 37°C) using a Langendorff 
apparatus (Xi et al., 1998). Coronary flow was assessed by collecting and 
weighing the effluent every minute during the perfusion. Heart temperature was 
controlled to 37°C using a heating jacket. 
 
Mononuclear BMC were injected via the side port of the aortic cannula (figure 
2.5). The space between the cell-injection site and the aorta of the perfused heart 
was minimised to avoid possible loss of injected BMC before reaching the heart. 
The GFP-positive cell number was counted in the coronary effluent, which was 
collected every 1 minute for a total of 30 minutes after BMC injection, using a 
haemacytometer under fluorescence microscopy. 
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Figure 2.5: BMC injection into coronary arteries under isolated heart perfusion. (A) 
An isolated mouse heart (white arrow) was perfused under Langendorff apparatus. (B) A 
schematic figure shows Langendorff perfusion of isolated mouse heart and injection of 
mononuclear BMC via the aortic cannula under the perfusion. 
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2.7  Materials used for analysis of tissue 
 
2.7.1 Primary antibodies 
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2.7.2 Secondary antibodies 
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2.7.3 PCR oligonucleotides 
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2.8 Analysis of DNA, RNA and protein from heart tissue 
 
For analysis of DNA, ribonucleic acid (RNA) and protein of heart tissues, the 
heart was excised after neck dislocation under 5% isoflurane inhalation at selected 
time-points for each experiment. Both atria and RVFW were removed on ice and 
LV (LVFW and IVS) were snap-frozen and crashed into powder using a pestle 
and mortar under liquid nitrogen, and stored at -80°C until analysis. 
 
2.8.1 Genomic DNA extraction from the heart 
 
Genomic DNA of the LV was extracted from frozen powdered tissue samples (25 
mg each) using a kit (DNeasy Kit, Qiagen; cat# 69504). This kit allows collection 
of DNA using silica-membranes without alcohol precipitation. The concentration 
and purity of DNA samples were determined by measuring the OD at 260 nm in a 
spectrophotometer (UV-1601, Shimadzu). Concentration was calculated by 
correcting for the dilution ratio and by assuming that 50 µg/mL of double-
stranded DNA has an OD260nm = 1. Sample DNAs whose OD260/280 ratio was 1.6 - 
1.8 were used for the assay. Sample DNAs were diluted with TE buffer (10 mM 
Tris-HCl, 1mM disodium EDTA pH8.0) to a concentration of 50 ng/µL and stored 
at -20°C until assays. 
 
2.8.2 Real-time PCR for Sry and Oesteopontin 
 
DNA extracted from female LV, which had been injected with male cells, was 
used for real-time PCR to test for Sry and Oesteopontin. Following quantification 
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of DNA using the spectrophotometer again, fluorescence-based real-time PCR 
assay was carried out (ABI PRISM 7700, Applied Biosystems). The reaction 
solution for PCR assay for each sample included; 2.5 µL 10×PCR buffer, 2.5 µL 
deoxyribonucleoside triphosphates (dNTPs [dATP. dCTP, dCTP, dTTP], 10 mM 
each, Roche), 2.5 µL primer forward (9 µM), 2.5 µL primer reverse (9 µM), 2.5 
µL primer probe (1 µM), 0.5 µL Taq polymerase (Roche), 100 ng sample DNA 
and H2O with a total volume of 25 µL. The PCR cycling conditions were 50°C for 
10 minutes and 95°C for 5 minutes, followed by 40 cycles of 95°C for 15 seconds 
and 60°C for 1 minute. 
 
Data obtained were analysed with the comparative cycle threshold (Ct) method 
using Sequence Detection System 1.7 (Applied Biosystems). Signals obtained by 
PCR assay for the Sry was normalised with those for the autosomal single copy 
gene Oesteopontin. 
 
2.8.3 RNA extraction and purification 
 
Total RNA was extracted from frozen powdered samples using TRIzol reagent 
(Invitrogen; cat# 15596). Samples (80 mg each) to which 1 mL of TRIzol was 
added were homogenised using a tissue homogeniser (Polytron). The homogenate 
was then placed on ice for 5 minutes to permit the complete dissociation of 
nucleoprotein complexes. Chloroform (0.2 mL) was added, mixed thoroughly for 
15 seconds and then allowed to stand on ice for a further 15 minutes. The 
homogenate was then centrifuged at 1,200 g at 4°C for 15 minutes. After 
centrifugation, the aqueous phase containing nucleic acids was carefully 
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transferred to a fresh tube and an equal volume of isopropanol was added. The 
samples were allowed to stand on ice for 10 minutes and then centrifuged at 
12,000 g at 4°C for 10 minutes. The supernatant was carefully removed and the 
RNA pellet washed twice with 1 mL of 75% ethanol, vortexed and centrifuged for 
5 minutes at 7,500 g at 4°C. The pellet was briefly air-dried for 5-10 minutes and 
resuspended in 50-100 µL of diethyl pyrocarbonate (DEPC) treated water 
(Invitrogen; cat# 750024).  
 
Subsequently, total RNA isolated by the TRIzol method was purified (RNeasy kit, 
Qiagen; cat# 74104) and treated with DNase (RNase-Free DNase set, Qiagen 
cat#; 79254) to increase the purity of mRNA. The concentration and purity of 
RNA samples were determined by measuring the OD at 260 nm in the 
spectrophotometer. Concentration was calculated by correcting for the dilution 
ratio and by assuming that 40 µg/mL RNA has an OD260nm = 1. Sample RNAs 
whose OD260/280 ratio was more than 2 were used for the assay. Sample RNAs 
were diluted with RNase free H2O to a concentration of 50 ng/µL and stored at -
80°C until use. 
 
2.8.4 Reverse transcription reaction and real-time PCR 
 
Following quantification of RNA again using spectrophotometer, 100 ng sample 
RNA was used in a reverse transcription reaction with random priming (Applied 
Biosystems; cat# N8080234). Reaction solution for each sample included; 1.0 µL 
10×RT buffer, 2.2 µL MgCl2 (50 mM), 2.0 µL dNTPs (10mM each), 0.5 µL 
Random Hexamers, 0.2 µL, RNase inhibitor, 0.625 µL Multiscribe enzyme, 100 
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ng sample RNA and H2O with a total volume of 10 µL. The cycling conditions 
were 25°C for 10 minutes, 48°C for 30 minutes, and 95°C for 5 minutes. 
Synthesised complimentary DNA (cDNA) was stored at 4°C until the PCR assay. 
 
cDNA (20 µg) was used for real-time PCR. PCR primers and TaqMan probes 
were purchased from Applied Biosystems. Levels of 18S ribosomal RNA were 
simultaneously measured using a preoptimised kit (Applied Biosystems; cat# 
4310893E) to normalise for variations in RNA loading between reactions. 
Reaction solution for each sample included; 10 µL 2×TaqMan universal PCR 
master mix (Applied Biosystems; cat# 4304437), 1.0 µL 20×ROD, 1.0 µL 
20×18S primer, 2.0 µL cDNA (20 µg) and 7.0 µL H2O with a total volume of 20 
µL. The PCR cycling conditions were 50°C for 10 minutes and 95°C for 5 
minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. 
Data obtained were analysed with the Ct method using Sequence Detection 
System 1.7 (Applied Biosystems). 
 
2.8.5 Protein extraction and estimation 
 
Powdered frozen samples (100 mg) were solubilised in SB20 (20% SDS and 0.15 
mol/L Tris, pH 6.8). An aliquot for each sample was used for protein estimation 
and 2-mercaptoethanol (Sigma; cat# M3148) was added to the remainder to a final 
concentration of 2.5%.  
 
The protein concentration was measured using the Bradford protein assay method 
(Dc Kit, Bio-Rad; cat# 500-0111) as follows. Solubilised samples (10 µL) for 
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protein estimation were diluted with H2O (90 µL) to make 1/10 dilution in 2% 
SDS. A half of diluted sample (50 µL) was further diluted with 2% SDS (50 µL) 
to make 1/20 dilution in 2% SDS. Forty µL of standard bovine IgG solution 
(2.5mg/ml) were diluted with 10 µL 20 % SDS, 50 µL H2O to make 100 µL 
1mg/mL solution in 2% SDS. Serial dilutions of the standard (50 µL standard + 
50 µL 2% SDS) were then carried out to make the following concentrations; 1, 0.5, 
0.25, 0.125, 0.0625, 0.03125 and 0 mg/mL.  
 
Sample or standard (25 µL),  reagent A’ (125 µL) and reagent B (1,000 µL) were 
mixed and incubated at room temperature for 30 minutes, followed by absorbance 
being read in a spectrophotometer at 750 nm. Values for samples were calculated 
using the standard curve generated by plotting standards vs. absorbance. Values 
for the samples of either 1/10 dilution or 1/20 dilution, which were within the 
range of the standard curve, were used to determine the protein concentration 
(mg/mL) 
 
2.8.6 Western blotting 
 
2.8.6.1 Material and solutions for western blotting 
12.5% SDS-polyacrylamide gels; 30% acrilamide; 4.2 mL, Tris pH 8.8; 2.5 mL, 
H2O; 3.1 mL, 10% SDS; 0.1 mL, 10% ammonium persulphate (APS); 0.05 mL, 
10% TEMED; 0.05 mL  
Running buffer; 192 mM Glysine, 25 mM Tris, 0.1% SDS 
Transfer buffer; 192 mM Glysine, 25 mM Tris, 10% methanol, 0.01% SDS 
Washing buffer; Tris buffered saline (TBS)/0.1% Tween 20 
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Blocking buffer; TBS/0.1% Tween 20, 5% dried milk powder.  
 
2.8.6.2 Procedures 
Ten micrograms of total protein per lane were run on 12.5% SDS-polyacrylamide 
gels at 100 volts under the running buffer and then electrophoretically transferred 
to polyvinylidene fluoride (PVDF) membrane at 30 volts overnight using the 
transfer buffer. Transfer was assessed by Ponceau S staining and the membrane 
was blocked with the blocking buffer. 
 
The membrane was then incubated with the appropriate primary antibody (diluted 
in TBS/0.1% Tween/1% bovine serum albumin [BSA]) for 1 hour at room 
temperature, washed with TBS/Tween for 15 minutes and incubated with alkaline 
phosphatase–conjugated secondary antibody (diluted in TBS/0.1% Tween20 and 
10% normal goat serum) for 1 hour with shaking. The membrane was washed 
with the washing buffer for 15 minutes and the enzyme activity was revealed 
using a freshly prepared NBT/BCIP substrate solution (Pierce and Warriner Ltd). 
Reaction was stopped by washing with H2O. Membranes were placed between 
filter-papers to dry. Protein expression was semi-quantitatively analysed using 
National Institute of Health (NIH) image-analysing software (ImageJ 1.38X).  
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2.9  Histological analysis of heart tissue 
 
2.9.1 Fixation and cryosection 
 
For histological analysis, rat hearts were excised after neck dislocation under 5% 
isoflurane inhalation and perfused with 10 mL of 4°C PBS, followed by 5 mL of 
4°C, 4% paraformaldehyde (Sigma; cat# P6148), through a 18 gauge cannula 
inserted into the ascending aorta. After 30-minutes immersion fixation in 4% 
paraformaldehyde on ice, the hearts were thoroughly washed with PBS and 
incubated with PBS containing 30% sucrose (w/v) at 4°C overnight. The fixed 
hearts were then cut transversely into 2 pieces at the middle level between the 
LCA ligation site and the apex. Each segment was embedded in OCT compound 
(VWR; cat# 361603E) using a polyethylene mould, frozen in liquid nitrogen-
cooled isopentane and stored at -80°C.  
 
In the case of mouse hearts, all the histological samples were prepared following 
Langendorff perfusion. One mL of 4°C, 4% paraformaldehyde was infused 
through the aortic cannula, followed by 30-minutes immersion fixation in 4% 
paraformaldehyde on ice. The hearts were then thoroughly washed with PBS and 
incubated with PBS containing 30% sucrose (w/v) at 4°C overnight. The fixed 
hearts were then transversely cut, embedded in OCT compound, frozen in liquid 
nitrogen-cooled isopentane and stored at -80°C. Cryosections (15-25 µm) were 
cut from each segment using a rotary cryotome (Leica), placed on polysine-coated 
glass slides (VWR; cat# 631-0107) and stored at -80°C. 
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2.9.2 Fluorescent immunolabelling 
 
Cryosections stored at -80°C were washed with PBS once and immersed in a 
blocking solution containing 1% BSA (Sigma; cat# A7906) and 0.5% rat serum 
(RS) in PBS for 60 minutes at room temperature. The sections were then 
incubated with primary antibodies {Chapter 2.7.1} which were diluted in an 
appropriate volume of the blocking solution for 120 minutes at room temperature. 
After washing with PBS for more than 5×5 minutes, the sections were incubated 
with secondary antibodies {Chapter 2.7.2} diluted in appropriate volume of the 
blocking solution for 60 minutes at room temperature. After washing with PBS 
for more than 5×5 minutes, the sections were further incubated with 1 µg/mL of 
DAPI (Molecular Probes; cat# D21490) diluted with PBS for 3 minutes, washed 
with PBS for 15 minutes and then mounted using fluorescent mounting medium 
(DAKO; cat# S3023) and cover glass (VWR; cat# 631-0167). The sections were 
stored in a light proof box at 4°C. 
 
2.9.3 Confocal microscopy 
 
Immunolabelled fluorescent sections were examined by a confocal laser scanning 
microscopy using a Zeiss LSM510 system, which was equipped with an argon, 
krypton and Ti:Sapphire (Chameleon ultra, Coherent, US) lasers and fitted with 
the appropriate filters (Cy5, FITC and DAPI) for the detection of fluorescence. 
The images recorded were either single images or projections of five consecutive 
single optical sections taken at 0.44 µm intervals. For the double-immunolabelled 
sections, sequential dual scanning was performed.  
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2.9.4 Non-fluorescent immunolabelling and visualisation 
 
Non-fluorescent immunohistochemistry was carried out using a horseradish 
peroxidise (HRP)-based kit (EnVision Kit, DAKO; cat# K4065). Cryosections 
stored at -80°C were washed with PBS once and immersed in 0.3% H2O2 (Sigma; 
cat# H1009) diluted with PBS to inactivate endogenous peroxidise activity for 15 
minutes. After washing with PBS twice, the sections were incubated with the 
blocking solution containing 1% BSA and 0.5% RS in PBS for 60 minutes at 
room temperature. The sections were then incubated with primary antibodies 
{Chapter 2.7.1}, which were diluted in an appropriate volume of the blocking 
solution for 120 minutes at room temperature, followed by washing with PBS for 
more than 5×5 minutes. Subsequently, the sections were incubated with a 
biotinylated secondary antibody (included in the EnVision Kit) for 60 minutes at 
room temperature, followed by washing with PBS for more than 5×5 minutes. 
Then, the sections were visualised by HRP-based avidin-biotin complex (ABC) 
method, followed by washing with H2O for 15 minutes. Subsequently, 
counterstaining was carried out by incubating with Meyer’s haematoxylin solution 
for 2 minutes, rinsed with tap water for 3 times, then mounted using aqueous 
mounting medium (DAKO; cat# S3025) and cover glass.  
 
Each labelled section was assessed under a microscope (AXIOSKOP, Zeiss). 
Images were recorded using a digital camera and computer software (LUCIA, 
Laboratory Imaging Ltd). 
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2.9.5 Picrosirus red staining and assessment of collagen volume 
 
Cryosections stored at -80°C were washed with PBS once and dried at room 
temperature overnight. The sections were then immersed in fast blue (0.15% Fast 
Blue in magnesium borate buffer [0.17 g MgSO4·7H2O; 0.38 g NaBO4·4H2O; 100 
mL H2O]) for 10 minutes at room temperature, rinsed in H2O and stained with 
0.1% picrosirus red F3B (0.1 g Sirus red in 100 mL saturated aqueous picric acid) 
for 10 minutes at room temperature. The sections were rinsed 5 times in H2O and 
then rinsed for 1 minute in picric alcohol (20 mL absolute alcohol; 70 mL H2O; 
10 mL saturated aqueous picric acid). They were then dehydrated through a 
methanol series and mounted in DPX (VWR; cat# 360292F). 
 
The collagen volume fraction was semi-quantitatively assessed using picrosirus 
red-stained sections. Images of high-power field (×400) were recorded and 
analysed using NIH image-analysing software, Image J. 
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2.10  Analysis of isolated living cells from heart 
 
2.10.1 Isolation of living single cell from the heart for flow cytometry 
 
Non-cardiomyocyte cardiac cell suspensions were prepared from the mouse heart 
for flow cytometry (Montanaro et al., 2004). After Langendorff perfusion, hearts 
of wild-type C57BL/6J mouse were minced and digested with 1.2 U/mL neutral 
protease (Worthington Biochemical Corporation; cat# LS02100), 5 mg/mL 
collagenase IV (Worthington Biochemical Corporation; cat# LS004188) and 5 
mM CaCl2 diluted with PBS for 45 minutes at 37℃ with shaking. The minced 
tissue weight in grams was multiplied by 4 and the number obtained was used as 
the volume in mL for each enzyme solution to be added. The digested suspension 
was filtered through a 100 µm and then a 40 µm cell strainer (BD Biosciences) 
and fractionated by layering onto a 55/70% Percoll gradient with centrifugation at 
1,600g for 20 minutes at 25℃. Cells at the interface layer were collected, washed 
and re-suspended with Phenol Red-free HBSS (Invitrogen; cat# 14025) containing 
2% FBS on ice. 
 
2.10.2 Immunolabelling of isolated living cells and flow-cytometry 
 
Suspended living cells were incubated with either fluorochrome or biotin-
conjugated monoclonal primary antibodies diluted in 50 µL of HBSS with 2% 
FBS for 15 minutes on ice, followed by washing with HBSS with 2% FBS twice. 
Cell suspensions labelled with biotin-conjugated primary antibodies were further 
incubated with Alexa Fuor 405-conjugated streptavidin (2 mg/mL, Molecular 
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Probes; cat# S32351) for 15 minutes on ice, followed by washing with HBSS with 
2% FBS twice. Subsequently, 10 µL of 7-amino-actinomycin D (AAD, 
eBiosciences; cat# 00-6993) diluted with 500 µL of HBSS with 2% FBS were 
added to the cell suspension in order to detect dead cells.  
 
The labelled cell suspensions were placed on ice and immediately analysed by 
using flow-cytometry and CellQuest software (BD Biosciences) (Wang et al., 
2006). Debris and dead cells were excluded by forward scatter (FCS), side scatter 
(SSC) and 7-AAD gating. 
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2.11  Statistical analysis 
 
All values are expressed as means±SEM. The differences in data between two 
groups were determined using the Student’s t-test or chi square test. Comparison 
between multiple groups with one variable was performed by one-way ANOVA 
followed by Bonferroni’s pot-hoc test for individual significant difference. 
Comparison between multiple groups with two variables was performed by two-
way ANOVA followed by Bonferroni’s pot-hoc test for individual significant 
difference. p<0.05 was regarded as a significant difference. 
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CHAPTER 3: ESTABLISHIING EXPERIMENTAL 
MODEL OF CELL THERAPY FOR ISCHAEMIC 
CHRONIC HEART FAILURE 
 
 
3.1 Introduction and Aim 
 
It was required to establish experimental model of cell therapy for treating post-
MI chronic HF prior to the main work, as the experimental model in which either 
SMB or BMC derived from male GFP-transgenic SD rat are injected into the 
female post-MI SD rat heart had not been frequently used previously. 
 
3.1.1 Rat post-MI chronic HF model 
 
Although LCA ligation is a common method to generate post-MI chronic HF 
model in male rat (DeFelice et al., 1989), the degree and time-course of change in 
cardiac parameters following LCA ligation have not been fully evaluated in the 
female SD rat.  In addition, it would be essential to review other typical features 
of post-MI chronic HF, such as changes in physical activity and ECG waves, 
occurrence of spontaneous arrhythmia, myocardial fibrosis and capillary density, 
in order to evaluate the therapeutic effects of cell therapy. 
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3.1.2 Use of donor cells derived from GFP-transgenic SD rat 
 
An SD rat model was used since only transgenic SD rats expressing GFP were 
available. As the GFP-transgenic SD rat had not been fully studied for cell therapy 
research, it was required to characterise SMB and BMC derived from male GFP-
transgenic rats and evaluate its suitability as donor cells injected into the post-MI 
hearts. In addition, establishing the methods to identify male GFP-transgenic rat-
derived donor cells in the female wild-type rat myocardium, including real-time 
PCR for Sry and immunolabelling for GFP, is important prior to the main work.  
 
3.1.3 Use of allogeneic model 
 
The model in which either SMB or BMC derived from male GFP-transgenic SD 
rat are injected into the female SD rat heart is unlikely to induce immune response 
against allogenicity, Y-chromosome or GFP based upon the previous research 
data (Suzuki et al., 1997; Miyahara et al., 2006). However, in order to firmly 
verify the suitability of this model as an autologous model, a set of experiments 
using female athymic nude rats as a recipient was carried out and the results were 
compared with that using female wild-type SD rats as a recipient. 
 
3.1.4 Aim of Chapter 3 
 
This chapter sets out the verification and establishment of the experimental cell 
therapy model in which either SMB or BMC derived from male GFP-transgenic 
SD rat were injected into the female wild-type SD rat heart with post-MI chronic 
HF generated by LCA ligation. 
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3.2 Results 
 
3.2.1 Evaluation of a post-MI chronic HF model in the  female rat 
 
The post-MI chronic HF model was generated by LCA ligation in female SD rats. 
The LCA was permanently ligated at the bottom level of the LA appendage in 
female wild-type SD rats (n=355) {Chapter 2.4.2}. Five rats (1.4%) were 
excluded due to a technical difficulty in ligating the LCA. Cardiac parameters, 
physical activity, extracellular collagen volume, capillary density, ECG waves and 
spontaneous occurrence of arrhythmia following LCA ligation were compared to 
those of normal rats (n=10). 
 
3.2.1.1 Procedural mortality and morbidity 
Among 350 rats in which the LCA was ligated, 15 rats (4.3%) were unable to be 
extubated due to acute LV dysfunction. Forty-six rats (13.1%) died within 48 
hours after extubation, presumably due to acute HF. All the rats surviving for 48 
hours after LCA ligation survived over the experimental period (from 21 to 105 
days after LCA ligation).  
 
Morbidities were found as follows; severe thoracic wall infection (2 rats, 0.6%), 
pathologically increased ascites (1 rat, 0.3%) or reduced activity with elevated 
breathing rate (3 rats, 0.9%). These rats were excluded from the study and 
sacrificed. Post-mortum study of the rats with thoracic wall infection showed a 
necrotic rib bone with intense adhesion to the left lung and the epicardium. Post-
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mortum study of the rats with severe ascites or reduced activity revealed severe 
pulmonary oedema and enlarged LV cavity, presumably due to LV dysfunction.  
 
3.2.1.2 Infarct area at 21 days after LCA ligation 
Hearts were removed to confirm the area and size of infarct at 21 days after LCA 
ligation (n=3). All the rat hearts showed a thin-white fibrous (infarct) region at 
antero-lateral LV free wall in the distal region of the LCA ligation site (figure 3.1). 
Adhesion between the heart and thoracic wall or left lung was easily dissected 
without damaging the heart or lung. 
 
 
 
 
 
 
 
Figure 3.1: Infarct area following LCA ligation. Representative pictures of the heart 
(transversely cut) at 21 days after LCA ligation (lower slices) show a thinner antero-lateral 
LV wall (arrow heads) and enlarged LV cavity, compared to the same level of the normal 
heart (upper slices). Black arrow indicates the site of LCA ligation. 
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3.2.1.3 Deteriorated cardiac function after LCA ligation 
Echocardiography was serially carried out before and after LCA ligation under 
isoflurane inhalation over 105 days to assess changes in cardiac parameters 
(n=10) {Chapter 2.5.1}. Following LCA ligation, all the rats showed 
asymmetrical LV dilatation associated with akinetic antero-lateral LV wall motion 
and enlarged atrial peak flow through the mitral valve by 21 days, compared to 
the normal rat hearts (figure 3.2).  
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Figure 3.2: Echocardiography before and after LCA ligation. Representative 2-
dimensional tracing shows LV cavity (surrounded by white dot line) and LV wall 
(surrounded by yellow line) in diastolic phase of the normal heart (A) and the heart at 21 
days after LCA ligation (B). A larger LV cavity and asymmetrical thin LV wall are 
observed in the post-MI heart. Representative M-mode of the same heart shows akinetic 
anterior wall and enlarged LV diastolic (white arrow) / systolic (yellow arrow) dimensions 
in the post-MI heart (D) compared to the normal heart (C). Representative trans-mitral 
spectral Doppler of the same hearts show a smaller ratio in diastolic (yellow arrows) / 
atrial (white arrows) waves in the post-MI heart (F) compared to the normal heart (E).  
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Serial measurement of LVEF by 2-dimensional tracings showed a marked 
decrease at 7 days after LCA ligation (42.8±0.8%), compared to before LCA 
ligation (71.3±0.3%, p<0.001, figure 3.3). Further reduction in LVEF was 
observed until 21 days (34.6±0.5%). LVEF between 21 and 105 days after LCA 
ligation were not significantly different (34.4±0.5% at 28 days, 32.4±0.7% at 49 
days and 31.2±0.6% at 105 days). 
 
 
 
 
 
 
 
Figure 3.3: Serial change in LVEF following LCA ligation. Two-dimensional mode 
echocardiography revealed that LVEF was markedly decreased by 7 days followed by a 
gradual, but continuous decrease until 21 days after LCA ligation. LVEF was then not 
significantly changed until 105 days. 0 indicates the day of LCA ligation (data was taken 
just before LCA ligation). n=10 at each time point. *p<0.0001 vs. 0 day; †p<0.05 vs. 7 
days; ‡p<0.05 vs. 14 days. 
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HR did not significantly change during the experimental period analysed, whereas 
LV dimensions were enlarged and peak E/A flow was significantly reduced by 21 
days after LCA ligation (table 3.1). LVDd was further enlarged by 105 days and 
peak E/A flow was further reduced until 105 days. 
 
 
 
 
 
 
Table 3.1: Change in cardiac parameters following LCA ligation. Data of normal 
hearts were taken just before LCA ligation. n=10 at each time point. *p<0.05 vs. the 
normal hearts; †p<0.05 vs. 21 days. 
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3.2.1.4 Reduced physical activity after LCA ligation 
Physical activity of the rats following LCA ligation was assessed by telemetry 
{Chapter 2.5.2} as an indicator of the degree of HF and symptoms. The 
biocompatible transducers for telemetry were implanted in 8 female wild-type SD 
rats. Among them, 4 rats underwent LCA ligation through left thoracotomy 
immediately after the transducer implantation (Failing group). In the other 4 rats, 
only left thoracotomy was carried out (Normal group). Signal strength of these 
rats was continuously recorded for 24 hours at 1, 21 and 49 days after the 
procedure (n=4 in each group at each time point).  
 
Mortality or morbidity relating to the transducer implantation, such as ileus, 
peritonitis or peritoneal bleeding, was not observed. The transducer was explanted 
after sacrifice of the rats. 
 
Activities of all the rats were low (1.3±0.3 count/min in the Normal group; 
0.8±0.2 count/min in the Failing group) at 1 day, presumably due to surgical stress 
(figure 3.4). At 21 days, physical activity was significantly different between the 
two groups (7.4±1.2 count/min in the Normal group; 3.7±0.5 count/min in the 
Failing group, p<0.05). The significant difference continued until 49 days. Either 
group showed no significant change in activity between 21 and 49 days.  
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Figure 3.4: Physical activity following LCA ligation. Continuous monitoring of physical 
activity, assessed by radio-telemetry, revealed a significant difference between the 
Normal and Failing groups at 21 and 49 days after LCA ligation. n=4 at each group at 
each time point. *p<0.05 vs. the Failing group. 
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3.2.1.5 Increased extracellular collagen volume after LCA ligation 
Fibrosis of the hearts after LCA ligation was assessed with picrosirus red staining 
as an indicator of the degree of chronic HF and semi-quantitatively compared with 
that of the normal hearts (n=4 in each group) {Chapter 2.9.5}. Ten individual 
high-power (400×) fields of each peri-infarct and infarct-remote areas were 
analysed per one heart. 
 
Collagen was markedly accumulated in the extracellular space of the peri-infarct 
area of the hearts at 21 and 49 days after LCA ligation (22.0±1.7% and 23.4±1.3% 
of collagen volume fraction, respectively) compared to the LV free wall of the 
normal hearts (7.0±1.0%, p<0.05; figure 3.5). The infarct-remote area or 
interventricular septum (IVS) also showed accumulation of collagen in the hearts 
at 21 and 49 days (15.3±1.7% and 14.7±1.5%, respectively) compared to the IVS 
of the normal hearts (6.7±1.2%, p<0.05). Collagen was less accumulated in the 
infarct-remote area than in the peri-infarct area in the failing hearts. Collagen 
volume of either peri-infarct or infarct-remote area were not significantly different 
between the hearts at 21 and 49 days. 
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Figure 3.5: Fibrosis in the post-MI chronic HF model. Representative picrosirus red 
staining in the peri-infarct area of the hearts at 21 and 49 days after LCA ligation (B, C, E 
and F) show a marked extracellular collagen accumulation (red colour), compared to the 
LVFW of the normal heart (A and D). Collagen is also markedly accumulated in the 
infarct-remote area of the failing heart (H and I) compared to the IVS in the normal heart 
(G). Collagen volume fraction was significantly larger in both the peri-infarct and infarct-
remote areas of the failing hearts than the normal hearts (J). Collagen volume fraction 
was not significantly different between the hearts at 21 and 49 days after LCA ligation. 
Scale bar = 500 µm (50×); 100 µm (400×). n=4 in each group. *p<0.05 vs. peri-infarct 
area (LVFW) of the normal hearts; †p<0.05 vs. infarct-remote area (IVS) of the normal 
hearts.  
 
 
 
 
3.2.1.6 Angiogenesis in the peri-infarct area after LCA ligation 
As an indicator of the degree of HF, capillary density in the peri-infarct area of the 
normal hearts and the hearts at 21 and 49 days after LCA ligation was assessed by 
immunofluorescent labelling for von Willebrand factor (vWF) using confocal 
microscopy {Chapter 2.9.2}{Chapter 2.9.3} (n=4 in each group). Ten individual 
high-power (400×) fields of the peri-infarct area were recorded as projections and 
analysed per one heart.  
 
Endothelium of capillaries, venules and arterioles were successfully labelled in 
the myocardium (figure 3.6). The capillary densities of the hearts at 21 days 
(657±45 /mm2) and 49 days (668±63 /mm2) were significantly smaller than that in 
LVFW of the normal hearts (1,007±105 /mm2, p<0.05). There was no significant 
difference in capillary density between the hearts at 21 days and 49 days after 
LCA ligation. 
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Figure 3.6: Vascular formation in post-MI chronic HF model. Capillary density was 
assessed in LVFW of the normal hearts and peri-infarct area of the hearts at 21 and 49 
days after LCA ligation by immunolabelling for vWF. Representative pictures at high-
power (400×) show that there was no non-specific signal by the secondary antibody (A) 
and that the capillary number was greater in the normal heart (B) than in the failing hearts 
(C and D). Capillary density of the normal hearts was significantly larger than in the 
hearts at both 21 and 49 days after LCA ligation (E). Scale bar = 20 µm. n=4 in each 
group. *p<0.05 vs. the normal heart.  
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3.2.1.7 ECG waves and arrhythmia occurrence in post-MI chronic HF model 
The ECG was continuously monitored using radio-telemetry {Chapter 2.5.2} in 
rats following LCA ligation. The transducer was implanted in the peritoneal 
cavity and the two electrodes were fixed at the right shoulder and the left axilla. 
Four rats underwent LCA ligation through the left thoracotomy immediately after 
the transducer implantation (Failing group) and the other 4 rats underwent only 
left thoracotomy without LCA ligation (Normal group). Continuous ECG 
monitoring was carried out for 24 hours at 21 and 49 days after the procedure.  
 
The ECG waves showed a difference between the two groups at 21 days (figure 
3.7). All the rats after LCA ligation showed a typical ECG pattern in transmural 
MI including negative Q and inverted T waves, while the rats without LCA 
ligation showed a normal ECG. 
 
The ECG waves were analysed and the data was expressed as an average of the 
24-hour recording (table 3.2). The rats at 21 and 49 days after LCA ligation 
showed a significantly larger duration in P wave and QRS complex, compared to 
the rats without LCA ligation. RR, PR or QT intervals were not significantly 
different between the two groups. 
 
The frequency of VPC was less than one per hour in both groups at 21 and 49 
days after the procedure. Neither multiform VPC or VT were found in any rats. 
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Figure 3.7: Change in ECG waves in post-MI chronic HF model. The ECG was 
continuously monitored using the telemetry in rats with or without LCA ligation. 
Representative ECG waves show a normal wave pattern in a rat from the Normal group 
(A) and a typical ECG pattern in transmural MI in a rat from the Failing group (B) at 21 
days after the procedure. 
 
 
 
 
Table 3.2: Change in ECG measurements following LCA ligation. n=4 in each group 
at each time point. *p<0.05 vs. the Normal group. 
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3.2.2 Maintenance of GFP-transgenic rat 
 
GFP-transgenic SD rats were originally purchased from Rat Research & Resource 
Centre and maintained in my laboratory. The appearance and activity of The GFP-
transgenic rat were not different form those of wild-type SD rats. Genotyping for 
GFP locus was carried out by PCR using genomic DNA extracted from the tail at 
3 weeks of age {Chapter 2.2}. The samples showing two bands (at 799 and 1050 
base pairs [bps]) were regarded as being derived from heterozygous GFP-
transgenic SD rats, while the samples showing one band at 799 bps were regarded 
as being derived from wild-type rats and one band at 1050 bps were regarded as 
homozygous GFP-transgenic SD rats (figure 3.1) (Lois et al., 2002).  
 
 
 
 
 
 
 
Figure 3.8: Genotyping of GFP-transgenic SD rat. A representative gel picture for PCR 
products of genotyping for GFP-transgenic SD rat is shown. Samples which have two 
bands at 799 bps and 1,050 bps (lane 2, 3, 5, 6, 8 and 9) on 1% agarose gels were 
regarded as a heterozygous GFP-transgenic rat. The samples with one band at 799 bps 
were regarded as wild-type rats (lane 1, 4 and 7). Marker = 1 Kb ladder (1 µg) 
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Breeding of wild-type SD rats, heterozygote GFP-transgenic rats and homozygote 
GFP-transgenic rats was started at 10 weeks of age (n=5 in each). Fertility was not 
different among wild-type rats (10.8±0.9 pups), heterozygote GFP-transgenic rats 
(11.0±1.2 pups) and homozygote GFP-transgenic rats (10.2±1.4 pups). 
Heterozygote GFP-transgenic SD rats were used in the work in this thesis. 
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3.2.3 Characterisation of GFP-transgenic SD rat-derived cells 
 
3.2.3.1 GFP expression in myofibres and SMB from GFP-transgenic rat 
Expression of GFP in myofibres, which were enzymatically dissociated from the 
EDL of a GFP-transgenic rat, was assessed by inverted fluorescence microscopy 
in each donor {Chapter 2.3.1} (n=17). All of the living myofibres expressed GFP 
throughout their entire length (figure 3.2A and B). GFP expression in cultured 
SMB, which migrated from the myofibres and proliferated {Chapter 2.3.2}, was 
also assessed by the fluorescence microscope. GFP was expressed in 
approximately 70% of the SMB (figure 3.2C and D). 
 
 
 
 
 
Figure 3.9: GFP-expression in myofibres and SMB derived from GFP-transgenic rat. 
Myofibres expressed GFP along their entire length (phase contrast; A and fluorescence; 
B). Approximately 70% of the undifferentiated SMB also expressed GFP (phase contrast; 
C and fluorescence; D). Scale bar = 50 µm. 
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GFP-positivity in cultured SMB derived from GFP-transgenic SD rats was 
quantitatively assessed by flow-cytometry {Chapter 2.10.2} (n=4). Within the 
total cell suspensions from the cultured SMB loaded in the flow cytometry, cell 
population was identified by FSC/SSC gating and analysed by GFP signal 
strength, showing that 72.3±4.5% of cells from GFP-transgenic rat expressed GFP 
(figure 3.10). 
 
 
 
 
 
Figure 3.10: GFP-positivity in SMB derived from GFP-transgenic rat. GFP positivity 
in SMB from GFP-transgenic rat was analysed, using SMB from wild-type rat as the 
control. Representative pictures show identification of cell population from the whole 
suspensions of cultured SMB derived from wild-type rat (squared area in A) and from 
GFP-transgenic rat (squared area in C) by using SSC and FSC gating. Analysis of GFP 
signal strength was then carried out for the cell population (B and D, respectively). 
Among total cells from GFP-transgenic rat, 70.5% expressed GFP (D). 
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3.2.3.2 Proliferation/differentiation capacity of SMB from GFP-transgenic rat 
Primary SMB were extracted from the EDL of male wild-type and GFP-
transgenic SD rats by the single fibre method {Chapter 2.3.1} and cultured in the 
proliferation medium and passaged every 48 hours to keep an undifferentiated 
state at less than 50% confluency (n=6 each). Doubling times of the cells, 
calculated at each passage, was neither different between the passages for each 
species or between the two species at each passage (figure 3.11). 
 
 
 
 
Figure 3.11: Doubling time of primary SMB. Doubling time was not different between 
the passage numbers or between the two rat species.  
 
 
The myogenic differentiation capacity of the primary SMB derived from GFP-
transgenic rats was confirmed by switching the culture medium to the low-serum 
medium at a sub-confluent state {Chapter 2.3.2} (n=3). Fusion and formation of 
GFP-expressing myotubes was observed at 48 hours after the change of the 
medium (figure 3.12). 
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Figure 3.12: Myogenic differentiation of SMB derived from GFP-transgenic rat. 
Myotubes, differentiated in vitro, expressed GFP (phase contrast; A and fluorescence; B). 
Scale bar = 100 µm. 
 
 
 
 
3.2.3.3 Characterisation of BMC derived from GFP-transgenic SD rat 
Mononuclear BMC were extracted from the femur and tibia of GFP-transgenic 
SD rats and the GFP-expression in BMC was assessed by fluorescence 
microscopy {Chapter 2.3.3}. GFP-expression in BMC was clearly identified 
(figure 3.13A and B). Quantitative assessment of GFP-positivity by flow 
cytometry revealed that GFP was expressed in 64.3±7.5% of BMC from GFP-
transgenic SD rat (n=4). 
 
Expression of CD34 and CD45 in BMC from GFP-transgenic rats, analysed using 
flow cytometry {Chapter 2.10.2}, showed a similar proportion to that in BMC 
from wild-type SD rats (n=4 each). BMC from GFP-transgenic rats expressed 
CD34 in 4.5±1.7% and CD45 in 75.5±4.3% (figure 3.13C), while BMC from 
wild-type rats expressed CD34 in 5.2±2.3% and CD45 in 78.9±3.8%.  
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Figure 3.13: Characterisation of BMC derived from GFP-transgenic rat. 
Representative pictures of mononuclear BMC extracted from GFP-transgenic rats (phase 
contrast; A and fluorescence; B) show expression of GFP in BMC. Representative flow-
cytometry analysis for CD34 and CD45 expression in BMC from GFP-transgenic rat 
shows that 4.6% were positive for CD34 and 75.5% were positive for CD45 (C). GFP-
positive cells were 62.5% (green dots) of total mononuclear BMC, while GFP-negative 
cells were 37.5% (yellow dots). Scale bar = 20 µm.  
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3.2.4 Quantitative assessment of male cells in female heart 
 
The presence of male donor-derived cells in the female LV was quantitatively 
assessed using real-time TaqMan PCR for the Y-chromosome specific Sry gene 
{Chapter 2.8.2}. Serial dilution series (1, 1/3, 1/9, 1/27, 1/81 and 1/243) of the 
DNA extracted from a mixture of either male SMB (5×106) or BMC (1×107) and 
female entire LV walls at 21 days after LCA were tested for the Sry detection in 
order to examine the sensitivity of the PCR (n=3 each). Three female LVs at 21 
days after LCA ligation without mixture of male cells were used for the control. 
Each sample was triplicated and the PCR assay was simultaneously performed. 
Data were analysed using the Ct method.  
 
All the samples without male cells showed Ct value being more than 38. Standard 
curves generated by the Sry levels of each serial dilution series showed  R2 > 0.99 
in both SMB and BMC, suggesting that Sry signal was stably detected up to 1/243 
(0.41%) of 5×106 of male SMB and 1×107 of male BMC in the female failing LV 
(figure 3.14).  
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Figure 3.14: Standard curves for Sry detection. Standard curves were generated by 
real-time PCR for Sry in serial dilution series of the DNA extracted from a mixture of 
5×106 male SMB (A) or 1×107 male BMC (B) with a female failing LV. Both curves (up to 
1/243 dilution) showed R2 > 0.99. n=3 in each. 
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3.2.5 Visualisation of grafted cells in the native myocardium 
 
In order to establish the histological method to identify donor cells derived from 
GFP-transgenic rat in the native myocardium, either 5×106 of SMB or 1×107 of 
BMC, derived from male GFP-transgenic SD rat, were injected into the female 
wild-type SD rat heart at 21 days after LCA ligation via the IM route (n=3 each). 
At 3 days after cell injection, the hearts were removed, perfused with 4% 
paraformaldehyde, cut transversely and frozen {Chapter 2.9.1}. Cryosections (20 
µm) of these hearts were labelled with polyclonal anti-GFP primary antibody 
followed by either fluorescent {Chapter 2.9.2} or non-fluorescent {Chapter 2.9.4} 
visualisation for the grafted cells in the myocardium.  
 
The sections without GFP-labelling showed that endogenous GFP expression was 
insufficient to identify either the GFP-positive SMB or BMC in the wild-type 
myocardium which had a slight green auto-fluorescence (figure 3.15A and C), 
while GFP-labelling of the adjacent sections showed a largely amplified GFP 
signal in both SMB and BMC (figure 3.15B and D). Non-fluorescent HRP-based 
visualisation also clearly identified both the SMB and BMC in the myocardium 
(figure 3.15F and H). The secondary control of the adjacent sections confirmed 
the specificity of the secondary antibody used with the endogenous peroxidise 
activity being efficiently quenched by H2O2 treatment (figure 3.15E and G).  
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Figure 3.15: Visualisation of GFP-positive cells in the myocardium of wild-type rat. 
Representative confocal micrographs of direct fluorescent imaging of GFP-expressing 
SMB (A) and BMC (C) show that endogenous GFP-expression is insufficient for clear 
graft-identification in the myocardium, while GFP-immunolabelling in the adjacent 
sections clearly identified GFP-positive cells (B; SMB, D; BMC). Representative pictures 
of non-fluorescent HRP-based visualisation following GFP-immunolabelling with 
haematoxylin counterstaining show clear identification of the grafted GFP-expressing 
SMB (F) and BMC (H). The secondary control of the adjacent sections did not show non-
specific labellings (E and G). Scale bar = 100 µm.  
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3.2.6 Justification of use of SD rat for cell therapy model 
 
As there is a concern that SMB or BMC derived from male GFP-transgenic SD rat 
could be impaired by host immune response following injection into the heart of 
female wild-type SD rat, a set of experiments was carried out to verify suitability 
of this model by using female nude rats as a host animal.  
 
Either SMB (5×106, n=6) or BMC (10×106, n=3) were injected into the hearts of 
female nude rats (10 weeks of age, 125-175 g) at 21 days after LCA ligation via 
the IM route {Chapter 2.4.3} (Nude-SMB and Nude-BMC group, respectively). 
Cardiac function and graft survival after cell injection were compared to the 
groups in which the same number of SMB (n=8) or BMC (n=8) were injected into 
the hearts of female wild-type SD rats (10 weeks of age, 200-250 g) via the IM 
route (WT-SMB and WT-BMC groups, respectively). In addition, female wild-
type SD rats (10 weeks of age, 200-250 g) were injected PBS only (n=8) via the 
IM route for the control.  
 
3.2.6.1 Cardiac function 
As a result, an almost identical degree and time-course of LVEF improvement 
were observed after injection of either SMB or BMC into either nude or wild-type 
rats (figure 3.16). LVEF in these 4 groups was significantly greater than the 
control at 7 and 28 days after injection (p<0.05). 
 
Other cardiac parameters such as HR and peak E/A flow following cell injection 
also showed no significant difference between the nude and wild-type rats (table 
3.3), though diastolic/ systolic LV dimensions of the nude rat hearts were smaller 
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than those of wild-type rat hearts before cell injection, probably due to a smaller 
body size in nude rats. 
 
 
 
 
 
 
Figure 3.16: Comparison of LVEF after cell therapy between nude and wild-type 
rats. LVEF, assessed by echocardiography, in the WT-SMB (n=8) group, the Nude-SMB 
group (n=6), the WT-BMC group (n=8) and the Nude-BMC group (n=3) was similarly 
greater than the WT-PBS group (n=8) at day 7 and 28. *p<0.05 vs. the WT-PBS group, -1 
indicates one day before cell injection. 
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Table 3.3: Cardiac parameters before and after cell therapy in the nude and wild-
type rats. n=8 in the WT-PBS group, the WT-SMB group and the WT-BMC group, n=3 in 
the Nude-SMB group and the Nude-BMC group. *p<0.05 vs. the WT-PBS group. 
 
 
 
 
 
3.2.6.2 Graft survival 
Real-time PCR for the Y-chromosome specific Sry gene was performed to 
quantitatively examine survival of the grafted cells in the LV {Chapter 2.8.2}. Sry 
levels were normalised to DNA amount using the autosomal single copy gene 
oesteopontin. The number of surviving cells was estimated by correcting relative 
Sry expression by using the standard curves (figure 3.14).  
 
There was no significant difference in graft survival of either SMB or BMC in the 
hearts of wild-type and nude rats (figure 3.17). After SMB injection, the Sry-
positive cell number at day 7 was 1.9±0.4×105 (3.8% of total injected cells) in the 
wild-type rat heart, which was comparable to 2.6±0.5×105 (5.2% of total injected) 
in the nude rat heart. The Sry-positive cell number in both the WT-SMB and 
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Nude-SMB groups was decreased by day 28. In addition, at day 28 after BMC 
injection, the number of Sry-positive cell detected in the wild-type rat LV 
(0.6±0.5×105, 0.6% of total injected) and the nude rat LV (0.3±0.3×105, 0.3% of 
total injected) was not significantly different. 
 
 
 
 
 
 
Figure 3.17: Graft survival following cell therapy in the nude and wild-type rat 
hearts. Either SMB (5×106) or BMC (1×107) derived from male GFP-transgenic SD rat 
was injected into the female wild-type or nude rat heart 21 days after LCA ligation. 
Survival of male GFP-transgenic donor-derived cells in the female failing LV was 
quantitatively analysed by real-time PCR for Sry. (A) The number of donor-derived cells 
in the WT-SMB group (n=6 at each time point) and the Nude-SMB group (n=3 at each 
time point) was not significantly different at day 7 or 28. (B) Number of donor-derived 
cells in the WT-BMC group (n=6) and the Nude-BMC group (n=3) was not significantly 
different at day 28. 
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3.3 Discussion 
 
This Chapter covered work validating the post-MI chronic HF model in female 
SD rats, generated by LCA ligation. In addition, SMB and BMC derived from 
male GFP-transgenic SD rat were characterised in vitro and were successfully 
identified following injection into the post-MI heart of female SD rats by means 
of both real-time PCR for the Y-chromosome specific gene, Sry, and 
immunolabelling for GFP. Therapeutic effects and graft survival following direct 
IM injection of either SMB or BMC derived from male GFP-transgenic rat into 
the post-MI heart of the wild-type SD rats were not different from those of the 
nude rats, suggesting that the host immune response against allogenicity, GFP or 
Y-chromosome do not affect the efficacy of cell therapy in the model using SD 
rats. 
 
3.3.1 Rat post-MI chronic HF model 
 
3.3.1.1 Evaluation of post-MI chronic HF in female SD rat 
Both systolic and diastolic cardiac functions of female SD rats were consistently 
deteriorated following LCA ligation. Furthermore, physical activity was reduced 
following LCA ligation in this model. Importantly, these haemodynamic and 
physiological changes were associated with increased collagen content and 
reduced capillary density in the myocardium, which are typical features of 
ischaemic chronic HF in clinical settings (Anversa et al., 1986; Waller et al., 
2001). In addition, all the rats at 21 days after LCA ligation showed typical 
features of ECG waves in transmural MI, such as negative Q wave and inverted T 
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wave. Longer durations in P wave and QRS complex in the post-MI rats than the 
normal rats might suggest reduced conduction velocity and deteriorated LV 
function caused by LCA ligation. 
 
3.3.1.2 Time-course of change in the heart following LCA ligation 
There was no significant difference in LVEF between 21 and 105 days after LCA 
ligation in female rats, while LVEF at 14 days was significantly greater than that 
at 21 days. However, LVDd was enlarged and peak E/A flow was reduced at 105 
days, compared to those at 21 days. These findings suggest that systolic LV 
dysfunction might be established in 21 days after LCA ligation, while diastolic 
LV dysfunction could be progressive over time in female SD rats.  
 
DeFelice et al reported that LV end-diastolic pressure and LV dP/dtmax were 
deteriorated within 4 weeks after LCA ligation in male SD rats and did not further 
deviate up to 35 weeks, while cardiac output index was gradually deteriorated 
from 4 to 35 weeks after LCA ligation (DeFelice et al., 1989). The findings by 
DeFelice et al were similar to the data reported in this work. In addition, work 
reported in this Chapter demonstrated that physical activity, collagen content, 
capillary density and ECG waves were not different between 21 and 49 days after 
LCA ligation in female SD rat. 
 
Thus, it would be reasonable to suggest that post-MI chronic HF is established in 
21 days following LCA ligation in female SD rats. Therefore, female SD rats 21 
days following LCA ligation were selected as a post-MI chronic HF model in the 
main work. 
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3.3.1.3 Possible limitations of the rat post-MI chronic HF model 
One could speculate that the nature and progression of HF in a rat post-MI chronic 
HF model generated by LCA ligation are different from the clinical settings. 
Firstly, there are differences in cellular, molecular and genetic properties between 
rat and human myocardium (Doggrell and Brown, 1998). Secondly, in a rat post-
MI chronic HF model, the coronary arteries are not involved in long-standing 
hypertension and associated atherosclerotic change which is frequently seen in 
post-MI chronic HF in human (Dei Cas et al., 2003). Thirdly, different heart rate 
between rat and human could affect arrhythmogenicity. Finally, most of the 
patients with post-MI chronic HF have a number of infarct regions in the 
myocardium, which was generated by a series of ischaemic events and/or 
reperfusion (treated or spontaneous) (Phillips et al., 2007), whereas the rat post-
MI chronic HF model has just one large infarct region by one event without 
reperfusion.  
 
However, the studies reported here showed that the post-MI chronic HF model in 
female SD rats had typical important features in ischaemic cardiomyopathy in 
human, including deteriorated cardiac function and physical activity associated 
with accumulated extracellular collagen contents and reduced capillary density. In 
addition, the rat post-MI chronic HF model has been frequently used for several 
purposes including pharmacological therapies for HF (Freed et al., 2005). These 
findings propose the utility of the rat post-MI chronic HF model for cell therapy 
research mimicking clinical settings. 
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3.3.2 Character of SMB and BMC derived from GFP-transgenic rat 
 
Heterozygous GFP-transgenic SD rats were successfully maintained in the 
laboratory with a similar fertility to wild-type SD rats. Primary SMB, collected 
from male GFP-transgenic SD rats using the single fibre method, showed a 
similar proliferation capacity to those from the wild-type rats. In addition, 
cultured SMB from GFP-transgenic rats had a similar myogenic differentiation 
ability in vitro, as seen in primary SMB from wild-type rats (Suzuki et al., 2001a). 
Mononuclear BMC, collected from male GFP-transgenic SD rats by Percoll 
gradient centrifugation, expressed similar surface makers such as CD34 and CD45, 
as seen in mononuclear BMC reported in clinical studies (Schachinger et al., 
2006). These findings might support adequate properties of GFP-transgenic rat 
derived-SMB and BMC for cell therapy research.  
 
While GFP was not expressed in approximately 30% of SMB or 35% of BMC 
derived from GFP-transgenic SD rat, real-time PCR for Y-chromosome specific 
gene would enable quantitative assessment of presence of male donor-derived 
cells in the female myocardium. 
 
3.3.3 Identification of grafted cells in the myocardium 
 
Identification and quantitative assessment of both SMB and BMC derived from a 
male donor in the female LV following LCA ligation was reliably (R2>0.995) 
carried out by real-time PCR for the Y-chromosome specific gene, Sry. The PCR 
assay suggested that Sry signal of at least either 2.06×104 of SMB or 5.12×104 of 
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mononuclear BMC present within the infarcted myocardium can be reproducibly 
detected. 
 
Moreover, visualisation of the grafted SMB or BMC derived from the GFP-
transgenic donor rat was successfully carried out by both fluorescent and non-
fluorescent techniques. Fluorescent observation using confocal microscopy would 
be useful in assessing differentiation and intercellular connections with the native 
cardiomyocytes using multicolour labelling, while non-fluorescent HRP-based 
visualisation would be useful in assessing distribution of the grafted cells in the 
myocardium in low-power fields with haematoxylin counterstaining.  
 
3.3.4 Possible immune response in the experimental model 
 
The degree of LVEF improvement following injection of either SMB or BMC 
derived from male GFP-transgenic SD rats into the wild-type SD rat post-MI heart 
was similar to that seen after injection of the same number of cells into the nude 
rat post-MI heart. Changes in other cardiac parameters including HR, LVDd/Ds or 
peak E/A were also not significantly different between the nude and wild-type rat 
hearts which were injected with male GFP-transgenic SD rat-derived cells. In 
addition, real-time PCR for Y-chromosome specific gene, Sry, showed that graft 
survival in both the early (day 7) and late (day 28) phases were similar between 
the nude and wild-type female rat hearts which were injected male GFP-
transgenic SD rat-derived cells. These findings suggested that the host immune 
response against allogenicity, GFP or Y-chromosome does not impair the 
fundamental behaviour of the grafted cells and consequent therapeutic outcomes. 
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3.3.5 Summary of Chapter 3 
 
At 21 days after LCA ligation in the female SD rat, typical features in post-MI 
chronic HF were observed, including deteriorated systolic and diastolic cardiac 
functions, enlarged LV cavity, reduced physical activities, negative Q and 
inverted T waves in ECG, increased fibrosis and decreased capillary density.  
 
Both SMB and mononuclear BMC, collected from male GFP-transgenic SD rats, 
were characterised in vitro. Both SMB and mononuclear BMC derived from male 
GFP-transgenic SD rats were reproducibly identified in the female rat post-MI 
heart by both real-time PCR for Sry and immunolabelling for GFP (fluorescent 
and no-fluorescent imaging).  
 
Cardiac parameters and graft survival were similar between the nude and wild-
type female rat hearts which were injected the same number of SMB or BMC 
derived from male GFP-transgenic SD rat.  
 
Therefore, it would be reasonable to conclude that the experimental model of cell 
therapy in which male GFP-transgenic SD rat-derived SMB or BMC were 
injected into the female wild-type SD rat heart 21 days after LCA ligation can be 
used as a model mimicking clinical cell therapy.  
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CHAPTER 4: THERAPEUTIC EFFICACY OF CELL 
THERAPY AND UNDERLYING MECHANISMS  
 
 
4.1 Introduction and Aim 
 
4.1.1 Therapeutic efficacy of cell therapy for post-MI chronic HF 
 
Clinical studies have suggested that the therapeutic effects of direct IM injection 
of SMB in treating post-MI chronic HF may not be as substantial as expected (Dib 
et al., 2005b; Siminiak et al., 2004; Jolicoeur et al., 2007). In addition, the 
therapeutic efficacy of injection of BMC for treating post-MI chronic HF is 
inconsistent (Perin et al., 2003; Beeres et al., 2006b; Strauer et al., 2005; Fuchs et 
al., 2003; Kuethe et al., 2005; Tse et al., 2003; Blatt et al., 2005). Therefore, it is 
essential to determine if cell therapy is able to provide therapeutic benefits in 
treating post-MI chronic HF using a reliable, reproducible model.  
 
4.1.2 Possible mechanisms of functional change 
 
Although identification of the mechanisms responsible for the therapeutic effects 
is crucial in understanding the treatment and enhancing the therapeutic efficacy, 
the fundamental behaviour of the grafted cells and associated changes in the 
native myocardium are not fully understood. 
 
165 
4.1.2.1 Direct mechanical contribution of grafted cells 
A possible mechanism is the generation of new cardiomyocytes and/or new 
vessels derived from the grafted cells, which form functional intercellular 
connections with the native cardiomyocytes and/or existing vessels to improve 
global cardiac function and/or to increase myocardial blood flow. However, it is 
controversial whether differentiation of the grafted cells into expected phenotypes 
could consistently occur in the native myocardium and/or contribute to the 
functional improvement.  
 
4.1.2.2 Paracrine effects on native myocardium 
Grafted SMB and BMC are reported to be able to improve cardiac function and 
perfusion of acute MI in a paracrine manner, in which mediators secreted by the 
grafted cells improve functions of native cardiomyocytes, enhance angiogenesis 
and modulate extracellular collagen contents, consequently improving global 
function and perfusion of the heart (Suzuki et al., 2001a; Niagara et al., 2007; 
Murtuza et al., 2004; Kamihata et al., 2001; Takahashi et al., 2006). However, 
these effects have not been fully studied in post-MI chronic HF. 
 
4.1.3 The use of retrograde IC route for cell-delivery 
 
 
Whereas direct IM injection has been frequently used for cell therapy in 
experimental and clinical studies to date, this method was reported to have 
disadvantages including formation of islet-like cell-clusters and induction of 
myocardial damage in normal and acute MI-hearts (Reinecke et al., 2002; Suzuki 
et al., 2004b; Suzuki et al., 2004a).  
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Unlike IM injection, IC injection is reported to disseminate donor cells widely 
with less myocardial damage (Saito et al., 2003; Suzuki et al., 2004d). Thus, 
donor cells grafted via the IC route might show a different behaviour in the native 
myocardium from those grafted via the direct IM route, consequently affecting the 
therapeutic benefits in post-MI chronic HF. In addition, retrograde IC injection 
(injection into the cardiac veins) might have little risk of coronary embolism, 
which is a concern of antegrade IC injection of either SMB (Suzuki et al., 2000a) 
or BMC (Vulliet et al., 2004). Therefore, both direct IM and retrograde IC 
injections were tested and compared in this work. 
 
4.1.4 Aim of Chapter 4 
 
The aim of this Chapter is to report on the comprehensive investigations into the 
pattern and mechanism of the therapeutic effects following either SMB or BMC 
injection for treating post-MI chronic HF and to compare these effects between 
the direct IM and retrograde IC injections. 
 
For this purpose, the experimental model, in which donor cells derived from GFP-
transgenic SD male rats are injected into the post-MI chronically failing heart of 
wild-type female SD rats, was used, as its suitability was verified in the Chapter 3.  
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4.2 Results 
 
Injection of donor cells from male GFP-transgenic SD rats into the heart was 
carried out at 21 days after LCA ligation in female wild-type SD rats {Chapter 
2.4.3, 2.4.4} (n=260). The rats with LVEF ≥40% (insufficient LV dysfunction), 
assessed by 2-dimensional mode echocardiography just before cell injection, were 
excluded from the study. By injecting either SMB, BMC or PBS only via either 
the IM or retrograde IC route, 6 experimental groups were generated. 
 
PBS-IM group (n=42): IM injection of 100 µL of PBS only. 
PBS-IC group (n=43): IC injection of 500 µL of PBS only. 
SMB-IM group (n=44): IM injection of 5×106 SMB in 100 µL of PBS. 
SMB-IC group (n=44): IC injection of 5×106 SMB in 500 µL of PBS. 
BMC-IM group (n=43): IM injection of 1×107 BMC in 100 µL of PBS. 
BMC-IC group (n=44): IC injection of 1×107 BMC in 500 µL of PBS. 
 
Ten rats in each group were sacrificed for histological and biochemical analysis at 
day 3 after cell injection. Five rats in each group were sacrificed for biochemical 
analysis at day 7. Ten rats in each group were then sacrificed for histological and 
biochemical analysis at day 28 after cell injection. Finally, 5 rats in each group 
were sacrificed for biochemical analysis at day 84. 
 
Data for the controls, including normal rats (no surgery) and sham-operated rats 
(LCA ligation and no injection), are described in the Chapter 3. 
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4.2.1 Procedural mortality and morbidity 
 
Procedural mortality following cell injection was similar in all groups; 4.8% 
(2/42) for the PBS-IM group, 7.0% (3/43) for the PBS-IC group, 9.1% (4/44) for 
the SMB-IM group, 9.1% (4/44) for the SMB-IC group, 7.0% (3/43) for the 
BMC-IM group and 9.1% (4/44) for the BMC-IC group. All the mortalities after 
cell injection occurred during or immediately after the procedure, presumably due 
to surgical stresses such as bleeding. No severe morbidity such as thoracic wall 
infection, ascites or extraordinarily low activity was observed after cell injection. 
 
4.2.2 Improved cardiac function after cell therapy 
 
Cardiac function, dimensions and HR were serially evaluated with 
echocardiography (n=10 in each group at each time point) {Chapter 2.5.1}. LVEF 
was assessed with 2-dimensional mode. LVDd/Ds and HR were measured with 
M-mode. Peak transmitral E/A flow were assessed by Doppler traces. All 
assessments were carried out by a single ultrasonographer (myself). 
 
4.2.2.1 LVEF after cell therapy 
LVEF one day before cell injection was not significantly different between any 
groups (36.5±0.4% in the PBS-IM group, 35.2±1.0% in the PBS-IC group, 
33.4±0.6% in the SMB-IM group, 34.5±0.6% in the SMB-IC group, 33.7±0.5% in 
the BMC-IM group and 33.1±0.6% in the BMC-IC group, figure 4.1).  
 
LVEF after PBS injection via either route was not significantly changed 
throughout the experimental period analysed. LVEF following injection of either 
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SMB or BMC via either route was significantly greater than that following 
corresponding PBS injections at day 7, 28 and 84 (p<0.001), but not at day 3. 
 
Following injection of SMB via either route, LVEF was improved by day 7 
(41.4±1.6% in the SMB-IM group and 43.9±0.7% in the SMB-IC group) 
compared to before injection (p<0.05, respectively), but not by day 3 (36.1±1.2% 
and 37.4±1.3%, respectively). The LVEF improvement in the SMB-IM group and 
the SMB-IC group continued until day 84 (37.6±1.1% and 39.4±1.2%, 
respectively).  
 
BMC injection via either route resulted in a similar trend in LVEF improvement 
to SMB injection. LVEF was improved by day 7 in the BMC-IM group 
(42.4±1.2%) and the BMC-IC group (46.4±0.7%) compared to before injection 
(p<0.05, respectively). The LVEF improvement lasted until day 84 (41.8±1.5% 
and 40.1±1.8%, respectively).  
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Figure 4.1: Change in LVEF after cell therapy. Serial analysis of 2-D mode 
echocardiography showed a significantly greater LVEF in all the cell injected groups than 
the PBS-IM group and the PBS-IC group at day 7, 28 and 84. -1; one day before cell 
injection. n=10 in each group at each time point. *p<0.05 vs. the PBS-IM group; †p<0.05 
vs. the PBS-IC group at each time point.  
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4.2.2.2 HR  after cell therapy 
HR after injection of either SMB or BMC into the post-MI chronically failing 
heart via either route was significantly lower than that of the corresponding PBS 
injections at day 28 (p<0.05), but not at day 84 (table 4.1). While PBS injection 
via either route increased HR by day 28 compared to before injection (p<0.05), 
the hearts after injection of either SMB or BMC via either route did not develop 
HR increase.  
 
4.2.2.3 LV dimensions after cell therapy 
LVDs after injection of either SMB or BMC via either route was significantly 
smaller than that after PBS injection via either route at day 28 (p<0.05), but not at 
day 84 (table 4.1). LVDd was not significantly different between any groups at 
day 28 or 84. Although LVDs was enlarged by day 28 after PBS injection via 
either route compared to before injection (p<0.05), such enlargement was not 
observed at day 28 after injection of either SMB or BMC via either route. In 
contrast, LVDd was enlarged by day 28 in all the groups compared to before 
injection (p<0.05). 
 
4.2.2.4 Peak E/A flow ratio after cell therapy 
Peak E/A after injection of either SMB or BMC via either route was significantly 
larger than that after PBS injection via either route at day 28 (p<0.05), while peak 
E/A at day 84 was not significantly different between any groups. Although peak 
E/A was reduced at day 28 after PBS injection via either route compared to before 
injection (p<0.05), such reduction was not observed at day 28 after injection of 
either SMB or BMC via either route. 
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4.2.3 Improved physical activity after cell therapy 
 
Physical activity after cell therapy was assessed using telemetry {Chapter 2.5.2}. 
Twenty-four hours continuous monitoring of the signal strength was carried out at 
day 1, 7, 14, 28, 56 and 84 (n=7 in the PBS-IM group, the PBS-IC group, the 
BMC-IM group and the BMC-IC group, n=8 in the SMB-IM group and the SMB-
IC group, at each time point).  
 
All the groups showed an improvement in physical activity by day 7, though this 
was not statistically significant, presumably due to recovery from the surgical 
stress. Whereas physical activity did not increase after PBS injection via either 
route, injection of either SMB or BMC via either route improved physical activity 
by day 28 (figure 4.2). Improved activity after cell injection continued until day 
84.  
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Figure 4.2: Change in physical activity after cell therapy. The daily average of 
physical activity, analysed by 24 hours continuous monitoring using the telemetry, was 
greater in the SMB-IM, SMB-IC, BMC-IM and BMC-IC groups compared to the PBS-IM 
and PBS-IC groups at day 28, 56 and 84.  n=7 in the PBS-IM group, the PBS-IC group, 
the BMC-IM group and the BMC-IC group; n=8 in the SMB-IM group and the SMB-IC 
group at each time point. *p<0.05 vs. the PBS-IM group and †p<0.05 vs. the PBS group at 
each time point.  
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4.2.4 Poor graft survival in the native myocardium 
 
The presence of male donor-derived cells in the female hearts was quantitatively 
assessed using real-time TaqMan PCR for the Y-chromosome specific Sry gene at 
day 3, 7, 28 and 84 {Chapter 2.8.2}(n=5 in each group at each time point). Sry 
levels were normalised for the DNA amount by the autosomal single copy gene 
oesteopontin. The number of surviving grafted cells was estimated by correcting 
relative Sry expression using the standard curves generated in the Chapter 3 
{Chapter 3.2.4}. 
 
4.2.4.1 Graft survival after SMB injection 
At day 3 after 5×106 SMB injection via the IM and IC route, the Sry-positive cell 
number present in the LV walls was only 67.2±22.8×104 (13.5±4.6% of the total 
cell number injected) and 51.7±26.6×104 (10.3±5.3% of the total cell number 
injected), respectively (figure 4.3A). The grafted cell number decreased to 
18.9±3.7×104 (3.8±0.8%) and 19.8±9.6×104 (4.0±0.9%) by day 7 and further 
decreased by day 28 (1.6±0.8×104 and 1.4±1.0×104, respectively). A small 
number of Sry-positive cells were still detected in the native LV at day 84 
(1.4±0.7×104 and 2.5±1.7×104, respectively). 
 
4.2.4.2 Graft survival after BMC injection 
At day 3 after IM and IC injection of 1×107 BMC, only 14.5±2.7×104 cells 
(1.4±0.3% of the total cell number injected) and 18.4±2.7×104 cells (1.8±0.3% of 
the total cell number injected) were still detected in the LV, respectively (figure 
4.3B). The Sry-positive cell number present in the native LV was decreased by 
day 7 (0.7±0.2×104 and 0.8±0.2×104 cells, respectively). A small number of Sry-
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positive cells were detected in the native LV at day 28 (6.0±4.8×104 and 
0.7±0.0×104, respectively) and day 84 (0.3±0.2×104 and 0.3±0.2×104, 
respectively). 
 
 
 
 
 
 
Figure 4.3: Graft survival in the myocardium after cell therapy. Quantity and time-
course of male donor-derived cells present in the female LV were analysed by real-time 
PCR for the Y-chromosome specific Sry gene. (A) The survival in the SMB-IM group and 
the SMB-IC group at day 3 was only 13.5±4.6% and 10.3±5.3% of total injected cells, 
respectively. This was further decreased by day 28. (B) The survival in the BMC-IM group 
and the BMC-IC group at day 3 was only 1.4±0.3% and 1.8±0.3% of total injected cells, 
respectively. This was decreased by day 7. The surviving cell number in the BMC-IM 
group and the BMC-IC group was smaller than that in the SMB-IM and SMB-IC group at 
day 3 and 7. n=5 in each group at each time point.  
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4.2.5 Distribution of grafted cells in the myocardium 
 
Grafted cells in the native myocardium were visualised by their GFP expression at 
day 3 and 28 (n=5 in each group at each time point). Endogenous GFP signals 
were amplified by immunolabelling using the GFP specific primary antibody. 
Morphology and distribution of the grafted cells in the native myocardium were 
assessed by non-fluorescent imaging with haematoxylin counterstaining {Chapter 
2.9.4}. Sections at 10 different levels of the heart were examined per one heart. 
 
4.2.5.1 Graft distribution after SMB injection 
At day 3 after direct IM injection of SMB, all the hearts showed localised cell-
clusters containing brown-stained GFP-positive cells with disruption of the native 
myocardium in the peri-infarct area (figure 4.4A). These cell-clusters consisted of 
GFP-positive grafted cells and also accumulated native (GFP-negative) cells 
(figure 4.4B). GFP-positive grafted cells, which showed a spindle-shape, were 
identified in only 3 hearts out of 5 at day 28 after IM injection of SMB (figure 
4.4C). The grafted cell-clusters, whose size was much smaller than those at day 3, 
appeared to be isolated from the native myocardium at day 28. 
 
In contrast, all the hearts at day 3 after retrograde IC injection of SMB showed 
widely distributed GFP-positive grafted cells (figure 4.4D) in the infarct (figure 
4.4E) and peri-infarct (figure 4.4F) areas with less inflammation than those at day 
3 after direct IM injection. The grafted cells in the peri-infarct area appeared to 
have direct contacts with the native cardiomyocytes (figure 4.4F). There was no 
finding indicating coronary embolism after retrograde IC injection of SMB in any 
hearts. At day 28 after retrograde IC injection of SMB, GFP-positive grafted cells, 
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which showed a spindle-shape or myotube-like morphology (figure 4.4G), were 
identified in only 3 hearts out of 5. 
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Figure 4.4: Graft distribution and morphology after SMB injection. Grafted SMB 
were visualised by HRP-based immunohistochemistry for GFP counterstained with 
haematoxylin. Representative picture at day 3 after IM injection shows formation of 
brown-stained GFP-positive cell-clusters (arrow heads) with disrupting native myocardium 
in the peri-infarct area (A). In higher magnification (400×) of the outlined area in A, the 
cell-clusters were found to consist of GFP-positive cells and accumulated GFP-negative 
cells (B). At day 28 after IM injection, a smaller size of GFP-positive cell-clusters than day 
3 was detected in the native myocardium (C). Representative picture at day 3 after 
retrograde IC injection of SMB shows no disruption of the myocardial structure by the 
grafted cells (D). Higher magnification (400×) of the outlined areas in D shows GFP-
positive cells in infarct (E) and peri-infarct (F) areas with less inflammation than IM-
injected heart. At day 28 after retrograde IC injection of SMB, myotube-like shaped GFP-
positive cells were detected (G). Scale bar = 300 µm in A and D; 50 µm in B, C, E, F and 
G. 
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4.2.5.2 Graft distribution after BMC injection 
BMC injection via the direct IM or retrograde IC route demonstrated a similar 
graft distribution to SMB injection in all the hearts (n=5 in each group at each 
time point). At day 3 after direct IM injection, cell-clusters containing GFP-
positive grafted cells were present with disruption of the native myocardial 
structure in the peri-infarct area (figure 4.5A). These grafted cell-clusters 
consisted of the grafted GFP-positive cells and accumulated native cells (figure 
4.5B). A small number of GFP-positive grafted cells were detected in the peri-
infarct area in 3 hearts out of 5 at day 28 after IM injection of BMC (figure 4.5C).  
 
In contrast, retrograde IC injection of BMC disseminated the cells widely with 
less inflammation than direct IM injection at day 3 in all the hearts (figure 4.5D 
and E). A small number of GFP-positive grafted cells were still detected in 2 
hearts out of 5 at day 28 after retrograde IC injection of BMC (figure 4.5F).  
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Figure 4.5: Graft distribution and morphology after BMC injection. Grafted BMC 
were visualised by HRP-based immunohistochemistry for GFP counterstained with 
haematoxylin. A representative picture at day 3 after IM injection of BMC shows formation 
of brown-stained GFP-positive cell-clusters (arrow heads) with disruption of the native 
myocardium in the peri-infarct area (A). Higher magnification (400×) of the outlined area 
of A shows that GFP-positive cells were surrounded by numerous native GFP-negative 
cells (B). At day 28 after IM injection, a small number of GFP-positive cells were detected 
(C). A representative picture at day 3 after IC injection shows no disruption of the native 
myocardial structure by the grafted cells (D). Higher magnification (400×) of the outlined 
area of D shows disseminated GFP-positive cells with less inflammation than IM-injected 
heart (E). At day 28 after IC injection, a small number of GFP-positive cells were detected 
(F). Scale bar = 300 µm in A and D, 50 µm in B, C, E and F. 
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4.2.6 Behaviour of the grafted cells in the myocardium 
 
The behaviour of the grafted cells at day 28 was assessed by immunolabelling for 
GFP and either Cx43 for SMB-injected hearts or CD45 for BMC-injected hearts 
(n=5 in each group). Cryosections, cut consecutively with a thickness of 20 µm, 
were labelled every 25-30 sections from the apex to LCA ligation site. As a result, 
20-30 sections were labelled and examined per one heart sample. Each labelled 
section was assessed by confocal microscopy. Cardiomyogenic differentiation 
and/or fusion with a native cardiomyocytes were determined by a GFP-positive 
cardiomyocyte-like morphology with formation of Cx43-gap junctions with 
adjacent cardiomyocytes. Vascular differentiation and/or fusion with existing 
vessels were determined by integration of GFP-positive CD45-negative cells into 
vessel walls. 
 
4.2.6.1 Fate of grafted SMB 
After direct IM injection of SMB, all the GFP-positive cells detected were present 
in the peri-infarct area without having cardiomyogenic morphology (table 4.2 and 
figure 4.6A). These cells did not have direct contacts with the native 
cardiomyocytes. In contrast, the GFP-positive cells following retrograde IC 
injection of SMB were present in both the peri-infarct and infarct areas (figure 
4.6B and C). While most of the cells showed an elongated myotube-like 
appearance, one GFP-positive cell in total 2447 GFP-positive cells detected 
(0.04%) had a cardiomyocyte-like morphology forming Cx43-gap junctions with 
native cardiomyocytes (figure 4.6G).  
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4.2.6.2 Fate of grafted BMC 
After direct IM injection of BMC, all the GFP-positive cells detected were present 
in the peri-infarct area (table 4.2). Although most of the cells showed an elongated 
morphology in the fibrous tissue with or without expressing CD45 (figure 4.6D), a 
small number of cells (0.35%) were integrated into vessel walls without 
expressing CD45 (figure 4.6H). On the other hand, the GFP-positive cells 
following IC injection of BMC were present in both the peri-infarct and infarct 
areas (figure 4.6E and F) with a small number of cells (0.77%) being integrated 
into vessel walls. 
 
 
 
 
 
 
 
Table 4.2: Differentiation/fusion of GFP-positive cells in the myocardium. n=5 in 
each group. Differentiation/fusion means either GFP-positive cardiomyocyte-like 
morphology with formation Cx43-gap junctions with adjacent cardiomyocyte or GFP-
positive CD45-negative cells integrating into vessel walls. 
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Figure 4.6: Behaviour of the grafted cells at day 28. Morphology and function of the 
grafted cells at day 28 were assessed by immunolabelling for GFP (green) and either 
Cx43 (red) or CD45 (red). Nuclei were stained with DAPI (blue). Following SMB injection, 
a small number of GFP-positive cells were found in the peri-infarct area of the IM-injected 
heart (A) and in the peri-infarct (B) and the infarct (C) areas of the IC-injected heart. 
Following BMC injection, a small number of GFP-positive cells were also found in the 
peri-infarct area of the IM-injected heart (D) and in the peri-infarct (E) and the infarct (F) 
areas of the IC-injected heart. Whereas most of the GFP-positive cells at day 28 did not 
show differentiation into cardiomyocyte or endothelial-like phenotype, an extremely small 
number of GFP-positive cells showed a cardiomyocyte-like morphology with Cx43-gap 
junctions with native cardiomyocytes (G) or were integrated into vessel walls (H). The 
secondary control for either Cx43 or CD45 did not show non-specific labelling (I). Scale 
bar = 50 µm. 
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4.2.7 Attenuated fibrosis after SMB injection 
 
As a target of cell therapy-induced paracrine effects, collagen deposition of the 
native myocardium was assessed by picrosirus red staining {Chapter 2.9.5} at day 
28 after cell injection (n=5 in each group). Five individual fields of both peri-
infarct and infarct-remote areas at two different levels of the LV (apex and base 
side) were analysed per one heart (total 20 different fields per one heart).  
 
4.2.7.1 Collagen deposition at peri-infarct area 
The collagen-rich red-stained infarct area was clearly separated from the orange-
coloured non-infarct areas (figure 4.7). A difference in collagen accumulation 
between the IM and IC-injected hearts was not seen. 
 
Higher magnification (400×) revealed less extracellular-collagen accumulation in 
the peri-infarct area at day 28 after SMB injection via either route compared to 
that after injection of PBS or BMC via either route (figure 4.8). Collagen volume 
fraction in the peri-infarct area, semi-quantitatively assessed by NIH image-
analysis software (10 individual fields per one heart, n=5 in each group), was 
significantly smaller after SMB injection via the direct IM (15.6±0.6%) or 
retrograde IC (14.1±0.5%) route compared to the other groups, while collagen 
volume after BMC injection via either the IM (21.8±0.6%) or IC (22.5±1.0%) 
route was not significantly different from that after PBS injection via either the 
IM (24.3±0.9%) or IC (23.0±1.0%) route (figure 4.8).  
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Figure 4.7: Changes in fibrosis after cell therapy for post-MI chronic HF. 
Representative pictures of picrosirus red staining at day 28 clearly show collagen-rich 
infarct area (red colour) and peri-infarct area (orange colour) in the SMB-IM group (B) 
and the SMB-IC group (E), compared to the PBS-IM group (A), the PBS-IC group (D), the 
BMC-IM group (C) and the BMC-IC group (F). Scale bar = 500 µm.  
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Figure 4.8: Changes in fibrosis in the peri-infarct area after cell therapy. 
Representative pictures of picrosirus red staining in the peri-infarct area (400×) at day 28 
showed less accumulation of collagen in the extracellular space of the SMB-IM group (B) 
and the SMB-IC group (E) compared to the PBS-IM group (A), the PBS-IC group (D), the 
BMC-IM group (C) and the BMC-IC group (F). Scale bar = 100 µm. Semi-quantitative 
evaluation by image-analysing software showed a significantly less collagen volume 
fraction in the SMB-IM and SMB-IC groups compared to the corresponding PBS and 
BMC groups (G). n=5 in each group. *p<0.05 vs. the PBS-IM group and the BMC-IM 
group; †p<0.05 vs. the PBS-IC group and the BMC-IC group.  
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4.2.7.2 Collagen deposition at infarct-remote area 
Extracellular collagen accumulation in the infarct-remote area, assessed by 
picrosirus red staining, was smaller than that in the peri-infarct area in all the 
groups (figure 4.9). The hearts at day 28 after SMB injection via either route 
showed less collagen accumulation than those after corresponding PBS or BMC 
injections via either route. 
 
Collagen volume fraction in the infarct-remote area was assessed by NIH image-
analysis software (10 individual fields per one heart, n=5 in each group). SMB 
injection via the direct IM (12.7±0.4%) or retrograde IC (11.3±1.2%) route 
resulted in a reduced collagen volume in the infarct-remote area, compared to PBS 
injection via either route (15.8±0.5% and 15.0±0.8%, respectively) or BMC 
injection via either route (15.6±0.8% and 14.5±0.7%, respectively). Any 
differences in collagen deposition in the infarct-remote area were not seen 
between the IM and IC-injected hearts. 
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Figure 4.9: Changes in fibrosis in the infarct-remote area after cell therapy. 
Representative pictures of picrosirus red staining in the infarct-remote area (400×) at day 
28 show less extracellular collagen accumulation in the SMB-IM group (B) and the SMB-
IC group (E) than the PBS-IM (A) group, the PBS-IC (D) group, the BMC-IM (C) group 
and the BMC-IC group (F). Scale bar = 100 µm. Collagen volume fraction in the infarct-
remote area was significantly less in the SMB-IM group and the SMB-IC group than the 
corresponding PBS and BMC groups (G). n=5 in each group. *p<0.05 vs. the PBS-IM 
group and the BMC-IM group; †p<0.05 vs. the PBS-IC group and the BMC-IC group.  
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4.2.8 Enhanced capillary density after BMC injection 
 
As a target of cell therapy-induced paracrine effects, vascularity of the native 
myocardium following cell injection was assessed in transverse sections of the 
heart by immunolabelling for von Willebrand factor (vWF) at day 28 {Chapter 
2.9.2} (n=5 in each group). Five individual high-power fields (400×) of the peri-
infarct area at two different levels of the LV were analysed per one heart using 
confocal microscopy {Chapter 2.9.3}. 
 
Capillary vessels which consist of only one or two endothelial cells were 
identified between native cardiomyocytes which had a slight green auto-
fluorescence (figure 4.10). The number of capillaries appeared to be greater in the 
hearts after BMC injection via either route than that in the corresponding SMB 
and PBS injection groups, while the hearts after SMB injection via either route 
showed a similar capillary density to those after PBS injection via either route. 
 
Capillary number in the peri-infarct area was counted in the recorded pictures (10 
individual pictures per one heart) and the capillary density, expressed as the 
number per mm2, was analysed among the groups (n=5 in each group). Capillary 
density was significantly greater in the hearts after BMC injection via either the 
direct IM (978±79/mm2) or retrograde IC (877±39/mm2) route, compared to those 
after PBS injection via the IM (685±24/mm2) or IC (660±36/mm2) route and SMB 
injection via the IM (711±13/mm2) or IC (711±13/mm2) route (figure 4.10).  
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Figure 4.10: Changes in myocardial capillary density after cell therapy. Capillary 
vessels in the peri-infarct myocardium at day 28 after cell injection were assessed by 
immunolabelling for vWF. Representative confocal micrographs (red for vWF, blue for 
nuclei, green for cardiomyocytes) showed a greater number of capillary vessels in the 
BMC-IM group (C) and the BMC-IC group (F), compared to the PBS-IM group (A), the 
PBS-IC group (D), the SMB-IM group (B) and the SMB-IC group (E). Scale bar = 50 µm. 
Semi-quantitative evaluation shows significantly greater capillary density in the BMC-IM 
group and the BMC-IC group than the corresponding PBS and SMB groups. n=5 in each 
group (G). *p<0.05 vs. the PBS-IM group and the SMB-IM group; †p<0.05 vs. the PBS-IC 
group and the SMB-IC group.  
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4.3 Discussion 
 
This Chapter demonstrates that both direct IM and retrograde IC injection of 
either SMB or BMC consistently improve cardiac function of post-MI chronic HF 
over 84 days analysed. Furthermore, it was for the first time shown that 
improvement in cardiac function following cell injection was associated with 
improved physical activity using a rat post-MI chronic HF model. The therapeutic 
benefits from the retrograde IC injection were no less than those from the direct 
IM injection of the same number of either SMB or BMC. Cell-distribution was 
markedly different between the two delivery routes, but overall graft survival was 
not significantly different.  
 
Regardless of the route of injection, SMB injection decreased extracellular 
collagen deposition in both peri-infarct and infarct-remote areas, but did not affect 
vascular formation. In contrast, BMC injection via either route increased capillary 
density in the peri-infarct area, but did not affect collagen deposition in either the 
peri-infarct or infarct-remote areas. Cardiomyogenic trans-differentiation of the 
grafted cells or fusion of the grafted cells with the native cardiomyocytes was 
only rarely found and only a small number of the grafted BMC formed vessel 
walls. These findings suggest an important role of paracrine effects in the 
observed therapeutic benefits from cell injection. 
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4.3.1 Improved cardiac function and physical activity after cell therapy 
 
Both systolic (i.e. LVEF) and diastolic (i.e. peak E/A flow) cardiac functions of 
post-MI chronic HF were improved following either SMB or BMC injection via 
either the direct IM or retrograde IC routes in an established rat model. As cell 
injection, regardless of the cell-type or cell-delivery route, failed to suppress 
progression of LV dilatation (i.e. LVDd), improvement in systolic LV function 
after cell injection appeared to be largely dependent on reduced LVDs. In addition, 
reduced HR at 28 days after injection of either SMB or BMC, compared to that 
after PBS injection, may be relevant to improved cardiac function after cell 
therapy.  
 
Moreover, data presented here showed that physical activity, which is another 
important indicator of HF (Reid et al., 2006), was significantly improved after 
injection of either SMB or BMC via either route, while change in physical activity 
following cell therapy have not been evaluated using experimental model to date. 
These findings indicate that injection of either SMB or BMC via either route is 
able to consistently improve cardiac function of post-MI chronic HF. 
 
However, LVEF tended to be reduced from day 28 onwards (though not 
significantly) regardless of the cell-type or cell-delivery route, whereas 
improvement in physical activity following cell injection did not show any 
downward trend over the 84 days analysed. In addition, at day 84, HR and LVDs 
after cell injection were not significantly smaller than those after PBS injection. 
Peak E/A flow was not significantly different among all the groups at day 84. 
These findings suggest that the therapeutic effects of cell therapy could be 
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transient regardless of the cell-type or cell-delivery route, as suggested in clinical 
studies of cell therapy using SMB (Hagege et al., 2006) and BMC (Meyer et al., 
2006). Further long-term study is required to determine the durability of the 
benefits of cell therapy for post-MI chronic HF. 
 
4.3.2 Efficiency of retrograde IC cell injection for post-MI chronic HF 
 
The degree of improvement in cardiac function and physical activity in post-MI 
chronic HF was, contrary to the expectation, not significantly greater in retrograde 
IC cell injection than direct IM cell injection. Although retrograde IC injection 
achieved a wide dissemination of the grafted cells with less myocardial damage, 
survival of the grafted cells was similarly poor to that after direct IM injection 
which formed islet-like clusters of the grafted cells accompanied by an intense 
inflammatory response.  
 
As regards to retrograde IC cell injection, initial engraftment of donor cells, 
including adherence to endothelium and subsequent trans-endothelial donor cell-
migration into the myocardial interstitium, may be a limiting process for the 
number of donor cells present in the native myocardium (Hou et al., 2005). 
However, this limiting process (initial cell-engraftment), which is not relevant to 
IM injection, could be improved by increasing injection pressure or extending 
incubation time, resulting in enhancement of overall graft size and consequent 
therapeutic effects.  
 
Direct cellular contacts between the grafted cells and the native cardiomyocytes 
appeared to be greater in the hearts following retrograde IC cell injection than 
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direct IM cell injection. However, trans-differentiation of the grafted SMB or 
BMC was only rarely identified in either the IC-injected or IM-injected hearts. 
Direct intercellular contacts, which reportedly enhance cardiomyogenic trans-
differentiation in vitro (Iijima et al., 2003; Fukuhara et al., 2003), might not be 
sufficient to induce differentiation of the grafted SMB or BMC into a 
cardiomyogenic phenotype in vivo. In addition, paracrine effects, such as 
attenuation in collagen deposition and increase in capillary density, were not 
different between the IC-injected and IM-injected hearts. 
 
4.3.3 Mechanisms of functional improvement  
 
4.3.3.1 Low frequency of trans-differentiation or fusion 
It was reported that trans-differentiation of the surviving grafted cells into 
cardiomyogenic and/or vascular phenotypes in the myocardium is one of the 
important possible mechanisms of functional improvement after cell therapy 
(Iijima et al., 2003; Kajstura et al., 2005; Kocher et al., 2001). However, in this 
work, both the grafted SMB and BMC via either route poorly survived in the 
myocardium at 28 days after injection (only less than 100,000 cells per one heart 
which has more than 20,000,000 cardiomyocytes (Olivetti et al., 1990)) using an 
established quantitative cell-tracking method (Muller-Ehmsen et al., 2002; Yasuda 
et al., 2005; Hayashi et al., 2004). Furthermore, only a low frequency of 
cardiomyogenic trans-differentiation (less than 1% of surviving donor-derived 
cells) was found. Such a poor graft survival and a low frequency in trans-
differentiation (and/or fusion), which are consistent with previous reports 
(Hayashi et al., 2004; Huwer et al., 2003; Reinecke et al., 2002; Murry et al., 
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2004; Balsam et al., 2004; Nygren et al., 2004; Rubart et al., 2004), are highly 
unlikely to modulate global cardiac function via a direct mechanical/functional 
contribution.  
 
Only one cell was detected, which was positive for GFP (donor-derived) and have 
a cardiomyocyte-like morphology forming gap junctions with native 
cardiomyocytes at 28 days after retrograde IC injection of SMB. However, it is 
difficult to determine the origin of this cell; cardiomyogenic trans-differentiation 
of a grafted cell or fusion of a grafted cell with a native cardiomyocyte, as both 
GFP and Y-chromosome would be expressed in the cell through either event. 
Injection of GFP-positive female donor cells into the male wild-type heart might 
identify the origin by means of immunolabelling for GFP and in situ hybridisation 
for Y-chromosome. The cell which is positive for only GFP and negative for Y-
chromosome would be derived through cardiomyogenic trans-differentiation and 
the cell which is positive for both GFP and Y-chromosome would be derived 
through fusion with a native cardiomyocyte. However, no matter which event 
(trans-differentiation or fusion) occurred in the myocardium, such an extremely 
low-frequency events would not be an important factor for global cardiac function. 
 
In addition, only an extremely small number of GFP-positive cells (only 3.5% of 
total GFP-positive cells detected) were integrated into vessel walls, while grafted 
cells in the ischaemic/infarct myocardium were suggested to differentiate into 
vascular cells and consequently improve regional myocardial perfusion (Iwasaki 
et al., 2006; Kawamoto et al., 2006). However, these studies did not quantitatively 
analyse differentiation of the grafted cells into vascular cells integration into the 
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native vascular network. Low-frequency events in vascular differentiation, 
observed in this study, would not be sufficient to modulate global myocardial 
blood flow and function. 
 
Therefore, trans-differentiation and/or fusion of the grafted cells may not be an 
important mechanism for functional improvement after currently-used protocol 
for cell therapy using either SMB or BMC. Use of the cell-type which is more 
likely to differentiate into a cardiomyogenic phenotype such as ES cells could 
enhance cardiomyogenic differentiation and/or fusion and contribute for the 
functional benefits. 
 
4.3.3.2 Paracrine effects of the grafted cells on the myocardium 
Paracrine effects were suggested to be an important mechanism of functional 
improvement obtained in the work covered in this Chapter. There was a 
significant reduction of pathological collagen deposition not only in the peri-
infarct but also in the infarct-remote myocardium after SMB injection via either 
route. Interestingly, unlike acute MI (Suzuki et al., 2001a; Niagara et al., 2007; 
Jiang et al., 2006), neovascularisation was not enhanced by SMB injection in this 
study targeting post-MI chronic HF. In contrast, BMC injection via either route 
increased capillary density in the peri-infarct myocardium, but failed to attenuate 
extracellular collagen deposition in the post-MI failing hearts, while BMC were 
reported to be able to both increase myocardial perfusion and reduce collagen 
content in acute MI-hearts (Kobayashi et al., 2000; Tomita et al., 2002; Duan et 
al., 2003; Takahashi et al., 2006). These findings indicate that paracrine effects 
may be affected by the condition of the native myocardium.  Differently-diseased 
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myocardium could respond differently to the paracrine stimuli or might modulate 
the secretion from the grafted SMB or BMC. 
 
My laboratory examined possible mediators for collagen deposition and 
angiogenesis, such as MMPs, TIMPs, VEGF, FGF, PDGF, angiotrophin or HIF1-
α by real-time PCR and western blotting, using hearts generated in this work, 
suggesting that no single factor but a balanced expression of factors could 
contribute to the reduced fibrosis following SMB injection and increased capillary 
density following BMC injection.  
 
In addition, my collaborators investigated changes in electrophysiological 
properties of the native cardiomyocytes following cell therapy, using the same 
experimental model as described in this work (data not published). Individual 
cardiomyocytes were isolated by enzymatic dissociation at day 28 (n=6 in the 
normal female SD rats, n=5 in the PBS-IM group, the SMB-IM group and the 
BMC-IM group) (Hering et al., 1983). After perfusion with collagenase (1.3 
mg/mL, Worthington Biochemical) and hyaluronidase (0.6 mg/mL, Sigma), the 
LV tissue was cut into small pieces and further dissociated with the enzymes to 
yield a single-cell suspension. Only GFP-negative (under fluorescence 
microscopy) rod-shape viable cardiomyocytes were studied. The projected 2-
dimensional area for each cell was measured by NIH image-analysis software. 
The total cell number examined was 221 in the normal hearts, 225 in the PBS-IM 
group, 328 in the SMB-IM group and 259 in the BMC-IM group.  
 
Cardiomyocytes from the PBS-IM group were significantly larger in size than 
those from normal rats (4,143±68 µm2 vs. 3,074±61 µm2, p<0.05, figure 4.11). 
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This hypertrophy showed a significant, but not complete, regression in both the 
SMB-IM group (3,657±53 µm2) and the BMC-IM group (3,732±67 µm2) (p<0.05). 
Electrophysiological properties of these native cardiomyocytes are now under 
investigation by my collaborators. 
 
 
 
 
 
 
 
Figure 4.11: Cell area of the cardiomyocytes following cell therapy for post-MI 
chronic HF in rat. The size of the native cardiomyocytes was assessed by enzymatic cell 
isolation at day 28. The PBS-IM group showed a significantly larger cardiomyocyte-size 
than the normal hearts. Cardiomyocytes in the SMB-IM group and the BMC-IM group 
were significantly smaller than those in the PBS-IM group, but still larger than those from 
the normal hearts. n=6 in the normal group; n=5 in the PBS-IM group, the SMB-IM group 
and the BMC-IM group. *p<0.05 vs. the normal group; †p<0.05 vs. the PBS-IM group. 
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In addition, it was reported that progressive pathological hypertrophy of the native 
cardiomyocytes following acute MI was attenuated by SMB injection (Murtuza et 
al., 2004). While the mechanism of the positive effects of cell therapy on the 
native cardiomyocytes is still unclear, proinflammatory cytokines such as IL-1β or 
TNFα, which are reported to independently modulate cellular functions of 
cardiomyocyte via Toll-like receptors (McTiernan et al., 1997; Kumar et al., 
1996; Rozanski and Witt, 1994), might play a role on this effect. 
 
There may be other paracrine effects of the grafted cells on the myocardium. 
Cytoprotective factors, such as endothelial nitric oxide synthase (eNOS), secreted 
by the grafted cells were reported to attenuate apoptosis of the native 
cardiomyocytes following acute MI, consequently attenuating the infarct size and 
enhancing the functional recovery (Gnecchi et al., 2006; Uemura et al., 2006). In 
addition, injection of SMB, which secrete SDF-1 (Ratajczak et al., 2003), into the 
MI heart was reported to enhance recruitment of endogenous circulating stem 
cells, such as c-kit, Sca-1 or CD34 positive cells, and consequently regenerate 
damaged myocardium (Memon et al., 2005a). As most of these studies were 
carried out using an acute MI model, it might be interesting to further examine the 
paracrine effects using a post-MI chronic HF model.  
 
4.3.4 Summary of Chapter 4 
 
Retrograde IC injection of either SMB or BMC was able to consistently provide 
similar, or possibly greater, therapeutic benefits, including improvement in cardiac 
function and physical activity, in ischaemic cardiomyopathy, compared to direct 
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IM injection. This finding demonstrates the promising utility of the retrograde IC 
route for either SMB or BMC-delivery to treat post-MI chronic HF. Further 
research, including comparison with antegrade IC cell injection, will be useful in 
enhancing the therapeutic effects following retrograde IC cell injection.  
 
Survival of the grafted cells was extremely low and trans-differentiation of the 
grafted cells into cardiomyocyte or vascular-like phenotypes was only rarely 
observed in the myocardium following either SMB or BMC injection via the 
direct IM or retrograde IC routes. Instead, paracrine effects including attenuation 
of collagen deposition, increase in capillary density or reduction in pathological 
hypertrophy of native cardiomyocytes, were considered to play an important role 
in the therapeutic benefits of cell therapy for post-MI chronic HF. 
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CHAPTER 5: ARRHYTHMOGENICITY FOLLOWING 
CELL THERAPY 
 
 
5.1 Introduction and Aim 
 
5.1.1 Occurrence of ventricular arrhythmia after cell therapy 
 
Although clinical studies showed that direct IM injection of SMB into the post-MI 
heart induces serious ventricular arrhythmias including sustained VT (Menasche 
et al., 2003; Dib et al., 2005b; Siminiak et al., 2004), the pattern and time-course 
of the arrhythmias are not fully understood. Recent clinical research has reported 
that such a risk may not be troublesome (Hagege et al., 2006). However, they 
administered anti-arrhythmia drugs which could mask arrhythmogenicity. 
 
In addition, occurrence of arrhythmia has not been fully studied in the case of 
BMC injection into the heart. Although previous clinical studies rarely observed 
arrhythmia occurrence after either direct IM (Perin et al., 2003; Tse et al., 2003; 
Beeres et al., 2006b) or antegrade IC (Fuchs et al., 2003; Kuethe et al., 2005; Blatt 
et al., 2005; Strauer et al., 2005) injection of BMC, patients in these studies were 
also prescribed with anti-arrhythmia drugs, which could mask arrhythmogenicity. 
Furthermore, arrhythmia occurrence in these patients might not be adequately 
examined by appropriate continuous monitoring (Kuethe et al., 2005; Perin et al., 
2003; Tse et al., 2003; Beeres et al., 2006b; Blatt et al., 2005; Strauer et al., 2005).  
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Therefore, it is important to determine the true arrhythmogenicity following 
injection of either SMB or BMC in reproducible experimental models in the 
absence of anti-arrhythmia drugs. 
 
5.1.2 Possible mechanisms of arrhythmia occurrence 
 
5.1.2.1 Direct effects of grafted cells 
Possible mechanisms of arrhythmogenicity following cell therapy include direct 
adverse effects of the grafted cells which acquire both arrhythmogenic potential 
and intercellular connections with surrounding native cardiomyocytes (Zhang et 
al., 2002). Both SMB and BMC have been shown to acquire arrhythmogenic 
potential in vitro (Abraham et al., 2005; Chang et al., 2006). However, the work 
described in the Chapter 4 showed that graft survival in the myocardium was 
extremely poor following injection of either SMB or BMC, suggesting that 
ectopic stimuli derived from such a small number of surviving cells, if any, might 
be diluted by much larger number of surrounding cardiomyocytes and would not 
lead to ventricular arrhythmias. 
 
My previous studies (Chapter 4) suggested intense aggregation of undifferentiated 
SMB in the peri-infarct myocardium in the early period after direct IM injection. 
As undifferentiated SMB are known to be electrically connected each other via 
Cx43-gap junctions (Stagg et al., 2006; Formigli et al., 2005), direct IM injection 
could generate a large electrical network consisting of the grafted undifferentiated 
SMB. While grafted SMB in the myocardium were reported to be unable to form 
gap-junction with the native cardiomyocytes in vivo (Leobon et al., 2003; 
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Reinecke et al., 2004b), electrical communication between the exogenous network 
by aggregated undifferentiated SMB and the myocardium, if any, might modulate 
electrical conductance, leading to the occurrence of ventricular arrhythmia.  
 
5.1.2.2 Heterogeneity and inflammation in the myocardium 
In addition, the results reported in Chapter 4 showed the generation of 
heterogeneity and damage in the peri-infarct myocardium in the early period after 
direct IM cell injection regardless of the cell-type injected. This may be a cause of 
arrhythmia occurrence. Associated inflammation, which is known to lead to 
fluctuations in membrane potential of the cardiomyocytes (Klein et al., 2000), 
might also cause ventricular arrhythmia.  
 
5.1.2.3 Paracrine effects 
Earlier data (Chapter 4) suggested that properties of cardiomyocytes might be 
modulated by mediators secreted by the grafted cells. Expression of Cx43 in the 
native cardiomyocytes, which is the major gap junction protein of ventricular 
cardiomyocytes, could also be modulated by paracrine effects following cell 
therapy, leading to the occurrence of ventricular arrhythmias. 
 
5.1.3 Aim of Chapter 5 
 
The aim of this Chapter is to define arrhythmogenicity after injection of either 
SMB or BMC into the post-MI chronically failing heart whilst comparing 
between the direct IM and retrograde IC routes for cell-delivery, in the absence of 
anti-arrhythmic drugs with continuous ECG monitoring.  
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5.2 Results 
 
The transducer for the telemetry system was implanted in the peritoneal cavity of 
female wild-type SD rats at 20 day after LCA ligation {Chapter 2.5.2} (n=44). 
One day after transducer implantation, either SMB (5×106), BMC (1×107), 
collected from male GFP-transgenic SD rats, or PBS only were injected into the 
heart via either the IM or IC route (n=7 in the PBS-IM group, the PBS-IC group, 
the BMC-IM group and the BMC-IC group, n=8 in the SMB-IM group and the 
SMB-IC group).  
 
The ECG was continuously monitored from 1 day before cell injection until day 7 
after cell injection. Then, 24-hour continuous recordings were carried out at day 
14, 28, 42, 56 and 84. All the rats with the transducer were fed individually and 
the ECG monitored. 
 
Among the samples obtained previously (Chapter 4), histological analysis was 
carried out using the rats sacrificed at day 3 (n=5 in each group), day 7 (n=4 in 
each group) and day 28 (n=5 in each group). Five rats in each group were 
sacrificed for biochemical analysis at day 3, 7, 28 and 84. In addition, ex-vivo 
heart perfusion was carried out at day 84 to examine latent arrhythmogenicity 
(n=3 in the PBS-IM group and the PBS-IC group, n=6 in the SMB-IM group and 
the SMB-IC group, n=5 in the BMC-IM group and the BMC-IC group). Data 
from the controls, including normal rats and sham-operated rats, was reported in 
Chapter 3. 
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5.2.1 Widened QRS interval after SMB injection into the failing heart 
 
All the rats examined showed typical ECG waves in post-MI chronic HF, such as 
negative Q wave and inverted T wave, at all time points analysed (figure 5.1).  
 
 
 
 
 
 
 
 
Figure 5.1: ECG waves after cell therapy for post-MI chronic HF. Representative 
traces of ECG, recorded by telemetry, show negative Q wave and inverted T wave in all 
the groups at day 28. Scale bar = 500 msec. 
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The daily average of ECG measurements in each group was analysed at day 3, 7, 
28 and 84 using ECG analysis software (n=7 in the PBS-IM group, the PBS-IC 
group, the BMS-IM group and the BMC-IC group, n=8 in the SMB-IM group and 
the SMB-IC group at each time point, table 5.2).  
 
The RR interval, P wave duration, PR interval or QT complex duration were not 
significantly different among the groups at any of the time points analysed. The 
QRS complex duration at day 28 after SMB injection via either route was 
significantly longer than that after PBS injection or BMC injection via either route 
(p<0.05). The QRS complex duration at day 7 and 84 after SMB injection tended 
to be longer than the other groups, though it was not significant.  
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Table 5.1: ECG measurements after cell therapy for post-MI chronic HF. n=7 in the 
PBS-IM group, the PBS-IC group, the BMC-IM group and the BMC-IC group; n=8 in the 
SMB-IM group and the SMB-IC group. *p<0.05 vs. the PBS-IM group and the BMC-IM 
group; †p<0.05 vs. the PBS-IC group and the BMC-IC group. 
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5.2.2 Spontaneous occurrence of ventricular arrhythmia after cell therapy 
 
Occurrence of spontaneous arrhythmia following cell injection was assessed by 
continuous monitoring of ECG using telemetry {Chapter 2.5.2} (n=7 in the PBS-
IM group, the PBS-IC group, the BMS-IM group and the BMC-IC group, n=8 in 
the SMB-IM group and the SMB-IC group at each time point). The hourly 
number of VPC was calculated as an average of the 24-hour recordings. After 
PBS injection via either route, spontaneous VPC were rarely observed throughout 
the experimental period analysed (figure 5.2 and 5.3). 
 
5.2.2.1 Spontaneous VPC following SMB injection 
Direct IM injection of SMB caused frequent VPC (≥40/hour) within 24 hours 
after injection, which lasted until day 14 with a peak at day 3 (124±75/hour, figure 
5.2). Then, the number of VPC gradually decreased, but a small number of VPC 
(≥5/hour) persistently remained until day 84. The VPC number at day 1, 3, 7, 14, 
28, 42, 56 and 84 after IM injection of SMB was significantly larger than IM 
injection of PBS (p<0.05).  
 
In contrast, after retrograde IC injection of SMB, VPC rarely occurred until day 7 
(<5/hour). The VPC number at day 1, 3, 7 and 14 after retrograde IC injection of 
SMB was significantly less than that after IM injection of SMB (p<0.05). 
However, from day 14 onward, a small number of VPC were persistently 
observed following retrograde IC injection (5-20/hour). The VPC number at 28, 
42, 56 and 84 days after retrograde IC injection of SMB was significantly greater 
than that after IC injection of PBS (p<0.05).  
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Figure 5.2: Number of spontaneous VPC following SMB injection for post-MI 
chronic HF. The hourly number of spontaneous VPC was calculated as an average of 
VPC number detected in the 24-hour ECG recordings using telemetry. The SMB-IM 
group showed frequent VPC with a peak at day 3, which was decreased by day 42. In 
contrast, the SMB-IC group rarely showed VPC until day 7, while VPC number in this 
group gradually increased with a peak at day 28. A small number of VPC (<10/hour) were 
persistently observed between day 42 and 84 in the SMB-IM group and the SMB-IC 
group. The PBS-IM group and the PBS-IC group rarely showed VPC throughout the 
experimental period analysed. n=7 in the PBS-IM group and the PBS-IC group; n=8 in the 
SMB-IM group and the SMB-IC group. *p<0.05 vs. the PBS-IM group; †p<0.05 vs. the 
SMB-IC group; ‡p<0.05 vs. the PBS-IC group.  
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5.2.2.2 Spontaneous VPC  following BMC injection 
Direct IM injection of BMC also produced VPC as early as day 1 (15±5/hour), 
which lasted until day 14 with a peak at day 7 (108±73/hour, figure 5.3). However, 
unlike direct IM injection of SMB, the frequent VPC largely disappeared by day 
28 after IM injection of BMC, and persistent VPC were not observed. Retrograde 
IC injection of BMC rarely produced VPC throughout the experimental period 
analysed. 
 
 
 
 
 
 
Figure 5.3: Number of spontaneous VPC following BMC injection for post-MI 
chronic HF. The hourly number of spontaneous VPC was calculated as an average of 
VPC number detected in the 24-hour ECG recordings using telemetry. The PBS-IM group 
and the PBS-IC group rarely showed VPC throughout the experimental period analysed. 
The BMC-IM group showed frequent VPC until day 14 with a peak at day 7. VPC number 
then largely decreased by day 28. The BMC-IC group showed rare VPC throughout the 
experimental period analysed. n=7 in each group at each time point. *p<0.05 vs. the 
PBS-IM group. 
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5.2.2.3 Occurrence of multiform VPC and VT following cell therapy 
The frequency of spontaneously occurring multiform VPC and VT, which are 
severe types of ventricular arrhythmias, was also counted following cell injection 
with the recorded ECG data acquired by telemetry. Multiform VPC (figure 5.3A) 
were frequently observed in the early period (day 3 and 7) after direct IM 
injection of either SMB or BMC (table 5.2).  
 
Of note, approximately half rats at day 3 and 7 after direct IM injection of either 
SMB or BMC showed spontaneous occurrence of VT (figure 5.3B and C).  One 
rat after retrograde IC injection of BMC showed VT, while no rats showed VT in 
the other groups. No spontaneous VT was observed at day 28 or 84 in other 
groups. 
 
 
 
 
Figure 5.4: Multiform VPC and VT after direct IM cell injection. Representative traces 
of spontaneous arrhythmia, recorded by telemetry, show multiform VPC at day 3 after 
direct IM injection of BMC (A), VT at day 7 after direct IM injection of BMC (B) and VT at 
day 3 after direct IM injection of SMB (C). Scale bar = 500 msec. 
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Table 5.2: Frequency of spontaneous multiform VPC and VT. n=7 in the PBS-IM 
group, the PBS-IC group, the BMC-IM group and the BMC-IC group; n=8 in the SMB-IM 
group and the SMB-IC group at each time point. *p<0.05 vs. the PBS-IM group and 
†p<0.05 vs. the PBS-IC group at each time point. Multi; multiform VPC. 
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5.2.3 Induced ventricular arrhythmia by isoproterenol administration 
 
Isoproterenol was administered to the post-MI chronically failing heart following 
cell therapy under ex-vivo perfusion in order to examine latent arrhythmogenicity 
{Chapter 2.6.1} (n=3 in the PBS-IM group and the PBS-IC group, n=6 in the 
SMB-IM group and the SMB-IC group, n=5 in the BMC-IM group and the BMC-
IC group). The hearts were removed at day 84 and perfused using a Langendorff 
apparatus. After a 20-minute stabilisation period, 1×10-7 M isoproterenol was 
administered continuously via the perfusate for 10 minutes and the ECG 
monitored. Normal female rat hearts were perfused under the same conditions as 
the control (n=3).  
 
Isoproterenol administration increased coronary flow rate and HR in all groups 
(p<0.05, table 5.3, figure 5.5). The normal hearts did not show any ventricular 
arrhythmias during the perfusion. Although VPC were observed during 
isoproterenol administration in all the post-MI hearts, only the hearts after SMB 
injection via either route showed a significant increase in the VPC number after 
isoproterenol administration from the baseline. Of note, VT was induced in 83.3% 
hearts after SMB injection via either route (figure 5.5), while one heart after IM 
injection of BMC showed VT. No VT was induced in the other groups. 
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Table 5.3: Induced arrhythmia following cell therapy. “Baseline” means the data 
during stabilisation (without isoproterenol); “Isoproterenol” means the data during 
continuous isoproterenol administration for 10 minutes (1×10-7 M). n=3 in the normal 
hearts, the PBS-IM group and the PBC-IC group; n=6 in the SMB-IM group and the SMB-
IC group; n=5 in the BMC-IM group and the BMC-IC group. *p<0.05 vs. baseline values; 
†p<0.05 vs. the PBS-IM group and the BMC-IM group; ‡p<0.05 vs. the PBS-IC group and 
the BMC-IC group.  
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Figure 5.5: Occurrence of VT by isoproterenol administration. Representative traces 
of ECGs, acquired under Langendorff perfusion, show increased HR on isoproterenol 
administration (1×10-7 M) in all the groups, compared to the baseline. VT was observed 
by isoproterenol administration in the SMB-IM group and the SMB-IC group. Scale bar = 
500 msec. n=3 in the normal hearts, the PBS-IM group and the PBC-IC group; n=6 in the 
SMB-IM group and the SMB-IC group; n=5 in the BMC-IM group and the BMC-IC group. 
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5.2.4 Heterogeneity and inflammation following cell therapy 
 
Non-fluorescent imaging for the grafted cells in the native myocardium, described 
in Chapter 4, showed the generation of severe heterogeneity following direct IM 
cell injection, but not following retrograde IC cell injection, regardless of the cell-
type injected. In order to further examine the heterogeneity as a possible 
mechanism of occurrence of ventricular arrhythmias, distribution of the grafted 
cells and associated inflammatory response in the myocardium was assessed by 
fluorescent immunolabelling for GFP and CD45. 
 
Cryosections, cut consecutively with a thickness of 20 µm, were labelled with 
polyclonal anti-GFP and monoclonal anti-CD45 antibodies in every 50 - 60 
sections from the apex to the LCA ligation site in hearts from day 3, 7 and 28 
(n=5 in each group at day 3 and 28; n=4 in each group at day 7) {Chapter 2.9.2}. 
As a result, 10 – 15 sections were labelled and examined per one heart sample.  
Each labelled section was assessed by confocal microscopy. 
 
Distinct heterogeneity was generated in the peri-infarct myocardium of all the rats 
at day 3 after direct IM injection of either SMB or BMC (figure 5.6). Native 
myocardial structure was disrupted and the formation of cell-clusters consisting of 
the GFP-positive grafted cells and accumulated GFP-negative CD45-positive cells 
was observed in the peri-infarct myocardium following direct IM cell injection, 
regardless of the cell-type injected. Following direct IM injection of BMC, some 
GFP-positive grafted cells expressed CD45 (figure 5.6F). 
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In contrast, such heterogeneity was not generated in any hearts at day 3 following 
retrograde IC injection of either SMB or BMC. GFP-positive cells following 
retrograde IC injection were widely distributed in the peri-infarct and infarct areas. 
The number of GFP-negative CD45-positive cell was less in the retrograde IC cell 
injected hearts than in the direct IM cell injected hearts, following either SMB or 
BMC injection. However, the number of GFP-negative CD45-positive cells 
following retrograde IC injection of either SMB or BMC appeared to be higher 
than that following PBS injection. 
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Figure 5.6: Heterogeneity and inflammation at day 3 after cell therapy. 
Representative confocal micrographs (red for CD45, green for GFP, blue for nuclei) at 
day 3 show heterogeneity in the peri-infarct myocardium following direct IM injection of 
SMB (B) and BMC (C). The cell-clusters formed among the native myocardium consisted 
of GFP-positive cells and GFP-negative CD45-positive cells (E and F). GFP-positive cells 
following retrograde IC injection of SMB (H and K) and BMC (I and L) were widely 
distributed in the peri-infarct myocardium. The IC-injected hearts showed less 
accumulation of CD45-positive cells than the IM-injected hearts. Cells expressing both 
GFP and CD45 appear to be yellow (probably injected BMC, F and L). Scale bar = 250 
µm (100×); 50 µm (400×).  
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At day 7 after cell injection, distinct heterogeneity was still present in the peri-
infarct area of the IM cell injected hearts (figure 5.7B and C). However, the 
number of GFP-positive cells appeared to be decreased, while the surrounding 
GFP-negative CD45-positive cell number appeared to be increased. In contrast, 
GFP-positive cells in the retrograde IC cell injected-hearts were still widely 
distributed in the peri-infarct and infarct areas (figure 5.7H and I). Accumulation 
of CD45-positive cells following retrograde IC cell injection was similar to that 
following IC injection of PBS. 
 
At day 28, the size of cell-clusters, consisting of GFP-positive and negative cells, 
after IM cell injection was greatly decreased (figure 5.8). The clusters were 
isolated from the native cardiomyocytes. Following retrograde IC cell injection, a 
small number of GFP-positive cells were present in the peri-infarct myocardium.  
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Figure 5.7: Heterogeneity and inflammation at day 7 after cell therapy. 
Representative confocal micrographs (red for CD45, green for GFP, blue for nuclei) at 
day 7 show heterogeneity in the peri-infarct myocardium following direct IM injection of 
SMB (B) and BMC (C). The cell-clusters consisted of GFP-positive cells and a large 
number of surrounding GFP-negative CD45-positive cells (E and F). GFP-positive cells 
following retrograde IC injection of SMB (H and K) and BMC (I and L) were widely 
distributed in the peri-infarct myocardium. The IC-injected hearts showed less 
accumulation of CD45-positive cells than the IM-injected hearts. Cells expressing both 
GFP and CD45 (probably injected BMC) appear to be yellow (F). Scale bar = 250 µm 
(100×); 50 µm (400×).  
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Figure 5.8: Heterogeneity and inflammation at day 28 after cell therapy. 
Representative confocal micrographs (red for CD45, green for GFP, blue for nuclei) at 
day 28 show small cell-clusters in the peri-infarct myocardium following direct IM injection 
of SMB (B) and BMC (C). The cell-clusters consisted of GFP-positive cells and 
surrounding GFP-negative CD45 positive/negative cells (E and F). A small number of 
GFP-positive cells were present in the peri-infarct myocardium without forming cell 
clusters following retrograde IC injection of SMB (H and K) and BMC (I and L). Scale bar 
= 250 µm (100×); 50 µm (400×). 
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5.2.5 Intercellular connections between grafts and native myocardium 
 
As a possible cause of arrhythmia occurrence following cell therapy, intercellular 
connections between grafted SMB and the surrounding native cardiomyocytes at 
day 28 were assessed by immunolabelling for GFP and Cx43 using confocal 
microscopy (n=5 in each group at day 3 and 28, n=4 in each group at day 7).  
 
Following direct IM injection of SMB, the GFP-positive grafted cells were 
aligned along the native myocardial structure in the peri-infarct myocardium 
(figure 5.9). At day 3, Cx43 expression was observed in the GFP-positive grafted 
cells and among the adjacent native cardiomyocytes (figure 5.9D). However, no 
convincing evidence of Cx43-gap junction formation between the GFP-positive 
grafted cells and the surrounding native cardiomyocytes was obtained. At day 7 
after direct IM injection, the GFP-positive cells had not direct contacts with the 
native cardiomyocytes and no cellular contact was observed between the GFP-
positive cells and cardiomyocytes (figure 5.9E). The GFP-positive cells were 
further isolated from the native cardiomyocytes at day 28, with a large number of 
GFP-negative, Cx43-negative cells (presumably inflammatory cells or fibroblasts) 
being present between the grafted cells and native cardiomyocytes (figure 5.9F).    
 
In contrast, widely distributed GFP-positive cells following retrograde IC 
injection of SMB appeared to have direct contacts with the native cardiomyocytes 
in the peri-infarct myocardium at day 3, 7 and 28 (figure 5.11J, K and L, 
respectively). However, clear evidence of the formation of Cx43-gap junction was 
not obtained at any time points; except for only one case described in the Chapter 
4 (figure 4.6G). 
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Figure 5.9: Formation of gap junctions between grafted cells and cardiomyocytes. 
Representative confocal micrographs (red for Cx43, green for GFP, blue for nuclei) show 
the GFP-positive grafts aligned with the native myocardial structure at day 3 and 7 after 
direct IM injection of SMB (A and B). However, there was no clear Cx43-gap junction 
between the grafted cells and native cardiomyocytes at any time point (D, E and F). 
Widely distributed GFP-positive cells following retrograde IC injection of SMB appeared 
to have direct contacts with the native cardiomyocytes (J, K and L), but clear Cx43-gap 
junctions were not seen. Scale bar = 250 µm (100×); 50 µm (400×).  
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5.2.6  Cx43-gap junction in the native cardiomyocytes 
 
As a possible cause of arrhythmogenicity following cell therapy, the quantity and 
distribution of Cx43 in the LV were assessed by immunoconfocal microscopy, 
real-time PCR and western blotting.  
 
5.2.6.1 Distribution of gap junction protein 
The quantity and distribution of Cx43 in the native myocardium at day 28 after 
cell therapy was assessed in transverse heart sections which were immuno-
labelled for Cx43 {Chapter 2.9.2} (n=5 in each group). Single images of high-
power field (200×) of the peri-infarct and infarct-remote areas in two different 
levels of the LV were analysed per one heart using the confocal microscopy. 
Normal female SD rat hearts were used for the control (n=3). 
 
The secondary control did not show non-specific labelling (figure 5.10A). 
Immunolabelling for GFP in normal hearts showed a typical expression pattern  in 
IVS and LVFW (figure 5.10B and C, respectively). The expression of Cx43 was 
clearly reduced in the peri-infarct area of the hearts after either direct IM or 
retrograde IC injection of SMB (figure 5.10E and H), compared to the normal 
heart, PBS injection via either route (figure 5.10D and G) and BMC injection via 
either route (figure 5.10F and I). There was no difference in Cx43 expression 
between the IM and IC-injected hearts. The quantity and distribution of Cx43 in 
the infarct-remote area showed a similar pattern to that in the peri-infarct area in 
any group (figure 5.10J-O). 
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Figure 5.11: Distribution of Cx43 in the myocardium after cell therapy. 
Representative confocal micrographs (red for Cx43) in the peri-infarct area of the hearts 
after cell injection show less Cx43 expression in the hearts of the SMB-IM group (D) and 
the SMB-IC group (G), compared to the normal heart (B), the PBS-IM group (C), the 
PBS-IC group (F), the BMC-IM group (E) and the BMC-IC group (H). Cx43 expression 
was also less in the infarct-remote area of the hearts of the SMB-IM group (K) and the 
SMB-IC group (N), compared to the normal heart (C), the PBS-IM group (J), the PBS-IC 
group (M), the BMC-IM group (L) and the BMC-IC group (O). The secondary control did 
not show non-specific labelling (A). Scale bar = 100 µm. 
 
 
 
 
 
 
5.2.6.2 Expression of Cx43 mRNA in the myocardium 
Expression of mRNA of Cx43 in the entire LV at day 28 following cell injection 
was quantitatively assessed using real-time PCR {Chapter 2.8.4} (n=5 in each 
group). Each sample was duplicated for the PCR assay and the mean value was 
taken as the value of each sample and expressed as a relative expression of mRNA 
to normal LV (n=2).  
 
The Cx43 mRNA level after injection of PBS via either route was slightly smaller 
than that in the normal hearts (though not significant, figure 5.11). The hearts after 
injection of SMB via either route showed a significantly smaller expression of 
Cx43 than those after injections of the corresponding PBS or BMC at day 28, 
when spontaneous arrhythmia was persistently observed in the hearts after SMB 
injection via either route, but not after BMC or PBS injection.  
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Figure 5.11: Expression of Cx43 in the myocardium at day 28 after cell therapy. 
Cx43 mRNA level in the LV, analysed by real-time PCR, was significantly lower in the 
SMB-IM group and the SMB-IC group compared to the PBS-IM and BMC-IM groups and 
the PBS-IC and BMC-IC groups, respectively. n=5 in each group. *p<0.05 vs. the PBS-IM 
group and the BMC-IM group; †p<0.05 vs. the PBS-IC group and the BMC-IC group.  
 
 
 
5.2.6.3 Amount of Cx43 in the native myocardium 
Protein level of Cx43 in the myocardium at day 28 after cell therapy was assessed 
by Western blotting (n=5 in each group) {Chapter 2.8.6}. The Cx43 signal 
strength of each sample, quantified by NIH-image analysing software, was 
normalised to that of sarcomeric actin (figure 5.12A). The corrected signal of each 
sample was expressed as a relative amount to the PBS-IM group.  
 
Amount of Cx43 in the LV was consistently and significantly reduced in each 
sample following SMB injection at day 28, compared to that following injection 
of either PBS or BMC (figure 5.12). There was no difference in Cx43 expression 
between the PBS and BMC-injected hearts. 
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Figure 5.12: Quantity of Cx43 in the myocardium following cell therapy. Western 
blotting was carried out to assess expression of Cx43 in the LV at day 28. Expression of 
sarcomeric actin was used as the internal control. The signal for Cx43 was consistently 
less in the SMB-IM group than the PBS-IM group and the BMC-IM group (A). Semi-
quantitative analysis of the signal showed a significantly reduced Cx43 expression in the 
SMB-IM group, compared to the PBS-IM group and the BMC-IM group (B). n=5 in each 
group. *p<0.05 vs. the PBS-IM group and the BMC-IM group. 
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5.3 Discussion 
 
The studies reported in this Chapter demonstrate the occurrence of spontaneous 
ventricular tachy-arrhythmias including VT following cell therapy, using a rat 
post-MI chronic HF model in the absence of antiarrhythmia-drug. In addition, the 
studies provide important information that the pattern of the occurrence of 
ventricular arrhythmias is different between the SMB and BMC injections and 
that there are significant differences in the occurrence of arrhythmia between the 
direct IM and retrograde IC route for cell-delivery.  
 
In the early period, direct IM cell injection, regardless of cell-type, produced 
frequent VPC including spontaneous VT. Immunolabelling demonstrated that 
direct IM cell injection created heterogeneity associated with intense 
accumulation of inflammatory cells in the peri-infarct myocardium. In contrast, 
retrograde IC injections rarely produced arrhythmias in association with widely 
disseminated donor cells and less inflammation. In contrast, in the later period, a 
small number of spontaneous VPC were persistently observed after injection of 
SMB, but not injection of BMC, regardless of cell-delivery route. Isoproterenol 
administration evoked frequent VT only after SMB injection in the late period. 
Expression of Cx43 in the myocardium was reduced not only in the peri-infarct 
but also infarct-remote areas following SMB injection via either route, compared 
to injection of either BMC or PBS. 
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5.3.1 Occurrence of ventricular arrhythmia following cell therapy 
 
5.3.1.1 Arrhythmia occurrence following SMB injection 
The results described in this Chapter showed the two different patterns of 
spontaneous arrhythmia occurrence following direct IM injection of SMB into the 
post-MI heart; a large number of VPC including spontaneous VT in the early-
phase and less frequent but persistent VPC in the late-phase. In the previous 
clinical studies, it also appears that there are two different types of arrhythmias 
following direct IM injection of SMB into the ischaemic cardiomyopathy (Hagege 
et al., 2006; Dib et al., 2005b; Siminiak et al., 2004). Firstly, ventricular 
arrhythmias including VT frequently occurred in the early-phase, while these 
arrhythmias were successfully treated by use of amiodarone or corticosteroid. 
Then, sustained VT persistently occurred in a small number of patients.  
 
The peak of arrhythmia occurrence after IM injection of SMB reported in this 
work was at day 3, when the most frequent VPC (124/hour; classified into Lown 
2) were observed with multiform/consecutive VPC (Lown 3/4a) in 75% of treated 
rats and VT (Lown 4b) in 50%. In contrast, retrograde IC injection of SMB, 
which has not been applied to clinical arena to date, produced fewer arrhythmias 
in the early period after injection compared to direct IM injection, indicating that 
retrograde IC injection is a useful method for attenuating early-phase 
arrhythmogenicity following SMB injection into the post-MI heart.  
 
The work described here also showed latent arrhythmogenicity only after SMB 
injection regardless of cell-delivery route. Although the frequency of spontaneous 
VPC in the late-phase was less significant than that in the early-phase, 
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spontaneous VPC persisted for a long time. Moreover, stimulation by 
isoproterenol administration uncovered a high risk of VT occurrence after SMB 
injection regardless of cell-delivery route. Interestingly, the latent 
arrhythmogenicity was observed following not only direct IM but also retrograde 
IC injection of SMB, and not observed following BMC injection via either route, 
suggesting that a cell-specific mechanism might underlie the late-phase 
arrhythmogenicity.  
 
Mills et al also reported arrhythmogenicity in the late-phase following IM 
injection of SMB into the acute-MI heart, compared to those without cell injection 
using an optical electrical mapping technique in rat (Mills et al., 2007), suggesting 
that injection of SMB into the heart, regardless of the timing of cell injection, 
could produce latent arrhythmogenicity. 
 
5.3.1.2 Arrhythmia occurrence following BMC injection 
The occurrence of spontaneous VT following BMC injection into the post-MI 
heart shown in the work covered in this Chapter is original evidence, which would 
be important information to establish the clinical protocol. Arrhythmogenicity 
following BMC injection has not been extensively discussed to date, probably 
because previous clinical trials have rarely reported the occurrence of ventricular 
arrhythmias after this treatment (Perin et al., 2003; Tse et al., 2003; Beeres et al., 
2006b). However, the patients studied in these trials were medically treated with 
drugs having an anti-arrhythmic effect, such as β-blocker, which would have 
masked the arrhythmogenicity. In addition, for detecting arrhythmias, these 
studies monitored for only less than 2 days after cell injection (Beeres et al., 
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2006b) and/or at 1 month or later (Perin et al., 2003; Tse et al., 2003). However, 
these protocols for monitoring ECG might not be appropriate. The studies 
described in this Chapter demonstrates that the peak of arrhythmia occurrence is 
at day 7 after direct IM injection of BMC, when the most frequent VPC 
(108/hour; classified into Lown 2) were observed with multiform/consecutive 
VPC (Lown 3/4a) in 71% of treated rats as well as VT (Lown 4b) in 43%. This 
finding suggests that around day 7 after the treatment is extremely important in 
monitoring or treating the arrhythmogenicity of BMC injection.  
 
Unlike SMB injection, BMC injection via either route rarely produced 
spontaneous ventricular arrhythmia and did not show latent arrhythmogenicity 
from day 28 onwards.  
 
5.3.2 Possible mechanisms of arrhythmia occurrence following cell therapy 
 
5.3.2.1 Heterogeneity involving  inflammation 
One of the causes of the early-phase arrhythmias observed following direct IM 
cell injection regardless of cell-type might be local heterogeneity, geographical 
and/or biological, generated in the post-MI failing myocardium, which is likely to 
be sensitive to exogenous stimuli (Peters et al., 1997). After direct IM cell 
injection, the grafted cells formed isolated, islet-like clusters in the peri-infarct 
myocardium, which would cause serious disorder of the local myocardial 
structure and electrical conductance. In addition, the cell-clusters were associated 
with intense accumulation of inflammatory cells (particularly following SMB 
injection) up to 7 days after injection, which could amplify the disorder of 
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myocardial organisation and might also affect intercellular communication and/or 
electrical stability of the surrounding native cardiomyocytes. These pathological 
events could lead to generation of ventricular arrhythmias. Moreover, the early-
phase arrhythmias largely disappeared by 28 days when heterogeneity and 
inflammation had also largely disappeared, suggesting that heterogeneity in the 
peri-infarct myocardium and associated intense inflammatory response might be 
an important cause of the early-phase arrhythmias following direct IM cell 
injection. In contrast, retrograde IC injection disseminated either SMB or BMC 
widely (without forming localised cell-clusters) and caused much less ventricular 
arrhythmias in the early phase, compared to the direct IM injection.  
 
The peak of arrhythmia occurrence following IM cell injection was slightly 
different between the SMB and BMC-injected hearts. While IM injection of SMB 
produced most frequent VPC at day 3, IM injection of BMC produced a peak at 
day 7. Frequency in occurrence of multiform VPC and VT was not different 
between day 3 and 7 in either SMB or BMC-injected hearts. The precise reason 
for the difference in the peak of arrhythmia occurrence between SMB and BMC-
injected hearts is unclear. However, as the size of the graft, mechanical damage, 
degree of inflammation, and secretion from the donor cells are different between 
SMB and BMC (Kamihata et al., 2001; Gnecchi et al., 2006; Suzuki et al., 2001a), 
the electrical response of the myocardium following cell therapy might be 
different between the cell-type injected. 
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5.3.2.2 Cell-cell connections between SMB and cardiomyocytes 
While cell-cell connections between the grafted undifferentiated SMB and native 
cardiomyocytes via Cx43-gap junctions could be a cause of early-phase 
arrhythmia occurrence (Abraham et al., 2005; Stagg et al., 2006), such 
intercellular connections were not identified despite the thorough histological 
examinations at day 3 or 7. In addition, the studies have showed that cellular 
contacts between the grafted cells and native cardiomyocytes were physically 
disturbed by a number of accumulated Cx43-negative inflammatory cells in the 
IM-injected hearts at day 3. This disturbance was further exacerbated by 7 days 
after cell injection, when frequent VPC with spontaneous VT were still present. 
Moreover, at 7 days, the grafted SMB appeared to decrease the Cx43-expression 
and to be physically separated each other by the accumulated GFP-negative Cx43-
negative cells. Therefore, it would be reasonable to suggest that intercellular 
connections between undifferentiated SMB and native cardiomyocytes via Cx43-
gap junction are not a cause of the early-phase arrhythmias following IM injection 
of SMB. 
 
It has been suggested that SMB and BMC which have differentiated into a 
cardiomyogenic phenotype could acquire arrhythmogenic potential and 
electrically communicate with the adjacent native cardiomyocytes, consequently 
causing ventricular arrhythmias (Abraham et al., 2005; Chang et al., 2006). 
However, it is highly unlikely that the main cause of the arrhythmias following 
cell injection is the cardiomyogenic differentiation of the grafted cells, as the 
grafted cells which showed a cardiomyocyte-like morphology were rarely 
detected throughout the experimental period analysed. 
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5.3.2.3 Paracrine effects to induce arrhythmogenicity 
Another possible mechanism of the arrhythmia occurrence is the alteration of the 
cellular properties of the native failing cardiomyocytes following cell therapy, 
which may include inappropriate gap junction distribution and unsuitable 
excitation-contraction coupling.  
 
The work described in this Chapter shows that injection of SMB, but not injection 
of PBS or BMC, regressed the expression of both mRNA and protein of Cx43 in 
the LV at day 28, when a small number of spontaneous VPC were persistently 
observed in the hearts following SMB injection via either route. In addition, the 
hearts following SMB injection showed the latent occurrence of VT by 
isoproterenol administration, regardless of the cell-delivery route. In contrast, the 
hearts at day 28 after injection of BMC or PBS showed a similar level of Cx43 
expression and rarely developed VPC.  
 
Importantly, it has been suggested that regression of Cx43 in the ventricular 
cardiomyocytes is capable of inducing VT (Peters et al., 1997; Severs et al., 
2004a). These findings suggest that regression in Cx43 in the LV might be a cause 
of the latent arrhythmogenicity in the late phase following SMB injection. 
 
5.3.3 Treatment for arrhythmogenicity following cell therapy 
 
While the studies reported in this Chapter uncovered arrhythmogenicity of cell 
therapy for post-MI chronic HF, there are possible treatments. Clinical studies 
have shown that prophylactic use of amiodarone which stabilises electrical 
conductance, and corticosteroid which inhibits accumulation of inflammatory 
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cells are effective in reducing the early-phase arrhythmia following direct IM 
injection of SMB in post-MI chronic HF (Siminiak et al., 2004; Hagege et al., 
2006). This information suggests that treatment by amiodarone and/or 
corticosteroid might also be effective in attenuating arrhythmogenicity following 
direct IM injection of BMC, as the early-phase arrhythmia is considered to be 
induced by heterogeneity and associated inflammatory response in the peri-infarct 
myocardium, regardless of the cell-type injected. 
 
Modification of the protocol including the number of cells injected, number of 
injection sites/volume and use of human serum for SMB culture (Ott et al., 2005a; 
Chachques et al., 2004) could reduce heterogeneity and associated inflammation, 
and consequently be effective in attenuating arrhythmogenicity following direct 
IM cell injection. In further clinical application of the direct IM route for injection 
of either SMB or BMC, however, careful monitoring and appropriate treatment 
for the early-phase arrhythmia would be required. In addition, the clinical studies 
have suggested that ACD implantation was useful in recovering from the late-
phase sustained VT following cell therapy (Hagege et al., 2006; Dib et al., 2005b).  
 
5.3.4 Summary of Chapter 5 
 
The studies described in this Chapter demonstrate that cell therapy for post-MI 
chronic HF induces arrhythmogenicity. Ventricular arrhythmias including VT 
were frequently observed in the early-phase after IM injection of either SMB or 
BMC, associated with heterogeneity and an inflammatory response in the 
myocardium. While the early-phase arrhythmia had largely disappeared in the 
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late-phase after BMC injection, SMB injection persistently induced latent 
arrhythmogenicity over the 84 days analysed, suggesting a donor cell-specific 
effect on arrhythmogenicity following cell therapy.  
 
Retrograde IC injection of either SMB or BMC produces much less arrhythmia 
occurrence in the early phase, compared to direct IM injection, proposing the 
promising utility of the retrograde IC route for cell-delivery to treat post-MI 
chronic HF. Persistent occurrence of ventricular arrhythmia in the late period, 
which was associated with a regression of Cx43 expression in the myocardium, is 
a concern of SMB injection regardless of the cell-delivery route.  
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CHAPTER 6: ENGRAFTMENT OF BONE MARROW 
CELLS FOLLOWING INTRACORONARY 
INJECTION 
 
 
6.1 Introduction and Aim 
 
6.1.1 Engraftment of injected cells via the retrograde IC route 
 
The studies reported in Chapters 4 and 5 suggest the promising use of the 
retrograde IC route for cell-delivery, as this method provides similar therapeutic 
benefits with less arrhythmogenicity compared to direct IM injection of the same 
number of either SMB or BMC. While graft survival following cell injection via 
either route was extremely poor, as shown in Chapter 4, poor efficiency in initial 
engraftment (adherence to the endothelium and subsequent trans-endothelial 
migration into interstitium) of the donor cells might be a cause of the poor graft 
survival following retrograde IC injection (Hou et al., 2005). Improvement in 
efficiency of cell-engraftment following retrograde IC injection could enhance 
overall graft size and, consequently, therapeutic benefits.  
 
Investigations of the efficiency and mechanisms of cell-engraftment following IC 
injection would provide important implications to explore a strategy to improve 
the efficiency in initial engraftment of donor cells. 
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6.1.2 Possible mechanisms of BMC engraftment following IC injection 
 
The studies reported in Chapter 4 and 5 suggest that mononuclear BMC are a 
more promising donor cell-type in treating HF than SMB, as mononuclear BMC 
provides similar therapeutic benefits and less arrhythmogenicity in the late-phase 
compared to SMB. Therefore, the efficiency and mechanisms of engraftment of 
mononuclear BMC into the heart following IC injection were studied in this 
Chapter.  
 
For the successful engraftment of BMC into the myocardium following IC 
injection, injected BMC firstly need to adhere to the endothelium and then 
undergo trans-endothelial migration into the myocardial interstitium. It is known 
that adherence and trans-endothelial migration of leukocytes during myocardial 
inflammation are regulated by a distinct set of adhesion molecules, such as P-
selectin/PSGL-1 and ICAM-1/CD18 (Frangogiannis et al., 2002). In addition, Wu 
et al suggested that intraventricularly injected bone marrow-derived CD34 
positive cells are recruited into the acute-MI myocardium via ICAM-1/CD18-
mediated interactions between the bone marrow-derived cells and endothelium 
(Wu et al., 2006). As ischaemia-reperfusion is known to upregulate adhesion 
molecules, which facilitate adherence and trans-endothelial migration of 
leukocytes (Frangogiannis et al., 2002), induction of ischaemia-reperfusion in the 
heart prior to BMC injection might enhance the cell-engraftment in the heart. 
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6.1.3 A possible model to investigate cell-engraftment following IC injection 
 
While efficiency in cell-engraftment into the myocardium following IC cell 
injection has been examined using a large animal model (Hou et al., 2005) and 
human (Hofmann et al., 2005), there is a concern about the cell-tracking methods 
used. Hou et al labelled peripheral blood-derived mononuclear cells with 111In 
prior to injection, but they described that the labelling efficiency was only 66±9%, 
measured by γ-counting (Hou et al., 2005). In addition, there is no proper in vivo 
model to investigate the efficiency and mechanisms of cell-engraftment following 
IC injection in small animals.  
 
The ex vivo model, in which donor cells are injected into the heart via the aortic 
cannula under Langendorff perfusion, might be suitable to quantitatively analyse 
the efficiency of mechanisms of cell-engraftment following IC injection. Firstly, 
in this model, donor cells can be reproducibly injected into the coronary arteries 
with a constant pressure and duration. Secondly, this model enables a quantitative 
evaluation of the efficiency of cell-engraftment following IC injection, by 
counting the donor cell number in the coronary effluent. Finally, global acute 
ischaemia can be reproducibly induced in this model to examine the mechanisms 
of cell-engraftment following IC injection.  
 
GFP expression in donor cells appears to be useful in tracking the donor cells in 
this model. As cells derived from GFP-transgenic mouse is known to exclusively 
express GFP compared to those from GFP-transgenic rat (Schaefer et al., 2001), 
mononuclear BMC derived from GFP-transgenic mouse were used as donor cells 
and wild-type mice were used as a recipient. 
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6.1.4 Aim of Chapter 6 
 
The aim of the experiments described in Chapter 6 is to clarify the pattern and 
efficiency of mononuclear BMC engraftment into the myocardium following IC 
injection and also to investigate possible underlying mechanisms. 
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6.2 Results 
 
6.2.1 Mononuclear BMC from GFP-transgenic mouse 
 
Mononuclear BMC were collected from the femurs and tibias of GFP-transgenic 
C57BL/6J mice using Percoll density gradient centrifugation {Chapter 2.3.3} 
(n=6). Each GFP-transgenic mouse yielded 20-30 million mononuclear BMC.  
 
Almost all isolated mononuclear BMC had a round morphology showing intense 
GFP signal under fluorescence microscopy (figure 6.1A and B). Analysis by flow 
cytometry demonstrated that 97.9±0.3% of collected BMC were viable (negative 
for 7-ADD) {Chapter 2.10.2}. Among the viable BMC, 98.1±0.3% were positive 
for GFP (figure 6.1C). GFP-positive viable mononuclear BMC expressed CD45 in 
95.4%±1.3%, CD34 in 0.9±0.2%, c-kit in 0.4±0.1%, Sca-1 in 6.4±0.5%, PSGL-1 
in 49.3±3.5% and CD18 in 57.5±6.2%.  
 
 
 
Figure 6.1: GFP positivity in BMC derived from GFP-transgenic mouse. 
Representative pictures of mononuclear BMC collected from the GFP-transgenic mouse 
(phase-contrast; A, fluorescent; B) show intense green-signal in almost all cells. Flow 
cytometry analysis showed 98.5% viable mononuclear BMC were positive for GFP (C). 
n=6. 
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6.2.2 Langendorff perfusion of mouse heart and ischaemia-reperfusion 
 
Hearts of wild-type C57BL/6J mice (18-20g) were excised after systemic IV 
injection of heparin and perfused at a constant pressure of 100 cm H2O using a 
modified Langendorff apparatus in order to investigate distribution of adhesion 
molecules by histological analysis (n=6) {Chapter 2.6.2}. Three hearts were 
immediately frozen under liquid nitrogen after 20 minutes stabilisation (normal 
hearts). Other 3 hearts were frozen after 30-minute ischaemia and 30-minute 
reperfusion, following 20 minutes stabilisation. 
 
After ischaemia-reperfusion, the coronary flow was significantly reduced (1.4±0.1 
mL/min) compared to that just before induction of global ischaemia (1.8±0.1 
mL/min, p<0.05). Expression of adhesion molecules, such as P-selectin and 
ICAM-1, in the myocardium was compared between the hearts with and without 
ischaemia-reperfusion using immunoconfocal microscopy.  
 
The secondary controls did not show any non-specific labelling (figure 6.2A and 
D). P-selectin was rarely expressed in the normal hearts (figure 6.2B), but greatly 
upregulated in the endothelium after 30-minutes ischaemia and 30-minutes 
reperfusion (figure 6.2E). In contrast, upregulation of ICAM-1 at 30-minutes after 
ischaemia-reperfusion was not observed, while ICAM was expressed at the 
endothelium of the normal hearts at a low level (figure 6.2C and F).  
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Figure 6.2: Expression of adhesion molecules in the myocardium following 
ischaemia-reperfusion. Representative confocal micrographs (red for P-selectin in B 
and E; ICAM-1 in C and F, purple for nuclei) show upregulated P-selectin after ischemia-
reperfusion (E) compared to that in the normal heart (B). ICAM-1 was expressed in the 
normal heart at a low level (C), and not upregulated after ischaemia-reperfusion (F). The 
secondary control did not show any non-specific labelling (A and D). Scale bar = 50 µm. 
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6.2.3 Distribution of BMC  injected via coronary arteries 
 
Distribution and morphological changes of mononuclear BMC injected into the 
myocardium via the coronary arteries was examined using confocal microscopy. 
Mononuclear BMC (1×106) from GFP-transgenic mice were suspended in 1 mL 
of modified Krebs-Henseleit buffer and injected into the isolated perfused wild-
type mouse heart via the aortic cannula after 20-minute stabilisation period 
(Normal group, n=4) {Chapter 2.6.2}. The same number of mononuclear BMC 
was also injected in the same manner after 30-minutes ischaemia and 30-minutes 
reperfusion, following 20-minutes stabilisation (Ischaemia-reperfusion group, 
n=4). Immediately after BMC injection, all the sample hearts were perfused with 
4% paraformaldehyde for fixation and frozen under liquid nitrogen.  
 
GFP-positive cells, visualised by direct fluorescent imaging, were widely 
distributed in the entire myocardium of the Normal group (figure 6.2B). Of note, a 
much larger number of GFP-positive cells were widely distributed in the hearts of 
the Ischaemia-reperfusion group compared to those of the Normal group (figure 
6.2C). There was no clear difference in the BMC distribution between the 
endocardial and epicardial sites of the myocardium in either group. 
 
Immunolabelling for platelet endothelial adhesion molecule (PECAM)-1, an 
endothelial marker, showed that the majority of GFP-positive cells showing an 
elongated morphology were localised outside the vessels (figure 6.2D). A small 
number of GFP-positive cells retained a round-morphology and appeared to be 
adhered to the endothelium at the capillary or post-capillary venules (figure 6.2E). 
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Histological evidence of coronary embolism was not obtained in either the 
Normal group or the Ischaemia-reperfusion group. 
 
 
 
 
 
 
 
Figure 6.3: Distribution of BMC injected into the coronary arteries. Representative 
confocal micrographs (red for PECAM-1, green for endogenous GFP, purple for nuclei) 
show distinct wide distribution of GFP-positive BMC in the normal myocardium after 
injection via coronary arteries under isolated-heart perfusion (B). Normal heart without 
BMC injection showed no positive green signal (A). Induction of ischaemia-reperfusion 
prior to BMC injection largely increased the GFP-positive BMC number in the 
myocardium (C). The majority of BMC injected via coronary arteries were present outside 
the vessel immediately after injection (D; arrow), but a small number of BMC was 
detected inside of the vessel (E; arrow). Scale bar = 100 µm (A-C); 10 µm (D and E).  
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6.2.4 Engraftment efficiency of BMC  by IC injection 
 
Efficiency of the engraftment (adherence and/or trans-endothelial migration) of 
mononuclear BMC injected via coronary arteries was assessed by counting the 
GFP-positive cell number in the coronary effluent using fluorescence microscopy. 
The difference between the injected mononuclear BMC number (1×106) and the 
GFP-positive cell number in the effluent was regarded as the number of 
mononuclear BMC engrafted into the heart. 
 
Mononuclear BMC injection was carried out either immediately after the 
stabilisation (Normal group; n=8) or after 30-minutes ischaemia and 30-minutes 
reperfusion following the stabilisation (Ischaemia-reperfusion group; n=8). In 
addition, either monoclonal anti-P-selectin (150 µg/Kg weight) or ICAM-1 (200 
µg/Kg weight) antibody was infused via the aortic cannula after the 30-minutes 
ischaemia and 30-minutes reperfusion, followed by the BMC injection, in order to 
inhibit the activity of P-selectin or ICAM-1 on the endothelium prior to BMC 
injection (P-selectin, ICAM-1 group, respectively; n=6 in each group).  
 
Flush-out of BMC into the effluent occurred immediately (within 1 minute) 
following cell injection. Almost 100% of the cells found in the effluent were GFP-
positive. The engraftment efficiency of BMC in the Normal group was estimated 
to be only 13.3±1.2% of the total BMC injected (figure 6.4). In contrast, 30-
minutes ischaemia and 30-minutes reperfusion markedly increased the 
engraftment efficiency to 36.5±1.6%. Of note, P-selectin inhibition by monoclonal 
antibody-administration into the heart prior to BMC injection totally diminished 
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the increased efficiency of BMC engraftment by ischaemia-reperfusion 
(8.3±0.8%). In contrast, inhibition of ICAM-1 did not affect engraftment 
efficiency after ischaemia-reperfusion (39.6±3.3% and 43.9±2.9%, respectively).  
 
 
 
 
 
 
Figure 6.4: Efficiency of BMC engraftment into the heart following IC injection. The 
number of BMC engrafted into the heart via coronary arteries was quantified by counting 
the GFP-positive cell number in the coronary effluent. The Ischaemia-reperfusion group 
showed significantly higher engraftment efficiency than the Normal group. The P-selectin 
group (ischaemia-reperfusion plus administration of anti-P-selectin antibody) showed a 
significantly reduced engraftment efficiency compared to the Ischaemia-reperfusion group. 
Engraftment efficiency in the ICAM-1 group (ischaemia-reperfusion plus administration of 
anti-ICAM-1 antibody) was similar to that in the Ischaemia-reperfusion group. n=8 in the 
Normal group and the Ischaemia-reperfusion group; n=6 in the P-selectin group and the 
ICAM-1 group. *p<0.05 vs. the Normal group; †p<0.05 vs. the Ischaemia-reperfusion + P-
selectin group. 
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6.2.5 Changes in surface marker expression of BMC during engraftment 
 
Expression of surface markers in BMC before and after injection into the heart 
was assessed to further explore the mechanisms of cell-engraftment following IC 
injection. The GFP-positive BMC engrafted into the ischaemia-reperfused hearts 
were collected by enzymatic digestion and characterised by flow-cytometry (n=6) 
{Chapter 2.10.1}. The GFP-positive cell proportion was 6.8±3.2% of the total 
cells collected from the hearts after BMC injection (figure 6.5A).  
 
Although the proportion of PSGL-1 positive cells in the mononuclear BMC 
before injection was 49.3±3.5% (figure 6.5B), this proportion was much reduced 
in the BMC engrafted into the heart (1.3±0.4%, figure 6.5C and D). In contrast, 
the ratio of CD18 positive cells in the engrafted BMC (57.5±6.2%, figure 6.5F) 
was not changed from that before injection (59.6±1.8%, figure 6.5E and G). The 
proportion of Sca-1 positive cells was significantly higher in the engrafted BMC 
(17.5±0.9%, figure 6.5I and J) compared to BMC before injection (6.4±0.5%, 
figure 6.5H). PSGL-1 expression in Sca-1-positive BMC before injection 
(43.6±2.1%) was similar to that in the entire mononuclear BMC population before 
injection. 
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Figure 6.5: Analysis of engrafted BMC into the heart. Expression of surface markers 
in BMC before and after injection into the heart was assessed by flow-cytometry. 
Representative data sheets of flow cytometry analysis showing the identification of 
engrafted BMC by their GFP-expression in the enzymatically digested heart (A). 
Approximately one half of the injected BMC were positive for PSGL-1 before injection, 
while the degree of PSGL-1 expression varied widely (B). In contrast, PSGL-1 expression 
was almost negative in the engrafted GFP-positive cells (C and D). The pattern and 
proportion of CD18 expression was similar between the GFP-positive cells before 
injection and after engraftment (E-G). The proportion of Sca-1 positive cells was 
significantly larger in the engrafted cells compared to the cells before injection (H-J). n=6. 
*p<0.05 vs. GFP-positive cells before injection. 
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6.3 Discussion 
 
The studies described in this Chapter demonstrate that only 13.3±1.2% of injected 
BMC via the coronary arteries were engrafted into the normal myocardium. In 
other words, more than 85% of the injected cells were just flush-out from the 
heart. Induction of ischaemia-reperfusion prior to BMC injection increased the 
engraftment efficiency up to 36.5±1.6%. Immediately after injection, the majority 
of engrafted BMC had already migrated into the myocardial interstitium with a 
marked morphological change. This was associated with a rapid disappearance of 
PSGL-1 expression on the engrafted BMC. In addition, P-selectin inhibition in the 
native myocardium prior to BMC injection totally diminished the enhanced 
engraftment efficiency after ischaemia-reperfusion, suggesting an important role 
for the P-selectin-PSGL-1 interaction in the engraftment of BMC injected via the 
IC route. In contrast, ICAM-1 inhibition did not affect the engraftment efficiency 
at this protocol. It was also demonstrated that Sca-1 positive BMC showed higher 
engraftment efficiency compared to Sca-1 negative BMC. 
 
6.3.1 Enhanced engraftment efficiency by ischaemia-reperfusion 
 
While the engraftment efficiency of BMC into the normal heart following IC 
injection was poor (~13%) with more than 85% of injected BMC being flushed-
out into the coronary effluent, prior induction of ischaemia-reperfusion in the 
heart improved the engraftment efficiency of BMC (36.5%). This information 
suggests that cell injection after recanalisation could be advantageous in the cell-
engraftment into the heart with acute MI.  
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The enhanced engraftment efficiency by ischaemia-reperfusion, shown in this 
Chapter, was larger than that in the previous clinical (Hofmann et al., 2005) and 
experimental (Hou et al., 2005) studies. Hofmann et al reported that 1.3 to 2.6% 
of total injected BMC, which were radiolabelled before injection, were engrafted 
into the heart at 50 to 75 minutes after IC injection in patients with acute MI 
(Hofmann et al., 2005). Hou et al also reported that only 2.6±0.3% of 
radiolabelled peripheral blood mononuclear cells were engrafted into the heart at 1 
hour after IC injection in pigs with acute MI (Hou et al., 2005). However, it is 
difficult to directly compare the efficiency of cell-engraftment following IC 
injection between the work in this Chapter and previous reports, as cell-type and 
cell-labelling sensitivity are different between these studies. In addition, the 
timing of cell injection is also different. While cell injection was carried out at 30 
minutes after reperfusion in the studies described in this Chapter, Hofmann et al 
(Hofmann et al., 2005) and Hou et al (Hou et al., 2005) injected cells at 5-10 days 
after reperfusion.  
 
Survival and proliferation of the donor cells engrafted in the myocardium are also 
an important determinant of the therapeutic benefits of cell therapy (Suzuki et al., 
2004b). One could speculate that immediate injection of BMC following 
recanalisation may accelerate the death of engrafted cells, as the reperfusion-
induced myocardial inflammatory response is likely to be more severe in the early 
periods after recanalisation than that in the later days (Liuzzo et al., 1999). Further 
experimental investigations would be required to determine the optimal timing for 
BMC injection after MI in order to obtain the maximum number of engrafted and 
surviving donor cells, and consequently the maximum therapeutic efficacy. 
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Poor engraftment efficiency in the normal heart, observed in this Chapter, 
suggests that the engraftment efficiency of donor cells might be similarly poor, 
when IC injection of mononuclear BMC is applied to patients with heart disease 
in which the coronary endothelium is relatively normal, such as idiopathic dilated 
cardiomyopathy. Therefore, careful consideration will be needed to determine the 
clinical protocol of mononuclear BMC injection for treating such type of disease.  
 
6.3.2 Adhesion molecule-mediated cellular interaction 
 
P-selectin inhibition on the endothelium by antibody neutralisation totally 
diminished the increase in BMC engraftment following ischaemia-reperfusion, 
suggesting that the P-selectin/PSGL-1 interaction plays an important role in the 
engraftment of mononuclear BMC. Interestingly, flow-cytometry analysis 
revealed that the majority of the engrafted BMC were negative for PSGL-1 
expression, though 49.3% were positive for PSGL-1 before injection.  
 
It was considered that this is not because PSGL-1 negative BMC were selectively 
engrafted into the heart, but because expression of PSGL-1 on the injected BMC 
was quickly down-regulated and/or removed after adhesion to the endothelium in 
order to facilitate the subsequent process of trans-endothelial migration (Gardiner 
et al., 2001). In addition, the majority of engrafted BMC had already completed 
trans-endothelial migration immediately after cell injection with a marked 
morphological change to an elongated appearance, while all mononuclear BMC 
were round before injection. These findings suggest that the process of adhesion 
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and subsequent trans-endothelial migration of BMC may complete in a short 
period following IC injection.  
 
In contrast, inhibition of ICAM-1 on the endothelium did not affect the 
engraftment efficiency of BMC into the ischaemia-reperfused heart. This negative 
results might be because ICAM-1 was not upregulated on the  endothelial cells at 
30 minutes of reperfusion, whereas P-selectin, a rapid responder to ischaemia-
reperfusion (Kokura et al., 1999), was already upregulated. It was considered that 
the dosage of antibodies used is high enough to block these molecules (Fukushima 
et al., 2006b; Segers et al., 2006), giving rise to a speculation that injected BMC 
might, once adhered to the endothelium via P-selectin/PSGL-1 interactions, be 
able to cross the endothelial barrier regardless of ICAM-1-related interactions.  
 
The role of ICAM-1/CD18 interactions in cell-engraftment following IC injection 
is still inconsistent among the previous reports. It was recently reported that 
interactions between CD18 and ICAM-1 play an important role in the engraftment 
of bone marrow-derived CD34 positive cells into the heart one hour after 
permanent LCA ligation (Wu et al., 2006). In contrast, Segers et al suggested that 
expression of vascular cell adhesion molecule (VCAM)-1, but not ICAM-1, has a 
regulatory effect on the engraftment of bone marrow-derived mesenchymal stem 
cells into the heart at 24 hours after 30-minutes temporal myocardial ischaemia 
(Segers et al., 2006). In addition, data described in this Chapter also demonstrated 
that inhibition of ICAM-1 did not affect the efficiency of cell-engraftment 
following IC injection. Further experimental studies would be essential to 
determine the role of ICAM-1/CD18 interactions in cell-engraftment, as it might 
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not be appropriate to directly compare the results of these studies using different 
experimental protocols, including species, donor cell types, molecule inhibition 
method (antibody-treatment of the native myocardium or donor cells), nature of 
MI (with or without reperfusion), perfusion (blood or crystalloid) and timing of 
cell injection following reperfusion, further  
 
6.3.3 Other possible  mechanisms of cell-engraftment 
 
Data described in this Chapter suggests that there may also be a mechanism of the 
engraftment of BMC irrelevant to the P-selectin/PSGL-1 mediated BMC-
endothelial interaction, as at least 13.3% of injected mononuclear BMC were 
engrafted into the normal heart. In addition, 8.3% of mononuclear BMC were 
engrafted into ischaemia-reperfused hearts even after P-selectin-inhibition. It is 
speculated that a specific population of mononuclear BMC, which are larger in 
cell size than others, such as mesenchymal stem cells, may be physically adhered 
to the arterioles, capillaries or venules and subsequently cross the endothelial 
barrier regardless of adhesion molecules. It was also shown that the proportion of 
Sca-1 positive cells was greater in the engrafted BMC (17.5%) compared to BMC 
before injection (6.4%), while the expression of PSGL-1 and CD18 on the Sca-1 
positive cells was similar to that on the total mononuclear BMC. These findings 
suggest that Sca-1-positive BMC might have a greater ability to adhere/migrate 
into the myocardium independent of P-selectin or ICAM-1-mediated interactions, 
compared to Sca-1 negative cells.  
 
257 
It has been suggested that CD34-positive BMC are preferentially engrafted in the 
myocardium (Gordon et al., 2006). However, as the CD34-positive population 
was extremely small (0.6±0.3%) in this mouse model, it was difficult to 
convincingly investigate such a preferential migration of CD34-positive BMC. 
The c-kit positive population in our mononuclear BMC was also too small 
(<0.5%) to investigate in a quantitative manner.  
 
6.3.4 Limitation of this Chapter 
 
This study used a Langendorff-crystalloid perfusion system in order to simplify 
the complicated situations with the principal aim of highlighting the effect of 
BMC-endothelium interactions on BMC engraftment into the heart. This model 
also enabled reproducible injection of BMC into the heart via the coronary arteries, 
which was key to the successful quantitative evaluation of engraftment efficiency. 
Reproducible in vivo models for antegrade IC cell injection in small animals have 
not been established, while perfusion of isolated hearts with full blood is difficult 
to stabilise. Further investigation using large animal models will be useful to 
confirm the observations shown in this study in a more clinically-relevant setting 
where blood cells and/or growth factors/cytokines could affect the engraftment 
efficiency of injected BMC. 
 
6.3.5 Summary of Chapter 6 
 
In summary, the engraftment efficiency of mononuclear BMC injected into the 
coronary arteries was poor in the normal heart, but improved after ischaemia-
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reperfusion stimuli. PSGL-1/P-selectin-mediated BMC-endothelial interactions 
may play an important role in the mechanism of the BMC engraftment into the 
myocardium. 
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CHAPTER 7: FINAL DISCUSSION – FUTURE 
DIRECTION OF CELL THERAPY RESEARCH – 
 
 
Experimental data presented in this thesis provide evidence that injection of either 
SMB or BMC is able to improve cardiac function of post-MI chronic HF. While 
the distribution of the grafted cells and associated inflammatory response were 
different between the direct IM and retrograde IC injections, survival of grafted 
SMB and BMC in the myocardium was similarly poor by either injection method. 
Arrhythmogenicity were observed in the early-phase after direct IM cell injection, 
but not retrograde IC cell injection, and in the late-phase after injection of SMB, 
but not BMC. As trans-differentiation or fusion of the grafted cells were only 
rarely observed, paracrine effects of the grafted cells are considered to be 
important for the therapeutic effects and arrhythmogenicity following cell therapy. 
Efficiency of engraftment of BMC in the myocardium following IC injection was 
extremely poor in the normal heart, but was enhanced by induction of ischaemia-
reperfusion prior to cell injection. Most of the enhanced cell-engraftment was 
dependent on P-selectin-mediated interaction between BMC and endothelium. 
 
This Chapter aims to discuss how to optimise the protocol for cell therapy for 
treating HF based upon the data obtained in this thesis. Points discussed include 
the optimal cell injection protocol and optimal cell-type, also suggesting the future 
direction of research on cell therapy for treating HF. 
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7.1 Optimal protocol of cell injection 
 
7.1.1 Cell-delivery route into the heart 
 
The studies described in Chapter 4 and 5 suggest the promising utility of the 
retrograde IC route for the delivery of either SMB or BMC into the post-MI 
chronically failing heart, compared to the direct IM route. Retrograde IC injection 
of either SMB or BMC achieved a similar improvement in cardiac function and 
physical activity to direct IM injection of the same number of donor cells, while 
the occurrence of spontaneous arrhythmia in the early-phase was much less after 
retrograde IC injection than direct IM injection, regardless of cell-type injected. 
 
In the clinical arena, retrograde IC cell injection can be safely carried out by a 
balloon catheter percutaneously inserted into the coronary sinus and cardiac veins 
under local anaesthesia (Thompson et al., 2003). In addition, retrograde IC cell 
injection can be repeatedly performed, which might prolong the therapeutic 
effects of cell therapy (Premaratne et al., 2006). In contrast, the direct IM injection 
requires either invasive open-chest surgery or highly-specialised equipment such 
as the NOGA system (Smits et al., 2003).  
 
However, further investigations, including optimisation of injection pressure, 
incubation time and cell number injected, will be needed to further prove the 
advantages of the retrograde IC injection over the direct IM injection or the 
antegrade IC injection. A large animal model would be more suitable for such a 
pre-clinical study than small animal models. 
261 
7.1.2 Cell number injected into the heart 
 
The cell number injected in the work described in Chapter 4 and 5 was chosen 
based upon the most common cell-number used in previous reports: 1-5×106 for 
SMB (Ghostine et al., 2002; Suzuki et al., 2001a) and 1-10×106 for mononuclear 
BMC in rat model (Memon et al., 2005b; Muller-Ehmsen et al., 2006).  
 
The number of the grafted cells present in the myocardium has been shown to be 
one of the most important determinants of the therapeutic effects of cell therapy 
(Pouzet et al., 2001; Mangi et al., 2003). However, there might be a concern that 
increasing cell number in the direct IM injection could exacerbate the formation 
of cell-clusters and associated intense localised inflammatory response, and 
consequently, increase the risk of arrhythmia occurrence in the early period, while 
increasing cell number in the antegrade IC injection might exacerbate coronary 
embolism (Suzuki et al., 2000a; Vulliet et al., 2004). In contrast, the number of 
cells injected could be safely increased by retrograde IC injection, as arrhythmias 
rarely occurred in the early period and there was no observation suggesting 
coronary embolism in histological or physiological studies following retrograde 
IC injection of either SMB or BMC.  
 
7.1.3 Enhancing engraftment and survival 
 
The studies described in Chapter 4 and 5 suggest only a small portion of donor-
derived cells remaining within the heart at day 3, followed by progressive death of 
donor-derived cells between day 3 and 28 after injection into the post-MI heart, 
regardless of cell-delivery route or cell-type injected. It is of great value to 
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improve donor cell-engraftment (adherence to endothelium and trans-endothelial 
migration) and subsequent survival of the grafted cells for enhancing the 
therapeutic efficacy of cell therapy. 
 
7.1.3.1 Enhancing engraftment of injected cells 
The work reported in Chapter 6 suggests that the efficiency of the engraftment is 
very poor in case of antegrade IC injection of mononuclear BMC (more than 85% 
of the injected cells were just flush-out from the heart) and that the cell-
engraftment might result from adhesion molecule-mediated cellular interaction 
between the injected cells and the endothelium.  
 
Retrograde IC injection is theoretically advantageous in trans-endothelial 
migration of donor cells from the intravascular space into the myocardial 
interstitium, compared to antegrade IC injection, as the retrograde IC route is able 
to directly deliver donor cells into the post-capillary venules, where a distinct set 
of adhesion molecules has been shown to play a role in cell-engraftment into the 
myocardial interstitium. Increasing injection pressure or extending incubation 
time in retrograde IC cell injection might further enhance cellular interaction 
between the injected BMC and the endothelium, consequently, improving the 
overall graft size and the therapeutic benefits. Ischaemic preconditioning of the 
myocardium prior to cell injection, which might upregulate P-selecting expression 
on the endothelium (Zhao et al., 2003), could also be useful in enhancing cellular 
interactions between the injected cells and the endothelium and, consequently, the 
engraftment efficiency. However, further research using a large animal model will 
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be needed to compare the efficiency of cell-engraftment between antegrade IC and 
retrograde IC injections. 
 
While the efficiency of cell-engraftment following IM injection was not studied in 
the work described in this thesis, Hou et al suggested that only 11% of injected 
cells were engrafted in the myocardium 1 hour after direct IM injection. 
Increasing the number of injection site and reducing the cell number injected in 
each site might be useful in enhancing the engraftment efficiency following direct 
IM cell injection (Ott et al., 2005a).  
 
7.1.3.2 Enhancing survival of grafted cells 
The work reported in Chapter 4 and 5 suggested that factors affecting the survival 
of the donor cells following engraftment in the heart are likely to be different 
between the direct IM and retrograde IC injections, as distribution of the grafted 
cells and associated inflammatory response were largely different. Therefore, 
different approaches to improve survival of the grafted cells might be required 
between the two injection methods. 
 
In case of direct IM cell injection, my laboratory has demonstrated that 
environmental stress including generation of ROS or the inflammatory response 
lead to both necrosis and apoptosis of grafted cells (Suzuki et al., 2004b; Suzuki et 
al., 2004a). Several approaches to attenuate necrosis and apoptosis of grafted cells 
following IM injection have been reported. My laboratory reported that 
administration of either SOD or anti-IL-1β antibody in combination with direct 
IM injection of SMB was effective in reducing acute (within 72 hours) donor cell 
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death (Suzuki et al., 2004b; Suzuki et al., 2004a). Tambara et al. suggested that 
administration of HGF in combination with IM injection of SMB attenuates 
apoptosis of the grafted SMB and increase the graft size in the myocardium 
(Tambara et al., 2005). Laflamme et al recently reported that death of donor cells 
grafted by IM injection occurs via multiple pathways and can be attenuated by 
cocktail of prosurvival factors, including Matrigel to prevent anoikis, a cell-
permeant peptide from Bcl-XL to block mitochondrial death pathways, 
cyclosporine A to attenuate cyclophilin D–dependent mitochondrial pathways, a 
compound that opens ATP-dependent K+ channels (pinacidil) to mimic ischaemic 
preconditioning, IGF-1 to activate Akt pathways and the caspase inhibitor ZVAD-
fmk (Laflamme et al., 2007). 
 
On the other hand, factors affecting graft survival following IC injection are not 
well understood. As the work reported in Chapter 5 suggested that IC cell 
injection induces less inflammatory response than IM cell injection, 
administration of SOD or anti-IL-1β antibody might not be effective in reducing 
acute donor cell death after IC injection. Suzuki et al suggested that heat shock 
treatment prior to antegrade IC injection of SMB into the acute MI heart improved 
tolerance to hypoxia-reoxygenation in SMB and enhanced graft survival for 28 
days (Suzuki et al., 2000b). Further experimental studies are required to 
understand and prevent the death of grafted cells following IC injection. 
 
7.1.3.3 Use of genetically engineered cells to enhance graft survival 
Genetic engineering of donor cells prior to injection into the heart has been shown 
to be useful in improving survival of grafted cells. Murtuza et al suggested that 
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sustained inhibition of IL-1 by SMB secreting IL-1 receptor antagonist, generated 
by liposome-based transduction, improved survival of the grafted SMB in the 
acute MI-heart and enhanced the therapeutic efficacy (Murtuza et al., 2004). Yau 
et al reported that over-expression of IGF-1, which has been shown to have 
various cytoprotective effects (Ren et al., 1999; Davis et al., 2006), in the bone 
marrow-derived cells enhanced survival of the grafted cells, attenuated apoptosis 
of the native cardiomyocytes and consequently improved cardiac function in 
ischaemic HF (Yau et al., 2005a). In addition, this group also suggested that 
enhanced neo-angiogenesis in the native myocardium by VEGF-overexpressing 
SMB effectively attenuated apoptosis of the grafted cells (Yau et al., 2005b). 
Mangi et al suggested that increasing Akt activity in bone marrow-derived cells 
by retroviral transduction was effective in protecting the donor cells from early 
cell death and enhancing the therapeutic effects (Mangi et al., 2003).  
 
While the use of genetically engineered cells appears to be useful in improving 
the survival of the grafts following either IM or IC injection, there remains a 
concern in the clinical application, particularly including safety such as virus-
related complications. 
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7.2 Optimal cell-type 
 
7.2.1 Promising utility of mononuclear BMC and SMB 
 
The studies reported in Chapter 4 and 5 indicate that both SMB and mononuclear 
BMC are the promising donor cell-type in improving cardiac function and 
physical activity of post-MI chronic HF. Injection of SMB induced latent 
arrhythmogenicity, which was rarely seen following injection of BMC, suggesting 
that BMC might be a more promising donor cell-type than SMB. 
 
The paracrine effects on the native myocardium were different between SMB and 
BMC, as shown in the studies described in Chapter 4 and 5. SMB, but not BMC, 
reduced fibrosis in both peri-infarct and infarct-remote myocardium, while BMC, 
but not SMB, increased capillary density. In addition, SMB, but not BMC, 
reduced Cx43 expression in the peri-infarct and infarct-remote myocardium. 
These findings suggest that SMB and BMC induce a different set of mediators to 
differently affect the myocardium. Further investigation of the mediators in each 
donor cell-type could provide important implications to enhance the paracrine 
effects. 
 
7.2.2 Enhancing cardiomyogenic differentiation 
 
Either SMB or mononuclear BMC only rarely differentiated into cardiac or 
vascular cells following injection into the post-MI heart in the work described in 
Chapter 4. Therefore, different cell-source from either SMB or mononuclear BMC, 
such as ES cells or cardiac stem cells, might be required to enhance 
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cardiomyogenic differentiation, which will be extremely useful in treating post-
MI chronic HF (Laflamme et al., 2007). However, further basic research will be 
required to generate 100% pure and stable cardiac grafts from ES cells or cardiac 
stem cells. Possible targets include genes or transcriptional factors relating to 
cardiomyogenic differentiation, protocol to generate sufficient donor cell numbers 
and prevention of immune rejection. 
 
The studies described in Chapter 4 and 5 demonstrate that retrograde IC injection 
provides direct intercellular contacts between the grafted cells and the native 
cardiomyocytes, compared to direct IM injection which forms isolated cell-
clusters from the native cardiomyocytes. This finding suggests that retrograde IC 
injection might provide a greater opportunity for grafted cells to undergo 
cardiomyogenic differentiation and direct mechanical contributions, no matter 
which cell-type is used.  
 
While formation of Cx43-gap junctions between the grafted cells and native 
cardiomyocytes were rarely identified in the work described in Chapter 4 and 5, 
over-expression of Cx43 in SMB might enhance the formation of gap junctions 
between these two cells. My laboratory reported that over-expression of Cx43 in 
SMB, by genetic modification, enhances intercellular connections between SMB 
and the mature adult cardiomyocytes in vitro (Stagg et al., 2006). SMB which 
have electrical communications with cardiomyocytes might, in turn, differentiate 
into functional cardiomyocytes (Iijima et al., 2003) and, consequently, improve 
global cardiac function via direct mechanical contributions. 
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7.2.3 Enhancing paracrine effects 
 
Work described in Chapter 4 suggests that paracrine effects, such as reducing 
fibrosis, enhancing neo-vascularisation and attenuating hypertrophy of native 
cardiomyocytes, play an important role in the therapeutic benefits of cell therapy. 
Analysing such paracrine effects would be important to obtain further therapeutic 
benefits. One of the approaches reported to enhance the paracrine effects is 
genetic engineering of donor cells to over-express a beneficial molecule prior to 
injection into the heart. This strategy is also termed as cell-based gene therapy.  
 
SMB over-expressing VEGF by viral transduction were reported to increase 
capillary density and improve cardiac function following injection into the 
ischaemic heart (Suzuki et al., 2001a; Askari et al., 2004). In addition, genetic 
over-expression of VEGF or FGF in bone marrow-derived cells also showed 
enhanced regional blood flow and capillary density following injection into the 
ischaemic heart (Yau et al., 2007; Matsumoto et al., 2005; Yang et al., 2007). 
Gnecchi et al suggested that bone marrow-derived cells over-expressing Akt 
enhanced the paracrine effects by increasing the secretion of soluble growth 
factors such as VEGF, FGF, HGF or IGF-1 from the genetically engineered donor 
cells (Gnecchi et al., 2006). Murtuza et al reported that over-expression of IL-1 
receptor antagonist in SMB enhanced improvement in systolic and diastolic 
cardiac functions of acute-MI heart, associated with enhanced survival of the 
grafted cells and reduced fibrosis in the myocardium (Murtuza et al., 2004).  
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Despite the possible beneficial effects of genetically engineered donor cells, there 
remain concerns. Sustained exposure to growth factors may lead to 
tumourgenicity in the myocardium in the long-term (Carmeliet, 2000; Lee et al., 
2000). In addition, it would also be important to determine the most beneficial and 
the least harmful vectors to transduct the gene.  
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7.3 Conclusion of this thesis 
 
Development of effective therapy for HF is a priority, as HF is still a major cause 
of human death and disability. This thesis demonstrates that cell therapy is the 
promising strategy to treat post-MI chronic HF and suggests that the therapeutic 
effects can be enhanced by optimising cell-injection protocol and donor cell-type. 
Although clinical trials of cell therapy have started, further laboratory research 
will be extremely important for future success of this treatment in clinical arena. 
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Direct Intramyocardial But Not Intracoronary Injection of
Bone Marrow Cells Induces Ventricular Arrhythmias in a
Rat Chronic Ischemic Heart Failure Model
Satsuki Fukushima, MD; Anabel Varela-Carver, PhD; Steven R. Coppen, PhD;
Kenichi Yamahara, MD, PhD; Leanne E. Felkin, BSc; Joon Lee, MRCS; Paul J.R. Barton, PhD;
Cesare M.N. Terracciano, MD, PhD; Magdi H. Yacoub, FRS; Ken Suzuki, MD, PhD
Background—Therapeutic efficacy of bone marrow (BM) cell injection for treating ischemic chronic heart failure has not
been established. In addition, experimental data are lacking on arrhythmia occurrence after BM cell injection. We
hypothesized that therapeutic efficacy and arrhythmia occurrence induced by BM cell injection may be affected by the
cell delivery route.
Methods and Results—Three weeks after left coronary artery ligation, wild-type female rats were injected with 1107
mononuclear BM cells derived from green fluorescent protein–transgenic male rats through either a direct intramyo-
cardial or a retrograde intracoronary route. Both intramyocardial and intracoronary injection of BM cells demonstrated
similar improvement in left ventricular ejection fraction measured by echocardiography and a similar graft size analyzed
by real-time polymerase chain reaction for the Y chromosome–specific Sry gene. Noticeably, intramyocardial injection
of BM cells induced frequent ventricular premature contractions (10873 per hour at 7 days after BM cell injection),
including multiform, consecutive ventricular premature contractions and ventricular tachycardia for the initial 14 days;
intracoronary injection of BM cells and intramyocardial injection of phosphate-buffered saline rarely induced
arrhythmias. Immunohistochemistry demonstrated that intramyocardial BM cell injection formed distinct cell clusters
containing donor-derived cells and accumulated host-derived inflammatory cells in the infarct border zone, whereas
intracoronary BM cell injection provided more homogeneous donor cell dissemination with less inflammation and
without disrupting the native myocardial structure.
Conclusions—BM cell injection is able to improve cardiac function in ischemic chronic heart failure but has a risk of
arrhythmia occurrence when the intramyocardial route is used. Such arrhythmias may be prevented by using the
intracoronary route. (Circulation. 2007;115:2254-2261.)
Key Words: arrhythmia  cell therapy  heart failure
Recent research has shown that injection of bone marrow(BM)–derived stem cells improves function and perfu-
sion of the heart with acute myocardial infarction (MI) in
animals1 and humans.2–4 However, therapeutic efficacy of
this approach for treating post-MI chronic heart failure (HF)
has not been fully established.5–11 In addition, arrhythmia
occurrence, which has been identified as a critical complica-
tion of skeletal myoblast injection,12 has not been fully
studied in the case of BM cell injection. Previous clinical
studies reported rare incidences of arrhythmia after intramyo-
cardial5,8,9 and antegrade intracoronary6,7,10,11 injection of BM
cells; however, patients in these studies were prescribed
antiarrhythmic drugs such as -blockers,5–9,11 which could
mask arrhythmogenicity of the treatment. In addition, ar-
rhythmia occurrence in these patients might not be adequately
examined by appropriate continuous monitoring.5,7–11 Eluci-
dating these issues by appropriate laboratory investigations is
now an urgent requisite for the further progress of clinical
application of the treatment.
Clinical Perspective p 2261
We hypothesized that therapeutic efficacy and arrhythmia
occurrence induced by cell injection into the post-MI heart
may be affected by the cell delivery route. The direct
intramyocardial route, either by an endocardial or epicardial
approach, can deliver cells selectively into target areas;
however, this method causes mechanical injury and subse-
quent acute inflammation.13,14 Such adverse processes could
limit graft survival and cause myocardial damage.14 In
addition, cells grafted via the intramyocardial route tend to
form isletlike cell clusters that are isolated from the host
myocardium.15,16 Such local heterogeneity in the myocardium
is considered a source of arrhythmias. In contrast, the
intracoronary route can deliver donor cells more homoge-
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neously with less mechanical damage and inflammation in
the myocardium.17 This ability may allow for enhanced
therapeutic effects and a reduced risk of arrhythmia.
In the present study, we investigated the therapeutic
benefits and arrhythmia occurrence after BM cell injection
for treating post-MI chronic HF by comparing intramyocar-
dial and intracoronary injection.
Methods
All studies were performed with the approval of the institutional
ethics committee and the UK Home Office. The investigation
conforms to the Principles of Laboratory Animal Care (National
Society for Medical Research) and the Guide for the Care and Use
of Laboratory Animals (National Institutes of Health). All surgical
procedures and evaluations, including assessment of ventricular
function, were carried out in a blinded manner.
Donor Cell Preparation
Mononuclear BM cells were collected from both femurs and tibias of
green fluorescent protein (GFP)–transgenic male Sprague-Dawley
rats18 (n13; 200 to 250 g; Rat Resource and Research Center,
Columbia, Mo) and purified by Percoll gradient centrifugation
(Amersham Biosciences, Piscataway, NJ) as previously described.13
Flow cytometry analysis (FACSAria, BD Biosciences, Erembode-
gem, Belgium) using monoclonal anti-CD34 (Santa Cruz Biotech-
nology, Santa Cruz, Calif) and anti-CD45 (BD PharMingen, Oxford,
UK) antibodies showed that 4.61.7% of the collected BM mono-
nuclear cells were positive for CD34 and 75.54.3% were positive
for CD45.
Generation of Chronic Ischemic HF
Wild-type Sprague-Dawley female rats (n150; 150 to 200 g;
Harlan Sprague Dawley, Indiannapolis, Ind) underwent left thora-
cotomy under 1.5% isoflurane inhalation and mechanical ventilation
using a volume-controlled ventilator (Harvard Apparatus, Eden-
bridge, UK). The left coronary artery (LCA) was permanently ligated
with 6-0 polypropylene (BearMedic, Chiba, Japan) at the level of the
bottom edge of the left atrial appendage.17 Ischemia was confirmed
by a change in the epicardial color and dyskinesis. The rats were
returned to the cage for recovery after chest and skin closure and
extubation.
Assessment of Cardiac Function
Cardiac function and dimensions of all the surviving rats were
assessed at 20 days after LCA ligation with echocardiography using
Sequoia 512 and 15-MHz probe (Siemens Medical, Berlin, Ger-
many) under 1.5% isoflurane inhalation via a nose cone.19 Left
ventricular ejection fraction (LVEF) was calculated from the data
obtained with 2-dimensional tracing. LV diastolic (LVDd) and
systolic (LVDs) dimensions and heart rate (HR) were measured with
M-mode echocardiography. Transmitral peak E/A flow ratio was
determined by spectral Doppler traces.20 Changes in cardiac param-
eters were assessed at 3, 7, 14, 28, and 84 days after cell injection
(n9 in each group). Therapeutic efficacy was evaluated primarily
by a positive change in LVEF after cell injection.
Arrhythmia Assessment by Telemetry
A transmitter for the radiotelemetry (Data Sciences International, St
Paul, Minn) was implanted in the peritoneal cavity 1 day before cell
injection for continuous ECG monitoring (n7 in each group).21 The
electrodes were implanted in the right shoulder and left axilla. The
ECG of these rats was monitored continuously from 1 day before
until 7 days after cell injection, followed by 24 hours of continuous
monitoring at 14, 28, 42, 56, and 84 days. The hourly number of
ventricular premature contractions (VPCs) was calculated as the
average number of the events observed in a 24-hour recording with
ECG analysis software (DSI Dataquest A.R.T. Analysis, Data
Sciences International). The frequency of multiform, consecutive
VPCs and ventricular tachycardia (VT) also was counted throughout
the periods studied.
Cell Injection Into the Heart
The rats that met the criteria (LVEF 40%) 1 day before cell
injection were assigned to cell injection. At 21 days after LCA
ligation, under 1.5% isoflurane inhalation and mechanical ventila-
tion, 1107 mononuclear BM cells were injected via either direct
intramyocardial (BMC-IM group; n34) or retrograde intracoronary
(BMC-IC group; n35) route through rethoracotomy. In the former
method, BM cells suspended with 100 L phosphate-buffered saline
(PBS) were injected into 2 sites of the infarct border zone: the
anterior-lateral and inferior-posterior walls.14 In the latter method,
the same number of BM cells in 500 L PBS was injected into the
left cardiac vein, which drains the entire LV free wall, through a
purse-string suture (7-0 polypropylene, BearMedic) placed on left
superior vena cava as recently described.17 The stem of the cardiac
vein was snared for 30 seconds after injection to prevent flushing the
injected cells into the vena cava. As controls, the same volume of
PBS without cells was injected via either route (PBS-IM group,
n26; and PBS-IC group, n28). The rats were returned to the cage
for recovery after chest and skin closure and extubation.
Survival of Grafted Donor Cells
The presence of grafted male cells in the female heart was quanti-
tatively assessed by real-time polymerase chain reaction for the Y
chromosome–specific Sry gene (ABI PRISM 7700 and TaqMan
Chemistry; Applied Biosystems, Foster City, Calif).22 At 3, 7, 28,
and 84 days after cell injection, the LV wall was collected (n4 to
6 at each time point in the BMC-IM and BMC-IC groups). Genomic
DNA was extracted from the sample and used for Sry detection. The
signals obtained were normalized for the amount of DNA used by the
autosomal single-copy gene osteopontin (Opn) as an internal stan-
dard.22 Primers used were as follows: Sry: forward, 5-
GCGGAGAGAGGCACAAGTTG-3; reverse, 5-TCCCAGCTG
CTTGCTGATCT-3; and probe, 5-TCAACAGAATCCCAGCA
TGCAGAATTCA-3; Opn: forward, 5-CCAATCGCCCCCAC
AGT-3; reverse, 5-CCTCAGTCCGTAAGCCAAGCT-3; and
probe, 5-TGTCCCTGACGGCCGAGGTGA-3. Female LV at 21
days after LCA ligation was mixed with male BM cells (1107), and
its serial dilution series was used for generating a standard curve
(n3).
Histological Analysis
The rats were killed at 3, 7, and 28 days after cell injection for
histological analysis (n4 to 5 at each time point in each group). The
hearts were perfused with 4% paraformaldehyde immediately after
collection and frozen in liquid nitrogen. Cryosections (10 m) were
labeled with a polyclonal GFP-specific primary antibody (Molecular
Probes, Carlsbad, Calif; 1:5000 dilution),23 which was visualized
with horseradish peroxidase–based EnVision kit (Dako, Glostrup,
Denmark) according to the manufacturer’s instructions. The samples
were counterstained with hematoxylin.
Statistical Analysis
All values are expressed as meanSEM. Statistical comparison of
LVEF, HR, LVDd/Ds, peak E/A, and number of VPCs was per-
formed with 1-way ANOVA, followed by Bonferroni’s test for
individual significant difference. A value of P0.05 was considered
statistically significant.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Mortality and Arrhythmia Occurrence
Mortality after LCA ligation before cell injection was 14%
(21 of 150). Among the 129 surviving rats, 6 (4.7%) were
excluded from the study before cell injection because their
Fukushima et al Arrhythmia After Cell Therapy 2255
 at Imperial College London (icl) on May 4, 2007 circ.ahajournals.orgDownloaded from 
LVEF was 40%. Mortality after cell injection was similarly
low in all groups: 5.9% (2 of 34) in the BMC-IM, 5.7% (2 of
35) in the BMC-IC, 3.8% (1 of 26) in the PBS-IM, and 7.1%
(2 of 28) in the PBS-IC group. All mortalities occurred during
the procedure or immediately after, presumably as a result of
surgical stresses such as bleeding.
Continuous ECG monitoring did not detect frequent (1
per hour) VPCs in any rats 1 day before cell injection,
whereas after cell injection, temporary but frequent VPCs
were observed in the BMC-IM group. In this group, a large
number of VPCs were detected as early as 1 day (155 per
hour) after cell injection. The number of VPCs peaked at 7
days (10873 per hour), and the frequent VPCs largely
disappeared by 28 days after BM cell injection (Figure 1A).
All other groups showed only a limited number of VPCs (1
per hour) throughout the periods studied. More than 70% of
rats in the BMC-IM group showed multiform (Figure 1B) or
consecutive VPCs between 1 and 7 days after BM cell
injection (Table 1). The proportion of rats showing VT
(Figure 1C) was 14% at 1 day, 43% at 7 days, 0% at 28 days,
and 0% at 84 days in the BMC-IM group. All other groups
did not show VT throughout the periods studied.
Improved Cardiac Function After BM
Cell Injection
Baseline values (intact normal rats; n11) of LVEF, HR,
LVDd/LVDs, and peak E/A were 74.11.4%, 36515 bpm,
6.70.3/3.70.2 mm, and 1.90.0, respectively. At 20 days
after LCA ligation (1 day before cell injection; n123),
echocardiography showed a consistently reduced LVEF
(33.60.4%; P0.001) and E/A (1.20.1; P0.001) and an
enlarged LVDd/LVDs (8.90.1/7.60.2 mm; P0.001)
compared with the baseline values. HR (3708 bpm) did not
show a significant change.
After cell injection, both the BMC-IM and BMC-IC groups
demonstrated a similar degree and time course of improve-
ment in LVEF (Figure 2). LVEF significantly increased by 7
days after cell injection but not at 3 days in the BMC-IM
(49.11.5%) and BMC-IC (49.01.4%) groups compared
with before cell injection (34.61.1% and 33.50.9%, re-
spectively). Significantly improved LVEF remained until 84
days in both groups. LVEF in the BMC-IM and BMC-IC
Figure 1. Ventricular arrhythmia after BM cell injection. ECG
was continuously monitored with a radiotelemetry system. A,
The number of VPC per hour was significantly higher in the
BMC-IM group at 1, 3, 7, and 14 days after injection among all
groups (*P0.001; n7 in each group). Representative patterns
of multiform VPC (B) and VT (C) observed in the BMC-IM group
are shown.
TABLE 1. Percent of Sample Showing >1 Multiform or Consecutive VPCs per Day
Days After Cell Injection
1 7 28 84
Multi, % Consec, % Multi, % Consec, % Multi, % Consec, % Multi, % Consec, %
PBS-IM 14 14 14 0 14 0 0 0
PBS-IC 14 0 0 14 0 0 0 0
BMC-IM 100 71 71 71 42 29 0 0
BMC-IC 14 14 14 29 29 0 0 25
Multi indicates multiform VPCs; Consec, consecutive VPCs. n7 each group.
Figure 2. Change in LVEF. Change in LVEF before and after cell
injection was assessed with echocardiography. The BMC-IM
and BMC-IC groups showed a similar increase in LVEF by 7
days, which lasted until 84 days after cell injection. LVEF in the
BMC-IM and BMC-IC groups was significantly higher than that
in the PBS-IM and PBS-IC groups, respectively, between 7 and
84 days. -1 Indicates 1 day before cell injection. *P0.05 vs
PBS-IM, †P0.05 vs PBS-IC group.
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groups also was significantly higher than that in the PBS-IM
and PBS-IC groups, respectively, throughout the periods
between 7 and 84 days after injection. The other cardiac
parameters also indicated improvement in cardiac perfor-
mance after BM cell injection via either route (Table 2). The
enlarged LVDs, reduced peak E/A, and increased HR ob-
served in the PBS-IM and PBS-IC groups at 28 days
compared with before cell injection did not occur in the
BMC-IM and BMC-IC groups.
Survival of Grafted Donor Cell
Survival of male donor cells in the female host failing heart
was quantitatively analyzed by real-time polymerase chain
reaction for Sry. The BMC-IM and BMC-IC groups showed
a similar small number of male cells present throughout the
time points studied (Figure 3). At 3 days after cell injection,
only 1.450.27% and 1.840.27% of total injected BM cells
were detected in the BMC-IM and BMC-IC groups, respec-
tively. The number of surviving donor cells further decreased
to 0.070.02% and 0.080.03% by 7 days, respectively. The
graft survival was then stable until 84 days after cell injection
in both groups.
Distribution of Grafted Cells in the Host Myocardium
Grafted cells were detected by immunohistochemistry for
GFP. The BMC-IM group showed GFP-positive, discrete cell
clusters in the border zone surrounding the infarcts at 3 days
after cell injection (Figure 4A). These cell clusters were
composed of GFP-positive grafted cells and GFP-negative
host-derived cells (Figure 4B). The BMC-IM group at 7 days
showed a persistent presence of the cell clusters but now
composed of a reduced number of GFP-positive cells and
many GFP-negative cells (Figure 4C). Most of the GFP-
positive cells at 3 and 7 days were hematopoietic-like round
cells, whereas some cells had a more elongated appearance.
Most GFP-negative cells found in the cell clusters were
identified as accumulated inflammatory cells, including poly-
morphonuclear leukocytes and lymphocytes having large
round nuclei.
In contrast, the BMC-IC group showed more homogeneous
cell dissemination into both infarct and noninfarct areas. The
structure of adjacent myocardium in the BMC-IC group was
better preserved compared with the BMC-IM group (Figure
4D). In the BMC-IC group at 3 and 7 days, inflammatory
cells were rarely detected around the disseminated GFP-
positive grafted cells (Figure 4E and F). Despite thorough
histological examinations, we did not detect any GFP-
positive cells entrapped in the vasculature, including cardiac
veins, venules, capillaries, arterioles, or arteries, in the
BMC-IC group. At 28 days after BM cell injection, a very
small number of GFP-positive cells were detected in the
infarct and border zones of both the BMC-IM and BMC-IC
groups, associated with little detectable inflammatory re-
sponse. Clear evidence of differentiation of GFP-positive
cells into mature cardiac phenotype was not found in any
samples of either the BMC-IM or BMC-IC group (data not
shown).
Discussion
The present article provides experimental evidence that direct
intramyocardial injection of BM cells can induce a serious
high frequency of and critical types of ventricular arrhyth-
mias for the initial 14 days after injection in post-MI chronic
HF. Such arrhythmia did not occur after retrograde intracoro-
nary injection of BM cells, despite the fact that the 2 injection
methods resulted in similar therapeutic benefits and similar
graft sizes. These data have important implications in devel-
oping the optimal protocol for cell therapy using BM cells.
Arrhythmogenicity of intramyocardial injection of BM
cells has not been discussed extensively, probably because
previous clinical trials have reported negative results.5,8,9
However, the patients studied in these trials were medically
treated with drugs having an antiarrhythmic effect such as
TABLE 2. Cardiac Parameters Before and After Cell Injection
Before Cell Injection 28 Days After Cell Injection
HR, bpm LVDd, mm LVDs, mm Peak E/A HR, bpm LVDd, mm LVDs, mm Peak E/A
PBS-IM 37320 8.80.2 7.30.2 1.30.2 40612 10.00.2 8.70.2 0.70.1
PBS-IC 37023 8.70.1 7.40.2 1.40.2 40111 9.50.2 8.80.2 0.80.1
BMC-IM 3577 9.10.1 7.60.1 1.10.1 35010* 9.60.1 8.10.1* 1.30.2*
BMC-IC 3888 8.90.1 7.60.1 1.10.1 3616† 9.90.2 8.00.2† 1.20.1†
n9 in each group.
*P0.05 vs PBS-IM, †P0.05 vs PBS-IC group at 28 days.
Figure 3. Survival of grafted cells. Survival of male donor cells
in the female host heart was analyzed by real-time polymerase
chain reaction for Sry. The BMC-IM and BMC-IC groups
showed a similar, but small, number of donor cells remaining in
the host LV throughout the time points studied.
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-blocker, which would have masked the arrhythmogenicity.
In addition, for detecting arrhythmias, these studies moni-
tored patients only for 2 days after cell injection9 and/or at
1 month or later.5,8 However, these protocols for monitoring
ECG might not be appropriate. Our results demonstrated that
arrhythmia occurrence peaked at day 7 after intramyocardial
injection of BM cells, when we observed the most frequent
VPCs (108 per hour; classified into Lown 2), with multiform/
consecutive VPCs (Lown 3/4a) in 71% of treated rats and VT
(Lown 4b) in 43%. This original information suggests that
approximately day 7 after treatment is extremely important in
evaluating the arrhythmogenicity of BM cell injection, there-
fore proposing that future clinical studies should include
intensive monitoring around this time point to further clarify
this issue in patients.
Our findings suggest that the ventricular arrhythmias ob-
served in the early phase after intramyocardial BM cell
injection might be due to the generation of cell clusters in the
border-zone myocardium. These isolated cell clusters, com-
posed of donor-derived cells and accumulated inflammatory
cells, would produce an adverse physical effect (severe local
heterogeneity within the myocardium), disturbing the myo-
cardial consistency and the conductance properties.15,16 In
addition, the accumulated inflammatory cells within the
clusters are likely to cause an adverse biochemical effect on
surrounding cardiomyocytes by inducing local myocardial
upregulation of various proinflammatory cytokines such as
interleukin-1 and tumor necrosis factor- as shown previ-
ously.13,14 Consequently, cardiomyocyte apoptosis, modula-
tion of gap junction formation, and/or deterioration of elec-
trical stability may be amplified particularly in the border
zone where native cardiomyocytes suffer post-MI adverse
remodeling processes, eventually causing ventricular arrhyth-
mias.24 This speculation is supported by the findings in our
study that homogeneously disseminated BM cells with little
inflammation by retrograde intracoronary injection or mild-
degree inflammation by intramyocardial injection of PBS
only did not cause significant ventricular arrhythmias. VPC
frequency appeared to be higher at day 7 compared with day
3 (although not significant) in our study. The precise reason
for this is unclear; however, persistent stress, including
continuous exposure to proinflammatory cytokines, might
progressively cause an adverse effect on failing cardiomyo-
cytes in the infarct border area, increasing the frequency of
VPCs toward day 7 after injection.
Another possible cause for ventricular arrhythmias after
BM cell injection is the direct adverse effect of the grafted
cells such as inappropriate cardiomyogenic differentiation,
fusion with native cardiomyocytes, and/or formation of inad-
equate intercellular connections with surrounding native car-
diomyocytes.25,26 It has been reported that BM cell–derived
cardiomyocytes trigger arrhythmogenic sparks in vitro.27,28
However, our results provided several pieces of negative
evidence for this view. First, arrhythmias observed after
intramyocardial injection of BM cells were largely absent by
retrograde intracoronary injection, despite a similar number
Figure 4. Distribution of grafted cells. Grafted cells were detected by immunohistochemistry for GFP. A, The BMC-IM group showed
brown-stained GFP-positive cell clusters in the infarct border zone (arrowheads) at 3 days after injection (50 magnification). B, Higher
magnification (400) of the outlined region in (A) showed the mixture of GFP-positive cells and accumulated GFP-negative inflamma-
tory cells. C, The BMC-IM group at 7 days also showed GFP-positive, discrete cell clusters. However, these clusters were composed
of a reduced number of GFP-positive cells (arrows) surrounded by many GFP-negative inflammatory cells. D, The BMC-IC group
showed disseminated GFP-positive cells in the LV free wall, although it is difficult to see these scattered small cells in the lower magni-
fication (50). E, Higher magnification (400) of the outlined region in C showed GFP-positive cells (arrows) disseminated with little
inflammatory response and with little disruption of the myocardium. F, The BMC-IC groups at 7 days showed disseminated GFP-
positive cells (arrow) without accumulation of inflammatory cells. A and D, Scale bar300 m; B, C, E, and F, scale bar50 m.
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of surviving grafted cells. If direct adverse effects of grafted
cells were the main cause of the arrhythmia, frequent arrhyth-
mias should have been similarly observed after intracoronary
BM cell injection. Second, frequent VPCs were found as
early as 1 day, with the peak frequency at 7 days, after
intramyocardial BM cell injection. Such a time course seems
too short for grafted BM cells to undergo cardiomyogenic
differentiation, which usually takes several weeks in vitro.29
Third, the frequency of such transdifferentiation events is
reported to be extremely low.29 In fact, we could not detect
any clear evidence indicating cardiomyogenic differentiation
of grafted cells despite thorough histological examinations. In
addition, ectopic stimuli derived from such a small number of
differentiated cells, if any, might be diluted by much larger
number of surrounding cardiomyocytes and would not lead to
ventricular arrhythmias.
Our study demonstrated the principal concept that in-
tramyocardial BM cell injection could induce serious ventric-
ular arrhythmias in a rat chronic ischemic HF model. How-
ever, because several differences exist in morphological and
electrophysiological properties between rat and human myo-
cardium,30 further large-animal or clinical studies would be
useful to verify our findings in a clinical setting. It also would
be interesting to investigate whether the modulation of
injection protocol, such as injections of a smaller volume into
a larger number of sites, could reduce arrhythmia occurrence
after intramyocardial injection. It has been reported that such
multiple injections of a smaller volume improve cardiac
function more efficiently compared with a single injection of
a large volume.31 Furthermore, electric mapping approaches,
available in human and large animals, may be useful for
identifying the high-risk areas for cell injection–induced
arrhythmia, possibly reducing the risk of arrhythmias.32
Therapeutic efficacy of mononuclear BM cell injection for
treating post-MI chronic HF was inconsistent among previous
clinical studies. Perin et al,5 Beeres et al,9 and Strauer et al11
observed a significant improvement in LVEF, whereas Fuchs
et al,6 Kuethe et al,7 Tse et al,8 and Blatt et al10 reported
negative results. Although the reasons of such a discrepancy
in LVEF improvement are not known, one may speculate that
it results from the heterogeneous nature of patients assigned
to the study, the small numbers of patients, the variable
quality of BM cells, and the different injection methods,
including the site for injection and the cell number injected.
On the other hand, in this study, we have provided evidence
that mononuclear BM cell injection by either route consis-
tently improves both systolic (ie, LVEF) and diastolic (ie,
peak E/A ratio) cardiac functions of post-MI chronic HF
using an established rat model. Because BM cell injection,
regardless of the cell delivery route, failed to suppress
progression of ventricular dilatation (ie, LVDd), LVEF im-
provement after BM cell injection appeared to be largely
dependent on reduced LVDs. It is therefore indicated that
mononuclear BM cell injection via either route can be an
effective therapy for treating post-MI chronic HF but is
subject to patient selection and optimization of the protocol.
Quantitative analysis of surviving donor-derived cells using
real-time polymerase chain reaction showed that 0.1% of
injected cells existed in the heart at day 7, whereas significant
functional improvement was observed. Although the direct
mechanical contribution of such a small number of surviving
donor-derived cells is unlikely to be sufficient to increase
global cardiac function, these cells could, by a paracrine
effect, improve the contractility of a much larger number of
surrounding failing cardiomyocytes. In addition, other para-
crine effects mediated by the donor-derived cells such as
increased neovascular formation would also be useful to
enhance cardiac function.13
Antegrade intracoronary injection has been shown to have
a similar ability to disseminate cells into the myocardium.33
However, retrograde intracoronary injection is believed to
have several possible advantages over antegrade intracoro-
nary injection.34 Although the antegrade intracoronary route
is commonly used in clinical trials,6,7,10,35 this method report-
edly carries a risk of coronary embolism.36 This risk will be
particularly critical during the treatment of post-MI chronic
HF when coronary arteries often show diffuse narrowing at
many sites with jeopardized collateral arteries. In contrast, the
risk of coronary embolism will be largely obviated in retro-
grade intracoronary injection. Furthermore, cells injected via
the retrograde intracoronary route may have a greater chance
for transendothelial migration from the intravascular space
into the myocardial interstitium. It is known that migration of
inflammatory cells into the myocardial interstitium takes
place at postcapillary venules rather than at capillaries or
arterioles as a result of the endothelial-leukocyte interaction
in which a distinct set of adhesion molecules plays a role.37
The retrograde intracoronary route is able to deliver cells
directly to this unique part of the vasculature, resulting in
enhanced transendothelial donor cell migration. Retrograde
intracoronary injection is feasible in clinical settings by use of
a balloon catheter34; however, further investigation is needed
to prove these advantages of retrograde intracoronary injec-
tion over antegrade intracoronary injection. Because a repro-
ducible model for antegrade intracoronary cell injection has
not been established in small animals, a large-animal exper-
iment will be more suitable for this purpose.
In summary, we provide evidence that direct intramyocar-
dial injection of BM cells induces temporary but serious
ventricular arrhythmias in a post-MI chronic HF model. Such
arrhythmias were largely absent when injected via the retro-
grade intracoronary route despite the similar therapeutic
efficacy. These data suggest that the retrograde intracoronary
route might be a safe, efficient route for BM cell injection for
treating post-MI chronic HF.
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CLINICAL PERSPECTIVE
Cell therapy using bone marrow cells is now being studied as a treatment for postinfarction chronic heart failure in patients.
Although previous clinical studies reported rare incidences of arrhythmia, the arrhythmia risk may have been masked by
the common use of antiarrhythmia drugs. In the present study, we compared the effects of intramyocardial and retrograde
intracoronary injection of bone marrow mononuclear cells on ventricular arrhythmias using an established rat model.
Injection of bone marrow cells by either route improved both systolic and diastolic ventricular function but with similarly
poor graft survival. Evidence for differentiation of donor cells into cardiomyocytes or vascular cells was very rare,
suggesting that paracrine effects may be important for the impact of therapy on ventricular function. Noticeably,
intramyocardial cell injection induced frequent ventricular arrhythmias, including ventricular tachycardia, for 14 days after
injection. Intramyocardial injection caused the formation of localized clusters of donor-derived cells and host-derived
inflammatory cells within the border-zone myocardium. In contrast, intracoronary injection disseminated cells with little
inflammation and rarely induced arrhythmias throughout the period. These results show that the method of cell delivery
can influence the inflammatory response and arrhythmogenesis. The findings support trials of bone marrow cell
transplantation for treating postinfarction heart failure but indicate that further study of arrhythmia risk, particularly in the
early phase after intramyocardial injection, is warranted.
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A Novel Strategy for Myocardial Protection by Combined
Antibody Therapy Inhibiting Both P-Selectin and
Intercellular Adhesion Molecule-1 Via Retrograde
Intracoronary Route
Satsuki Fukushima, MD; Steven R. Coppen, PhD; Anabel Varela-Carver, PhD;
Kenichi Yamahara, MD, PhD; Padmini Sarathchandra, PhD; Ryszard T. Smolenski, MD, PhD;
Magdi H. Yacoub, FRS; Ken Suzuki, MD, PhD
Background—Antibody therapy to inhibit either P-selectin or intercellular adhesion molecule-1 (ICAM-1) has been
reported to provide myocardial protection against leukocyte-mediated reperfusion injury. Because these molecules play
different roles in the leukocyte-endothelial interaction, co-inhibition of both may achieve further enhanced cardiopro-
tection. In addition, the therapeutic efficacy of such antibody therapy may be affected by the delivery route used.
Retrograde intracoronary infusion will offer an effective, direct access to the postcapillary venules, where the target
event (leukocyte–endothelial interaction) takes place. We investigated the feasibility and efficiency of the combined
antibody therapy targeting both P-selection and ICAM-1 via the retrograde intracoronary route to attenuate myocardial
ischemia-reperfusion injury.
Methods and Results—Lewis rats underwent 30-minute left coronary artery occlusion. Just before reperfusion,
anti-P-selectin monoclonal antibody (150 g/kg), anti-ICAM-1 monoclonal antibody (200 g/kg), both antibodies
together, or control antibody were retrogradely infused into the left cardiac vein. At 24 hours after reperfusion,
administration of either anti-P-selectin or anti-ICAM-1 antibody significantly (P0.05) improved left ventricular
ejection fraction and attenuated infarct size (40.63.2% and 34.83.5%, respectively) compared with the control
(56.83.4%). This was associated with reduced leukocyte accumulation and improved regional blood flow in the
ischemic area. Noticeably, co-administration of both antibodies achieved a much greater reduction in infarct size
(19.13.6%), associated with greater attenuation in leukocyte infiltration, compared with administration of either single
antibody.
Conclusions—Combined antibody therapy inhibiting both P-selectin and ICAM-1 via the retrograde intracoronary route
could be a promising new strategy for myocardial protection against ischemia-reperfusion injury. (Circulation. 2006;
114[suppl I]:I-251–I-256.)
Key Words: antibody therapy  cell adhesion molecules  leukocytes  myocardial protection  reperfusion
Myocardial ischemia-reperfusion injury remains a majorissue in clinical settings such as heart transplantation,
heart surgery using cardiac arrest (particularly in cases with
severely hypertrophied or deteriorated left ventricle [LV]),
and primary angioplasty for acute myocardial infarction
(MI).1 It is known that acute inflammation, which is initiated
and augmented by a series of reactions between leukocytes
and endothelial cells, is an important contributor to the
injury.2 The leukocyte–endothelial interaction and the conse-
quent transmigration of leukocytes into the myocardial inter-
stitium are regulated by adhesion molecules such as
P-selectin and intercellular adhesion molecule-1 (ICAM-1).3
Previous experimental studies have demonstrated that intra-
venous injection of either anti-P-selectin or anti-ICAM-1
antibody attenuates leukocyte-mediated reperfusion inju-
ry,4–8 suggesting the utility of antibody therapy for myocar-
dial protection. However, further refinement is needed for the
future success of this strategy in the clinical arena.
We hypothesized that co-inhibition of P-selectin and
ICAM-1 may provide enhanced cardioprotection compared
with inhibition of either single molecule, because these
molecules are involved in different processes of the leukocy-
te–endothelial interaction.2,3 In addition, the use of retrograde
intracoronary infusion as a delivery route for the antibodies
may augment the therapeutic efficacy. This route will offer a
more effective, direct access to the postcapillary venules,
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where the target antigens are upregulated to facilitate leuko-
cyte–endothelial interaction,2 as compared with any other
infusion methods including intravenous and antegrade intra-
coronary infusion. In this article, we investigated the feasi-
bility and efficiency of the combined antibody therapy
targeting both P-selection and ICAM-1 by retrograde intra-
coronary injection to attenuate myocardial ischemia-
reperfusion injury using our original model in rat.9
Methods
Induction of Myocardial
Ischemia-Reperfusion Injury
All studies were performed with the approval of the local ethical
committee. The investigation conforms to the Principles of Labora-
tory Animal Care (National Society for Medical Research) and the
Guide for the Care and Use of Laboratory Animals (NIH Publica-
tion). Male Lewis rats (300 to 350 grams; Charles River, UK)
underwent left thoracotomy under anesthesia with sodium pentobar-
bital (40 mg/kg, intraperitoneal) and mechanical ventilation.9 The
left coronary artery (LCA) was occluded for 30 minutes and then
released for reperfusion.10
Retrograde Intracoronary Infusion of Antibodies
Just before reperfusion, hearts were treated with retrograde intra-
coronary infusion of mouse monoclonal anti-P-selectin antibody
(150 g/kg, Santa-Cruz; P-selectin group), mouse monoclonal anti-
ICAM-1 antibody (200 g/kg, Santa-Cruz; ICAM-1 group), both
antibodies (co-inhibition group), or mouse IgG (350 g/kg, eBio-
science; control group). The antibody dosages were decided based on
the previous reports using intravenous infusion,4–8 because there
were no reports in which antibodies to P-selectin or ICAM-1 were
successfully infused into the coronary circulation. One-tenth of the
reported dosages were used for retrograde intracoronary infusion,
because the blood flow perfusing the heart is considered to be 5% to
10% of the systemic blood flow. Retrograde intracoronary infusion
was performed as we have recently described.9 The perfusion area by
this infusion method has been shown to fully encompass the whole
ischemic area after LCA ligation.9 Through a 24-gauge catheter,
which was inserted into the left cardiac vein, the appropriate
antibody suspended in 0.5 mL phosphate-buffered saline was in-
jected into the vein over a period of 5 seconds. Then, 25 seconds
after the end of injection, occlusion of LCA was released for
reperfusion. During this 30-second period, the stem of the cardiac
vein was snared to prevent flush out of infused reagents.
Assessment of Cardiac Function and Dimension
At 24 hours after reperfusion, all the other rats were again anesthe-
tized for echocardiography (n14 for each group) using the Sequoia
512 system (Acuson, Siemens).11 LV diastolic dimension (LVDd)
and LV systolic dimension (LVDs) were measured with M-mode.
LV ejection fraction (LVEF) was calculated with 2-dimensional
trace.11 After completion of echocardiography, the rats were used for
one of the following assessments: measurement of infarct size (n5
in each group), evaluation of regional myocardial blood flow (n4),
and histological analysis (n5).
Measurement of Infarct Size
The heart was again exposed under mechanical ventilation. Imme-
diately after re-occlusion of the LCA with the suture left in situ, 1.5
mL of 2% Evans Blue was injected into the femoral vein. The heart
was then removed and cut into 5 segments parallel to the apex–base
axis, which were incubated with 4% triphenyltetrazolium chloride
(TTC). Area at risk of infarction (negative for Evans Blue), infarct
area (negative for TTC), and the whole LV area were assessed using
National Institutes of Health image-analyzing software in a blind
manner.12 Infarct size was calculated as [infarct area/area at risk of
infarction]100 (%).
Evaluation of Regional Myocardial Blood Flow
The heart was exposed and 6105 colored microspheres (15 m
diameter, Dye-Trak, Triton Technologies) suspended in 0.5 mL of
saline containing 0.02% Tween 80 were injected into the LV
cavity.13 The heart was then excised and cut into 5 segments. The
area at risk of infarction was collected and digested by overnight
incubation in 1 mol/L KOH at 37°C. The number of microspheres
contained in each sample was counted with a hemocytometer.
Regional myocardial blood flow (RMBF) was defined as the
microsphere number divided by the sample weight. The degree of
reflow in the ischemic area was calculated as [RMBF in the area
at risk of infarction/RMBF in the area without risk of infarc-
tion]100 (%).
Histological Analysis for Acute Inflammation
The heart was excised, cut into 5 sections in base–apex axis, and
frozen in OCT compound. The embedded samples were cut into
10-m cryosections, which were fixed in 4% paraformaldehyde.
These sections were incubated with monoclonal anti-rat granulocyte
antibody (1:20; Serotec)14 and then with R-phycoerythrin conjugated
secondary antibody (1:200; Serotec). The sections were counter-
stained with 4,6-diamidino-2-phenyindole (DAPI; 1:1000). After
observation and recording with a fluorescence microscope (Zeiss;
Axioskop 40), the sections were stained with hematoxylin and eosin.
The number of polymorphonuclear leukocytes (PMNLs) per high-
power field was calculated to give an indication of the degree of
acute myocardial inflammation.6 Nine different fields of the area at
risk of infarction in each section were randomly selected and
analyzed.
Detection of Antibody Injected Into the Heart Via
Retrograde Intracoronary Route
In addition, monoclonal anti-ICAM-1 antibody was labeled with
Alexa Fluor 546 (Invitrogen) and was infused in the same manner of
retrograde intracoronary infusion (n2). The heart was reperfused
for 30 seconds and excised; 10-m cryosections were counterstained
with DAPI. After fluorescence recording, the sections were stained
with hematoxylin and eosin.
Statistical Analysis
All values are expressed as meansSEM. Statistical comparison of
the data were performed using 1-way ANOVA followed by Bonfer-
roni test for individual significant difference. A value of P0.05 was
considered statistically significant.
The authors had full access to the data and take full responsibility
for their integrity. All authors have read and agree to the manuscript
written.
Results
Distribution of Antibodies Injected Via Retrograde
Intracoronary Route
The Alexa Fluor 546-labeled monoclonal anti-ICAM-1 anti-
body was exclusively attached to endothelial cells of veins,
venules, and postcapillary venules (Figure 1A to 1D). No
arteries, arterioles, or capillaries were positively labeled. No
antibody was detected on cardiomyocytes.
Enhanced Cardiac Function After
Antibody Therapy
Cardiac function was measured with echocardiography (Ta-
ble 1). Baseline values (intact normal animals; n6) of heart
rate, LVDd, LVDs, and LVEF were 36515 bpm,
6.70.3 mm, 4.00.2 mm, and 78.31.2%, respectively.
After ischemia and reperfusion, all the groups demonstrated a
reduction of LVEF compared with the baseline data
(P0.05). However, both the P-selectin and ICAM-1 groups
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demonstrated improved LVEF compared with the control
group (P0.041 and P0.001, respectively). Furthermore,
LVEF in the co-inhibition group was enhanced compared
with the P-selectin group (P0.029). Heart rate in every
group tended to be higher (not significant) than the baseline,
presumably caused by surgical stress.
Reduced Infarct Size by Antibody Therapy
The area at risk of infarction and the infarct area were
determined by Evans Blue and TTC staining (Figure 2). The
area at risk of infarction was similar among all groups (% to
the whole LV; 51.22.6% in the control, 54.12.1% in the
P-selectin, 54.00.8% in the ICAM-1, and 53.81.4% in the
co-inhibition group). Both the P-selectin (40.63.2%) and
ICAM-1 (34.83.5%) groups demonstrated a significant
decrease in infarct size compared with the control group
(56.83.4%, P0.024 and P0.002, respectively; Figure 3).
Noticeably, the co-inhibition group (19.13.6%) demon-
strated a much greater reduction of infarct size compared both
to the P-selectin (P0.002) and ICAM-1 (P0.021) groups.
Improved Regional Myocardial Reflow by
Antibody Therapy
The degree of regional reflow in the ischemic myocardium
after reperfusion was evaluated with colored microspheres.
At 24 hours after reperfusion, both the P-selectin
(73.34.5%) and ICAM-1 (72.91.7%) groups demon-
strated significant improvement in the degree of regional
reflow compared with the control group (56.12.9%,
P0.021 and P0.009, respectively; Figure 4). The co-
inhibition group (81.74.3%) showed further improvement
in reflow compared with the control group (P0.001),
although this was not significantly different from the
Figure 1. Distribution of antibodies injected. The Alexa Fluor
546 (red)-labeled monoclonal anti-ICAM-1 antibody infused by
retrograde intracoronary infusion exclusively attached to endo-
thelial cells of veins, venules (A and B, bar100 m), and post-
capillary venules (C and D, bar20 m). Nuclei were stained in
blue (DAPI).
Cardiac Function After Ischemia-Reperfusion
Control P-Selectin ICAM-1 Co-Inhibition
Heart rate (bpm) 45213 44911 45612 44316
LVDd (mm) 6.20.2 6.00.3 5.90.2 6.20.2
LVDs (mm) 4.80.2 4.20.3 4.20.2 4.10.2
LVEF (%) 52.32.0 60.12.2* 65.11.3* 68.42.0*†
Cardiac function and dimensions were evaluated by echocardiography.
n14 in each group.
*P0.05 vs the control group.
†P0.029 vs the P-selectin group.
Figure 2. Myocardial infarction. The infarct area and the area at
risk of infarction were determined with Evans Blue and TTC
staining. The area not stained with Evans Blue was defined as
the area at risk of infarction. TTC staining separated the infarct
area (nonstained white area) from the viable area (red-stained
area). The P-selectin (B) and ICAM-1 groups (C) demonstrated
smaller infarct than the control group (A). The co-inhibition
group (D) showed the smallest size of infarct.
Figure 3. Infarct size. Infarct size in the P-selectin and ICAM-1
groups was smaller than that in the control group. The
co-inhibition group showed the smallest infarct size among all
the groups. *P0.05 vs the control group, †P0.002 vs the
P-selectin group, §P0.021 vs the ICAM-1 group.
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P-selectin or ICAM-1 group (P0.742 and P0.415,
respectively).
Attenuated Leukocyte Infiltration by
Antibody Therapy
At 24 hours after reperfusion, the myocardium of ischemic
areas had lost its regular structure and contained necrotic
cardiomyocytes and cell infiltration into the disrupted tissue
(Figure 5A to 5D). Immunofluorescence and hematoxylin/
eosin staining on the same section demonstrated that the
absolute majority of infiltrating cells were granulocyte
antigen-positive cells having polymorphonuclei (PMNL)
(Figure 5E and 5F). This myocardial damage and PMNL
infiltration are typically seen in the Control group (Figure
5A). These changes indicating acute inflammation post ische-
mia-reperfusion appeared to be attenuated by antibody ad-
ministration (Figure 5B to 5D), most clearly in the co-
inhibition group (Figure 5D). The number of PMNL
infiltrating into the ischemic myocardium was reduced in
both the P-selectin (10 178729 /mm2) and ICAM-1
(10 241518 /mm2) groups compared with the control group
(13 469433 /mm2, P0.027 and P0.031, respectively;
Figure 6). The co-inhibition group (6825895 /mm2) showed
further reduction in the PMNL number compared with all
other groups (P0.001 versus the control group, P0.024
versus the P-selectin group and P0.021 versus the ICAM-1
group).
Discussion
We demonstrated that either anti-P-selectin or anti-ICAM-1
antibody administration via the retrograde intracoronary route
limited infarct size and improved cardiac function after
ischemia-reperfusion injury. These effects were associated
with reduced leukocyte infiltration into the ischemic myocar-
dium and improved regional myocardial blood flow, suggest-
ing the underlying mechanism of the therapeutic effects
obtained. Noticeably, such cardioprotection against
leukocyte-mediated reperfusion injury was further enhanced
by co-inhibiting both molecules, highlighting the remarkable
effectiveness of the combined antibody therapy targeting both
P-selectin and ICAM-1 by retrograde intracoronary injection
to attenuate myocardial ischemia-reperfusion injury.
Myocardial damage after ischemia-reperfusion is acceler-
ated and augmented by acute inflammation that initiates and
progresses as a result of the leukocyte–endothelial interaction
Figure 4. Degree of regional myocardial reflow. RMBF was
measured with colored microspheres at 24 hours after reperfu-
sion. The degree of regional reflow in the ischemic area was
significantly improved in the ICAM-1, P-selectin, and
co-inhibition groups as compared with the control group.
*P0.05 vs the control group.
Figure 5. Histological findings. Myocardial damage and PMNL infiltra-
tion, which were typically seen in the control group (A), appeared to
be attenuated by antibody administration (B to D), most clearly in the
co-inhibition group (D, bar100 m). Immunofluorescence and hema-
toxylin/eosin staining on the same section (E and F, bar 20 m)
demonstrated that the majority of infiltrating cells were granulocyte-
antigen positive (red). Nulei are shown in blue (DAPI).
Figure 6. Number of PMNL infiltrating into the ischemic myocardium.
The number of PMNL infiltrating into the area at risk of infarction was
calculated at 24 hours after reperfusion. Both the P-selectin and
ICAM-1 groups demonstrated a significantly reduced number of
PMNLs compared with the control group. The co-inhibition group
showed the smallest number of PMNLs among the groups. *P0.05
vs the control group, †P0.024 vs the P-selectin group, §P0.021 vs
the ICAM-1 group (n5 in each group).
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at the postcapillary venules.2 Importantly, each step of the
interaction is regulated by a distinct set of adhesion mole-
cules. P-selectin, which is constitutively found in the endo-
thelial cells and is mobilized to the cell surface rapidly after
activation by inflammatory mediators, is known to mediate
the initial entrapment of leukocytes.15 Subsequent binding
between 2-integrin on the leukocytes and its ligand,
ICAM-1, on the endothelial cells strengthens the attachment
of leukocytes to the endothelium. ICAM-1 also facilitates the
transendothelial migration of leukocytes into the myocardial
interstitium.16 In this study, we demonstrated that inhibition
of either P-selectin or ICAM-1 reduced leukocyte infiltration
into the ischemic myocardium, preserved regional blood
flow, and reduced infarct size after ischemia-reperfusion.
These results, which are consistent with previous reports,4–8
corroborate the important roles of both molecules in
leukocyte-mediated reperfusion injury.
Although the efficiency of anti-P-selectin or anti-ICAM-1
antibodies for myocardial protection has not been tested in
patients, multicenter clinical trials to block 2-integrin–
ICAM-1 binding using an antibody to CD11/CD18, a sub-
strate of ICAM-1, or a CD11/18 leukocyte receptor blocker
has failed to limit infarct size after thrombolysis or angio-
plasty in acute MI.17–19 Thus, further refinement will be
needed for the future clinical success of antibody therapy for
myocardial protection. In this article, we have demonstrated
that co-inhibition of both P-selectin and ICAM-1 via the
retrograde intracoronary route provided exceptionally power-
ful cardioprotection. It is noticeable that this treatment
markedly reduced infarct size, from 56.8% (in the control
group) to as small as 19.1%.
Our results support the concept that co-inhibition of
P-selectin and ICAM-1 enhances the therapeutic efficacy
against myocardial ischemia-reperfusion injury compared
with inhibition of either single molecule alone. However,
Lefer et al8 reported that bolus intravenous infusion of both
anti-P-selectin and anti-ICAM-1 antibodies did not add fur-
ther protective effects against reperfusion injury to single
antibody administration in a canine model. Briaud et al10
reported that mice with a genetic deficiency of both P-selectin
and ICAM-1 showed a significant reduction of leukocyte
accumulation but without reduction in infarct size after
ischemia-reperfusion, compared with the wild-type. Although
reasons for these inconsistent results are uncertain, we would
speculate that it could be because of the different experimen-
tal models used. The former study used intravenous injection
for antibody delivery, by which the efficiency of injected
antibodies to reach the targeted myocardium might not be
consistent because of a varying degree of their degradation or
entrapment in other organs and vessels. Results of the latter
study employing knock out mice might potentially be con-
founded by the developmental effects of early lost of expres-
sion. Continuous total blockage of the P-selectin and ICAM-1
cascade since before birth might enhance alternative path-
ways of postreperfusion acute inflammation and myocardial
damage.
Antegrade intracoronary infusion and intravenous injection
are other feasible routes for the antibody therapy. Although
different from these, the retrograde intracoronary route allows
for direct access to the postcapillary venules where P-selectin
and ICAM-1 are upregulated and play a role in the leukocyte–
endothelial interaction.2 This unique ability could be a great
advantage as a route for antibody therapy targeting these
molecules. In addition, in the present study, the retrograde
intracoronary route was successful in delivering antibodies
into the ischemic myocardium before reperfusion with 30-
second controlled incubation time. This process is believed to
encourage the infused antibodies to effectively reach the
target tissue, and firmly bind to their antigens, which are
known to be upregulated even during the ischemic period.3,20
It is true that this strategy requires additional procedures to
the usual heart surgery or percutaneous coronary intervention
before reperfusion, which will delay reperfusion by several
minutes. However, we consider that this powerful treatment
will provide greater benefits far overweighting the loss
caused by the “several-minute delay” in reperfusion, thereby
improving the overall outcome. We did not compare the
effect of retrograde intracoronary infusion with that of ante-
grade intracoronary or intravenous infusion in this study,
which may be a limitation of the study. However, the
efficiency of intravenous injection in delivering antibody into
the heart is much poorer compared with local (intracoronary)
infusion methods, and there is lack of widely accepted,
reproducible models of antegrade intracoronary injection in
rats. This issue should be clarified using an appropriate large
animal model. The lack of dose-dependent analysis may be
another limitation of the study. However, we have carefully
decided on the antibody dose by considering all the relevant
previous reports and, using such the most promising dose of
each antibody, we have provided proof of principal that the
combined antibody therapy inhibiting both P-selectin and
ICAM-1 via the retrograde intracoronary route provides
effective myocardial protection.
In conclusion, the combined antibody therapy inhibiting
both P-selectin and ICAM-1 via the retrograde intracoronary
route could be a promising new strategy to attenuate myo-
cardial ischemia-reperfusion injury.
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Objective: We hypothesized that modification of the infusion route may improve the efficiency of superoxide dismutase (SOD)-induced
cardioprotection against reperfusion injury. The routes for SOD delivery previously examined were intravenous, via the left atrium, or by a
combination of these, all of which can deliver SOD into the ischemic myocardium only after reperfusion. In contrast, retrograde intracoronary
infusion may be able to deliver SOD before reperfusion. We investigated the feasibility and efficiency of the retrograde intracoronary infusion
of SOD to attenuate reperfusion injury.
Methods and results: Lewis rats underwent 30-min left coronary artery occlusion followed by reperfusion for 24 h. Just before reperfusion,
CuZn–SOD was administered intravenously (15,000 U/kg, V-SOD group) or by retrograde intracoronary infusion (1500 U/kg, R-SOD
group) through a catheter inserted into left cardiac vein via left superior vena cava as we have previously reported. This method has been
shown to perfuse the whole left ventricular free walls. Controls for each group were injected with phosphate buffer saline only via the same
routes (V-PBS and R-PBS group). The R-SOD group demonstrated significantly preserved left ventricular ejection fraction (LVEF;
71.3T1.7% vs. 60.8T2.3%, p =0.028), reduced infarct size (23.3T2.3% vs. 42.4T3.5%, p <0.001), and attenuated polymorphonuclear
leukocyte (PMNL) infiltration (11.8T0.4 vs. 14.8T0.2 103/mm2, p <0.001) compared to the V-SOD group. The V-SOD group demonstrated
significantly improved reflow (64.3T2.1% vs. 53.4T2.4%, p =0.017) and attenuated PMNL infiltration (14.8T0.2 vs. 16.8T0.7 103/mm2,
p =0.018) compared to the V-PBS group.
Conclusion: Retrograde intracoronary infusion is a promising, clinically applicable method to enhance the efficacy of SOD-induced
myocardial protection against ischemia–reperfusion injury.
D 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Reperfusion injury; Free radicals; Cardioprotection; Acute inflammation; Retrograde intracoronary injection1. Introduction
Although early reperfusion is the only established way to
save the ischemic myocardium, it is inevitably associated
with reperfusion injury, which remains one of the major
issues in clinical settings such as primary angioplasty for
acute myocardial infarction [1]. Superoxide dismutase0008-6363/$ - see front matter D 2005 European Society of Cardiology. Publishe
doi:10.1016/j.cardiores.2005.10.008
* Corresponding author. Cell and Gene Therapy Group, Harefield Heart
Science Centre, Harefield, Middlesex, UB9 6JH, UK. Tel.: +44 1895 453
846; fax: +44 1895 828 864.
E-mail address: k.suzuki@ic.ac.uk (K. Suzuki).(SOD) has been proposed to be a promising reagent to
attenuate reperfusion injury; however, its efficacy has not
been fully established in experimental or clinical reports [2–
13]. We hypothesized that the efficiency of this form of
therapy may be improved by modulating the delivery
method. The routes for SOD delivery previously examined
were intravenously, via the left atrium or by a combination
of these, all of which can deliver SOD into the ischemic
myocardium only after reperfusion [4–14]. It is highly
unlikely that SOD delivered by these methods efficiently
dismutate superoxides, which are generated within seconds
after reperfusion [3,15]. For inducing the maximum69 (2006) 459 – 465d by Elsevier B.V. All rights reserved.
S. Fukushima et al. / Cardiovascular Research 69 (2006) 459–465460protective effect, SOD has to be delivered into the ischemic
myocardium before reperfusion.
Retrograde intracoronary infusion could deliver SOD
into the myocardium during ischemia before reperfusion.
Using the recently established original model in rat [16,17],
we investigated the feasibility and efficiency of retrograde
intracoronary infusion of SOD to attenuate reperfusion
injury.Fig. 1. Method of retrograde intracoronary infusion. Under left thoracot-
omy, left coronary artery (LCA) was occluded for 30 min. A 24 gauge
catheter was inserted into left cardiac vein (LCV) through left superior vena
cava (LSVC). PBS with or without SOD was injected through this catheter
under constant pressure (arrow) just before the release of the occlusion of
LCA for reperfusion. (1) purse string suture to prevent bleeding from the
catheter insertion site, (2) snaring suture to prevent the flash back of the
reagents into LSVC. LA; left atrium, LV; left ventricle.2. Methods
2.1. Induction of myocardial ischemia–reperfusion injury
All studies were performed with the approval of the
institutional ethics committee and the Home Office, UK.
The investigation conforms to the Principles of Laboratory
Animal Care formulated by the National Society for
Medical Research and the Guide for the Care and Use of
Laboratory Animals (US National Institutes of Health
Publication No. 85-23, 1996). Male Lewis rats (300–350
g, Charles-River, UK) underwent left thoracotomy under
anaesthesia with sodium pentobarbital (40 mg/kg, intraper-
itoneal) and mechanical ventilation using a volume-control
ventilator (Harvard Apparatus, UK). The left coronary
artery (LCA) was completely occluded for 30 min and then
released for reperfusion.
2.2. Administration of SOD
Just before reperfusion, hearts were treated by either
retrograde intracoronary or intravenous infusion of SOD
after systemic heparinization (100 U/kg, intravenous).
Retrograde intracoronary infusion was performed as we
have described previously [16,17]. A 24 gauge catheter
(Vialon, UK) was inserted into left cardiac vein through a
purse string suture placed on the left superior vena cava. The
stem of the cardiac vein was snared to prevent flush out of
infused reagents by the venous flow into the vena cava (Fig.
1). Through the catheter, 1500 U/kg of CuZn–SOD (Sigma-
Aldrich, UK) suspended in 0.5 ml phosphate buffered saline
(PBS) or PBS only was injected into the left cardiac vein
over a period of 5 s (R-SOD and R-PBS group, respective-
ly). At 25 s after the end of the injection, occlusion of LCA
was released for reperfusion. For the V-SOD and V-PBS
group, 15,000 U/kg of CuZn–SOD suspended in 1.0 ml
PBS and PBS only, respectively, was injected intravenously
over a period of 5 s. Then, at 25 s after the end of the
injection, occlusion of LCA was released for reperfusion.
The dosages of SOD administered were determined
according to the previous publications [4–13]. The rationale
for the SOD dosage is further discussed in the Discussion.
The suture used for LCA occlusion was left in situ. The
chest was closed and the rats returned to their cages after
extubation. All these procedures were randomly assigned
and carried out in a blind manner.2.3. Assessment of cardiac function and structure
At 24 h after the reperfusion, the rats were again
anesthetized with intraperitoneal injection of 30 mg/kg
sodium pentobarbital for echocardiography (n =16 for each
group) with the Sequoia 512 system and 15-MHz probe
(Acuson). Both 2-dimensional (2-D) and M-mode images
were taken at the mid-papillary muscle level. LV diastolic
(LVDd) and systolic (LVDs) dimension was measured with
M-mode. Left ventricular ejection fraction (LVEF) was
measured by 2-D tracing using the formula; LVEF
(%)=[(LV diastolic areaLV systolic area) /LV diastolic
area]100, as previously described [18]. During the
measurement, we carefully regulated the factors, which
may affect the afterload, such as body temperature and
anaesthesia, as these may affect the cardiac function. After
the echocardiography examination, the rats were subsequent-
ly used for further assessments: measurement of infarct size
(n =6), evaluation of regional myocardial blood flow (n =5)
and histological analysis (n =5). All these assessments were
randomly assigned and carried out in a blind manner.
2.4. Measurements of infarct size
The heart was exposed through the previous incision
under mechanical ventilation. Immediately after re-occlu-
sion of the LCA with the suture left in situ, 1.5 ml of 2%
Evans Blue dye (Sigma-Aldrich, UK) was injected into the
left femoral vein to estimate the area perfused by the
occluded LCA. The heart was then removed and the LV was
cut into 5 segments parallel to the apex–base axis, which
were incubated with 4% triphenyltetrazolium chloride
(TTC, Sigma-Aldrich, UK). Area at risk of infarction
(negative for Evans Blue) and infarct area (negative for
TTC) was assessed with NIH Image program [19]. Infarct
Table 1
Cardiac function before and after ischemia– reperfusion
V-PBS R-PBS V-SOD R-SOD
Heart rate (bpm) 452T10 444T8 435T11 443T21
LVDd (mm) 5.9T0.2 6.0T0.3 6.0T0.2 6.3T0.2
LVDs (mm) 4.4T0.2 4.5T0.2 4.2T0.2 3.8T0.2
LVEF (%) 54.7T2.9 52.4T2.3 60.8T2.3 71.3T1.7*
Data were measured at 24 h after reperfusion with echocardiography. LVDd
and Ds were assessed with M-mode and LVEF with 2-D tracing. Data are
presented as meanTSEM. n =16 in each group. *p <0.05 vs. V-PBS, R-
PBS and V-SOD.
Fig. 2. Infarct size. The infarct area and the area at risk of infarction were
determined with Evans Blue and TTC staining. The infarct area was
calculated as the percentage to the area at risk of infarction. Infarct size in
the R-SOD group was the smallest among all other groups. The V-SOD
group did not show significant difference compared with the V-PBS groups.
*p <0.01 vs. V-SOD, R-PBS and V-PBS. n =6 in each group.
S. Fukushima et al. / Cardiovascular Research 69 (2006) 459–465 461size was calculated as a percentage of the infarct area to the
area at risk of infarction.
2.5. Evaluation of regional myocardial blood flow
The heart was exposed and 6105 coloured micro-
spheres (15 ı`m diameter, Dye-Trak, Triton Technologies)
suspended in 0.5 ml of saline containing 0.02% Tween 80
were injected into the LV cavity [20]. The heart was then
excised, the atria and the right ventricular free wall were
removed. In this assessment, we could not stain the
samples by Evans blue and TTC, as these dyes mask the
detection of the blue microspheres. The area at risk of
infarction was therefore determined by referring to the
typical samples for the infarct size measurement and
separated from the rest of the ventricular wall. Each
sample was digested with overnight incubation in 1 mol/
l KOH at 37 -C. The number of microspheres contained in
each sample was counted with a counting chamber
(improved Naubauer type). Regional myocardial blood
flow (RMBF) was defined as the microsphere number
divided by the weight of the sample. The degree of reflow
in the ischemic area was calculated as a percentage of
RMBF in the area at risk of infarction to that in the area
without risk of infarction.
2.6. Histological analysis for acute inflammation
Histological analysis was performed on separate hearts.
The heart was collected, cut into 4 sections and frozen in
OCT compound (BD Biosciences, UK). The embedded
samples were cut into 10-Am cryosections and stained with
haematoxylin and eosin. The number of polymorphonuclear
leukocytes (PMNLs) per high-power field was calculated as
an indicator of the degree of acute myocardial inflammation
[21]. Nine different fields of the area at risk of infarction in
each section were investigated.
2.7. Statistical analysis
All values are expressed as meansTSEM. Statistical
comparison of the data was performed using 1-way ANOVA
followed by Bonferroni test for individual significant
difference. A value of p <0.05 was considered statistically
significant.3. Results
3.1. Preserved cardiac function by retrograde intracoronary
SOD infusion
Cardiac function and dimension were measured with
echocardiography. Baseline values (intact normal animals;
n =7) of heart rate, LVDd, LVDs and LVEF were 385T17
bpm, 6.6T0.2 mm, 4.0T0.2 mm and 77.5T1.6%, respec-
tively. After 30-min ischemia and 24-h reperfusion, all the
groups demonstrated significantly ( p <0.05) decreased
LVEF compared to the baseline data. Importantly, the R-
SOD group demonstrated a significantly higher LVEF
compared with any other groups ( p <0.05, Table 1). LVEF
in the V-SOD group tends to be higher than that in the V-
PBS group ( p =0.111). There was no difference in LVEF
between the R-PBS and V-PBS groups. Heart rate in every
group tends to be higher than the baseline presumably due
to surgical stress. Neither LV diastolic nor systolic
dimensions showed significant differences among any
groups.
3.2. Reduced infarct size by retrograde intracoronary SOD
infusion
The area at risk of infarction and infarct area after
ischemia–reperfusion injury were determined by Evans
Blue and TTC staining. The area at risk of infarction was
similar among all groups (50.7T2.6% in the R-SOD,
50.1T1.9% in the V-SOD, 55.3T1.7% in the R-PBS and
50.6T2.2% in the V-PBS group). Infarct size was calculated
as a percentage of the infarct area to the area at risk of
infarction. The R-SOD group (23.3T2.3%) demonstrated
the smallest infarct size among all groups including the V-
SOD group (42.4T3.5%) (Fig. 2). In contrast, the difference
of infarct size between the V-SOD and V-PBS (47.4T3.4%,
p =0.330) groups was not significant. Infarct size in the R-
PBS group (48.9T2.8%) was similar to the V-PBS group.
Fig. 3. Degree of reflow. RMBF was measured with coloured microspheres
at 24 h after the reperfusion. Degree of reflow was defined as RMBF in the
area at risk of infarction divided by that in the area without risk of
infarction. The degree of reflow both in the R-SOD and the V-SOD group
was significantly larger than that of the R-PBS and the V-PBS groups.
*p <0.01 vs. R-PBS and V-PBS. .p <0.05 vs. R-PBS and V-PBS. n =5 in
each group.
Fig. 5. Number of PMNL infiltrating into myocardium. The number of
PMNL infiltrating into the area at risk of infarction per high-power field
was calculated as an indicator of acute inflammatory response at 24
h after reperfusion. The R-SOD group demonstrated the smallest number
of PMNLs among all other groups. The V-SOD group showed
significant reduction compared with the V-PBS groups. *p <0.01 vs.
V-SOD, R-PBS and V-PBS. .p <0.05 vs. R-PBS and V-PBS. n =5 in
each group.
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infusion
The degree of reflow in the area at risk of infarction after
ischemia–reperfusion was evaluated with coloured micro-
spheres. At 24 h after reperfusion, the degree of reflow inFig. 4. Histological findings. Acute inflammatory response was evaluated with haem
in each group was shown. PMNLs was infiltrating into the gap of disrupted myoc
group (D) compared with the V-SOD (C), the R-PBS (B) and the V-PBS (A). Bathe V-SOD (64.3T2.1%) and R-SOD (69.8T2.3%) groups
was significantly larger than that in the V-PBS (53.4T2.4%,
p =0.032 vs. V-SOD, p =0. 017 vs. R-SOD) and R-PBS
(54.4T2.4%, p <0.001 vs. V-SOD and R-SOD) groups (Fig.
3). The difference between R-SOD and V-SOD groups was
not statistically significant ( p =0.556).atoxylin and eosin staining at 24 h after reperfusion. Representative picture
ardium. It can be seen that number of PMNLs is the smallest in the R-SOD
r=100 Am.
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SOD infusion
Acute inflammatory response after ischemia–reperfusion
was evaluated by haematoxylin and eosin staining (Fig. 4).
The myocardium lost its regular structure and cardiomyo-
cytes were enlarged in the area at risk of infarction with
PMNLs infiltration into the gap of disrupted myocardium in
all samples analysed. The R-SOD group demonstrated
significant reduction in the number of PMNL infiltrating
into the area at risk of infarction compared with the V-SOD
group (11.8T0.4 vs. 14.8T0.2 103/mm2, p <0.001), (Fig. 5).
PMNL infiltration in the V-SOD group was significantly
reduced compared with the V-PBS group (16.8T0.7 103/
mm2, p =0.018). There was no significant difference in the
number of PMNL between the R-PBS (18.0T0.6 103/mm2)
and the V-PBS group.4. Discussion
Using an original experimental model in rat, we have
demonstrated that SOD-induced cardioprotection is en-
hanced by retrograde intracoronary administration com-
pared to intravenous systemic administration. While
intravenous infusion of SOD improved the reflow and
attenuated acute inflammation following ischemia–reperfu-
sion injury compared to intravenous PBS infusion, retro-
grade intracoronary infusion furthermore preserved LVEF
and reduced infarct size, with further attenuated acute
inflammatory response in the area at risk of infarction,
compared to intravenous SOD infusion. Retrograde intra-
coronary PBS infusion resulted in similar findings to that of
intravenous PBS infusion in terms of cardiac function and
acute inflammation, suggesting that mechanical injury in the
myocardium caused by this method is negligible.
The high level of free radicals generated during
myocardial ischemia–reperfusion causes cell necrosis as
well as apoptosis, impede RMBF and trigger inflammatory
cascades associated with induction of pro-inflammatory
cytokines [2,3]. Based on many previous reports, SOD has
been expected to be a useful reagent to attenuate such
myocardial ischemia–reperfusion injury by scavenging free
radicals [2–11,14]. Experiments using transgenic mice [22]
or in vivo gene transfection [14] consistently demonstrated
that SOD overexpression improves myocardial tolerance
against the reperfusion injury. However, on the other hand,
when recombinant CuZn–SOD is administered after reper-
fusion, the cardioprotective effect is inconsistent [4–13].
The reasons for such inconsistency may include the
insufficient amount of SOD used as well as the inappropri-
ate delivery method. The total amount of SOD used in
previous studies was in the range of 15,000–130,000 U/kg
with 15,000 U/kg being the most common dosage [4–13].
This was infused either intravenously, via the left atrium or
by a combination of these. In the present study, we used15,000 U/kg CuZn–SOD for the V-SOD group, while one-
tenth of this amount (1500 U/kg) was used for the R-SOD
group, as blood flow perfusing the heart is considered to be
5–10% of the systemic blood flow. As a result, intravenous
infusion of SOD demonstrated only a mild level of
cardioprotection. This is understandable considering that
the previous reports using the same amount of SOD
demonstrated the inconsistent results [5,6,8,9]. It may be
possible to improve the cardioprotective effect by adminis-
trating a higher dosage of SOD intravenously. However, in
contrast, retrograde intracoronary infusion of one-tenth
(proportionally the same) dosage of SOD showed markedly
enhanced cardioprotection, highlighting the superior effi-
ciency of this route.
Retrograde intracoronary infusion has been reported to
be useful in administrating cardioplegic solution, recombi-
nant peptide and vectors for gene therapy into the
myocardium [23–25]. We have demonstrated that skeletal
myoblasts are disseminated homogenously into the ische-
mic/infarcted myocardium when transplantated through this
route in rat [17]. In the present study, we have shown that
retrograde intracoronary infusion of SOD provides en-
hanced protection against reperfusion injury compared to
intravenous injection. This may be due to unique abilities of
retrograde intracoronary infusion to efficiently deliver SOD
into the myocardium. First, this route can effectively supply
SOD to the right place (post-capillary venules, where
inflammatory response takes place). In addition, retrograde
intracoronary infusion can perfuse the ischemic myocardi-
um before reperfusion, as we have described previously
[16,17]. This method also allows for certain incubation time
(25–30 s in our study) after injection, which will encourage
the delivered SOD to permeate into the myocardial tissues
and cells. This ability to provide SOD at the right place, at
the right time, with a high efficiency, is considered to be of
great value. Free radical generation is reported to start
during the first 10 s of reperfusion and peak at 10 min
[15,26]. Elevating the myocardial SOD level before
reperfusion by this treatment will effectively scavenge the
free radicals initially generated immediately after reperfu-
sion, resulting in enhanced reduction of subsequent and
overall reperfusion injury.
Bokestegers et al. [27,28] have recently reported the
safety and efficacy of retrograde intracoronary infusion of
arterial blood in attenuating myocardial ischemia during
percutaneous transluminal coronary angioplasty in human.
This suggests the possibility of clinical application of the
proposed strategy in the present paper, namely pretreatment
of the ischemic myocardium by retrograde intracoronary
infusion of SOD for myocardial protection against reperfu-
sion injury. This treatment is feasible by using a balloon
catheter in clinical settings of percutaneous coronary
intervention (PCI) for treating acute myocardial infarction.
Disadvantageously, it requires additional procedures (cath-
eter insertion into the coronary sinus) to the usual PCI,
which will delay the recanalization by several minutes.
S. Fukushima et al. / Cardiovascular Research 69 (2006) 459–465464Nevertheless, we consider that the treatment will induce
greater benefits which far outweigh the loss caused by the
‘‘several-minute delay’’ of recanalization, improving the
overall outcome of the PCI therapy. This concept, however,
has to be confirmed by further laboratory research in a
relevant experimental model using large animals. Investi-
gation of the efficiency of retrograde intracoronary SOD
infusion at later time points of reperfusion, which is more
easily applicable to patients, would be also worthwhile.
It has been reported that combined administration of
SOD and catalase effectively reduces myocardial reperfu-
sion injury [4]. It is therefore considered that co-
administration of catalase may further enhance the
cardioprotective effect of retrograde intracoronary infusion
of SOD. Other reagents such as Na+/H+ exchanger
inhibitors, calcium antagonists, renin–angiotensin system
antagonists, adenosine and nitric oxide donors have been
shown to provide cardioprotection during primary angio-
plasty for acute myocardial infarction [29]. Although
efficiency of these reagents has been demonstrated using
models of antegrade intracoronary or intravenous infusion,
retrograde intracoronary infusion may enhance the effi-
ciency by the same mechanisms as the present study using
SOD. In addition, antegrade intracoronary and intravenous
administration of anti-P-selectin and anti-intercellular
adhesion molecule (ICAM)-1 antibodies are also known
to attenuate myocardial ischemia–reperfusion injury [30].
As these molecules theoretically work at postcapillary
venules, retrograde intracoronary infusion, which has direct
access to this part, may be the ideal injection route for
these antibodies.
In conclusion, this study has shown that retrograde
intracoronary infusion is a promising clinically applicable
method to enhance the efficacy of SOD-induced myocardial
protection against ischemia–reperfusion injury.Acknowledgements
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